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 Inflammation is a key homeostatic host response to different stimuli including 
infections and antigen-antibody reactions, where a tissue responds by initiating repair and 
eventually leading to the restoration of structure and function of the injured tissue. 
However, prolonged or disproportionate inflammatory reaction has been a hallmark of 
inflammatory disorders and it can be managed by dampening the aberrant inflammatory 
process. One of the major contributing factor in inflammatory disorders is TNFα (Tumor 
Necrosis Factor alpha), a potent pro-inflammatory cytokine, important in triggering and 
amplifying inflammatory responses. Though anti-TNF therapies are being used in the 
management of inflammatory disorders, their side effects and lack of responsiveness in 
certain situations has made the search for alternatives a necessity. Recently, intracellular 
signaling mediators like MAPKs and transcription factors, participating in the 
transduction and amplification of the signaling process have gained attention and are 
being targeted to dampen inflammation. Lipid mediators like PLD (Phospholipase D) and 
SphK (Sphingosine kinase) are found to play vital roles in intracellular signaling and 
immune cell responses, including Fc receptor and complement mediated responses. 
Therefore, this study investigated the role of PLD and SphK in TNFα induced 
inflammatory signaling and effector responses. The human monocyte was chosen as the 
cell model. This study revealed that TNFα-induced effector responses like pro-
inflammatory cytokine production and chemotaxis were mediated by PLD. The results 
also showed that TNFα induces PLD activity and selective translocation of PLD1, from 
the cytosol to the cell periphery. It was also observed that PLD is essential for TNFα 
 xv 
triggered Raf-1 translocation and subsequent ERK1/2 activation. However, TNFα 
induced p38-phosphorylation was found to be independent of PLD activity in human 
monocytes. The results in the study indicate that TNFα triggered activation of NFκB, a 
key pro-inflammatory transcription factor was dependent on PLD. It was shown earlier 
that TNFα triggered NFκB activation and responses were mediated by SphK in human 
monocytes. In this study, it has been shown that TNFα induced SphK activity and 
cytosolic calcium release were downstream of PLD, indicating that PLD mediates at least 
some of its effects through SphK and calcium. PLD1 and PLD2 are the two major 
isoforms of PLD. It was shown that both the PLD isoforms are present in human 
monocytes. Following up on the selective translocation of PLD1 to TNFα stimuli, our 
antisense based investigation revealed the coupling of PLD1 to TNFα signaling and 
responses in human monocytes. Furthermore, we validated the in vivo role of PLD1 and 
SphK1 in TNFα induced peritonitis in BALB/c mice using short interfering RNA. 
Collectively, our results showcase a pivotal role for PLD1 and SphK1 in TNFα triggered 
inflammatory responses and suggests their potential in the therapeutic management of 
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Inflammation is a key homeostatic host response process, where a tissue responds 
to injury by initiating repair and eventually leading to the restoration of structure and 
function of the injured tissue (Florey, 1970). This homeostatic process is initiated as a 
response to different stimuli like infections, antigen-antibody reactions and also to 
physical, chemical and thermal insults to the tissues. Inflammation, apart from being a 
beneficial process by facilitating tissue homeostasis and host defense, is also a 
contributing factor in the pathogenesis of a variety of disease states. Prolonged or 
disproportionate inflammatory reaction has been a hallmark of inflammatory disorders 
like, rheumatoid arthritis, chronic bronchitis, asthma, glomerulonephritis, myocardial 
infarction, inflammatory bowel disease and autoimmune diseases including systemic 
lupus erythematosus (Boyd, 1992; Stanley L. Robbins, 1987). 
Inflammation is a tightly regulated process, well orchestrated by immune cells 
and inflammatory mediators which include chemokines, cytokines and lipid mediators. 
Prolonged or aberrant inflammation is mainly due to the disruption in the natural 
resolution process. There does exist, a natural resolution processes of inflammation 
which includes the removal of the initial stimuli, reducing the levels of pro-inflammatory 
mediators  and  removal of inflammatory cells and debris (Henson, 2005). Dysregulation 
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in any of the three above mentioned process would result in chronic, persistent 
inflammation and associated pathology. 
One of the major contributing factor in the pathogenesis of inflammatory 
disorders is TNFα (Tumour Necrosis Factor alpha), a potent pro-inflammatory cytokine. 
It is important in triggering and amplifying inflammatory responses. Dysregulation in 
TNFα production or signaling has been associated with septic shock syndrome, fever, 
acute phase response, cachexia, cerebral malaria, diabetes, cancer, atherosclerosis, liver 
disease, osteoporosis, allograft rejection and autoimmune diseases such as multiple 
sclerosis, rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel 
diseases (Aggarwal, 2003; Chen and Goeddel, 2002; Tracey and Cerami, 1993; Tracey 
and Cerami, 1994). Reviews by Lin et al and Wong et al have a detailed account of the 
contribution of TNFα in a variety of inflammatory disorders (Lin et al., 2008; Wong et 
al., 2008). The sheer number of patients receiving anti-TNFα therapies like monoclonal 
antibodies against TNFα and its receptors, and soluble TNFα receptors for the 
management of a range of inflammatory disorders will further emphasize the extent of 
TNFα in inflammation mediated pathologies. Though its success rate is  remarkable, 
there are associated side effects (like infections, Tuberculosis, congestive heart failure, 
malignancies, demyleinating disorders and even autoimmune diseases) and resistance to 
therapy in some patients (Lin et al., 2008). These factors have made the search for 
effective alternatives in the management of immune mediated inflammatory disorders 
(IMID) a necessity. One of  the promising alternative approaches is to target the signaling 
mediators like p38 kinase, NFκB and matrix metalloproteinases to dampen the aberrant 
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inflammatory response (O'Neill, 2006).  Intracellular signaling mediators regulated 
events including, phosphorylation, transcription factor activation and translocation among 
others, in a cell are key reactions to a stimuli, which determines the degree and type of 
response of the cell to the initial stimuli. Regulating or harnessing these signaling events 
will influence the inflammatory response and can result in the resolution of the associated 
pathology. Therefore, in this study, we shall be investigating the effects of phospholipid-
modifying enzymes and intracellular signaling regulators: Phospholipase D (PLD) and 
Sphingosine Kinase (SphK), in TNFα-triggered signaling and cellular responses; hence, 
evaluating the potential to target these enzymes in the therapeutic management of 
immune mediated inflammatory disorders.  The following sections in this chapter will 
discuss TNFα, PLD and SphK in detail. 
 
1.2 Tumor Necrosis Factor alpha  
TNFα (Tumor Necrosis Factor alpha) is a pleiotropic cytokine extensively studied 
for its role in the pathogenesis of a variety of disease conditions, which is known to have 
a wide range of beneficial and deleterious effects in humans (Tracey and Cerami, 1993; 
Tracey and Cerami, 1994). TNFα is produced by a variety of cells which include: 
macrophages, monocytes, lymphocytes, NK cells, eosinophils, keratinocytes, langerhan 
cells, kupffer cells, glial cells, adipocytes and fibroblasts (Baud and Karin, 2001; Tracey 
and Cerami, 1993; Tracey and Cerami, 1994). This cytokine is known to be produced in 
response to a wide range of stimuli such as, bacterial toxins (LPS), infections (bacterial, 
viral, fungal, mycobacterial and parasitic); antigen-antibody complexes; injury; host 
inflammatory agents (products of the complement activation, auto-antibodies and 
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cytokines); as well as toxic and non-toxic environmental challenges (Baud and Karin, 
2001; Tracey and Cerami, 1994). TNFα elicits a wide spectrum of cellular responses 
which mediates inflammation, regulates immune response and also induces apoptosis in 
certain types of cancer cells (Chen and Goeddel, 2002; MacEwan, 2002a). It brings about 
its immuno-modulatory and inflammatory functions by inducing the production of 
various cytokines, activation of leukocytes and lymphocytes, enhancing the expression of 
adhesion molecules, initiating adherence of neutrophils and monocytes to the 
endothelium, promoting inflammatory cell migration and it is also known to stimulate 
cellular proliferation and differentiation (Baud and Karin, 2001; Hehlgans and Mannel, 
2002; MacEwan, 2002a; Tracey and Cerami, 1993; Tracey and Cerami, 1994). 
Appropriate levels of TNFα are necessary for homeostatic functions like protection from 
infection, haematopoiesis, immune response regulation, tumor regression and immune 
surveillance (Aggarwal, 2003). Dysregulation in TNFα production or signaling has been 
associated with a range of inflammation based disorders (Aggarwal, 2003; Chen and 
Goeddel, 2002; Lin et al., 2008; Tracey and Cerami, 1993; Tracey and Cerami, 1994; 
Wong et al., 2008). 
The observations by Dr P Brunes, on spontaneous regression of tumors in patients 
with acute bacterial infections (Bruns, 1868) and the follow up study by William B Coley 
on tumor reduction by the use of bacteria-free filtrate preparation from bacterial extracts 
(Coley, 1891) more than a century ago, have been the real building blocks that led to the 
discovery of TNF. This factor found in the serum which is capable of causing regression 
of certain tumors was termed Tumor Necrosis Factor (TNF) in 1975 (Carswell et al., 
1975; Old, 1985). A decade later, successful attempts to isolate and characterize this 
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factor led to the identification of two structurally related factors, which were termed TNF 
(Tumor Necrosis Factor) or TNFα (Tumor Necrosis Factor alpha) and LT (Lymphotoxin) 
(Aggarwal et al., 1985; Aggarwal et al., 1984; Clark, 2007). Here, TNFα will be 
discussed in detail. 
 
1.2.1 TNFα ligand 
TNFα brings about its varied functions and responses through ligand-receptor 
complex formation mechanism, where TNFα is a ligand. It is a homotrimer of 157 amino 
acid subunits (Chen and Goeddel, 2002) and is a type II transmembrane protein 
(Hehlgans and Mannel, 2002). It is present as biologically active membrane bound 
(mTNF) and soluble (sTNF) forms. Soluble TNFα is originally expressed as a 26kDa 
membrane bound pre-protein which can be cleaved off by a metalloproteinase (TACE – 
TNF alpha converting enzyme) to be released as a 17kDa mature form of TNFα (Black, 
2002; Black et al., 1997; Gearing et al., 1994; Idriss and Naismith, 2000; Moss et al., 
1997). The secreted, mature TNFα subunits form non covalently bound homotrimers – 
sTNFα (Hehlgans and Mannel, 2002; MacEwan, 2002a). This trimerization is necessary 
for the TNFα to be biologically potent or activate its receptors (Sprang, 1992). The 
membrane bound form of TNFα ligand is useful in the transfer of signals by cell to cell 
contact and the effect is said to be localized, whereas the soluble form of TNFα  is said to 




1.2.2 TNF receptors 
The TNF ligand induces its different cellular responses by binding to TNF 
receptors TNFR type 1 (TNFR1 / p55TNFR / CD120a)  and/or TNFR type 2 (TNFR2 / 
p75TNFR / CD120b) (Chen and Goeddel, 2002; MacEwan, 2002a; MacEwan, 2002b; 
Smith et al., 1990; Vandenabeele et al., 1995). TNFRs are single transmembrane 
glycoproteins with homology in the extracellular domains but not in the intracellular or 
cytoplasmic domains. The binding process induces receptor trimerization and/or 
recruitment of signaling proteins to the cytoplasmic domains of the TNFα receptors and 
the subsequent cellular responses depends on the type of receptor bound to the ligand.  
Both receptors contain a PLAD (pre ligand binding assembly domain) that pre complexes 
the receptors and encourages them to trimerize, particularly upon activation by TNF 
ligand (Chan et al., 2000). TNFR1 can equally be activated by both sTNF and mTNF, 
where as mTNF is considered to be superior than sTNF in activating TNFR2 (Grell, 
1995; Grell et al., 1995). TNFα activates TNFR1 with higher efficiency due to the fact 
that it binds to TNFR1 with increased affinity (Kd of 19pM) and exhibits a slow rate of 
dissociation (t ½  = 33 mins) from the receptor, subsequent to binding (Grell et al., 1998). 
These kinetics are different for TNFR2, where the affinity of TNFα to TNFR2 is lower 
and the dissociation rate is faster compared to that of TNFR1 (Grell et al., 1998). TNFR1 
is said to be constitutively expressed in a vast majority of cells types and tissues 
including immune cells, whereas TNFR2 expression is mainly found in immune cells 
(Chen and Goeddel, 2002; Wajant et al., 2003). TNFR1 is considered to mediate most of 
the biological effects and responses induced by TNFα (Wajant et al., 2003). TNFR1 is 
the most widely studied type of TNFR in experimental set up. This is due to the use of 
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soluble recombinant TNFα, which predominantly activates TNFR1. A novel isoform of 
TNFR2 (icTNFR2 – intra cytoplasmic TNFR2) reported recently is thought to have 
originated from TNFR2 gene as a new transcriptional start followed by alternative 
splicing of the transcript  and it was found to be expressed only within the cell (Seitz et 
al., 2001). Though over expression studies have suggested that icTNFR2 signaling is 
similar to that of TNFR2 (Seitz et al., 2001), more work has to be done to evaluate the 
relevance of icTNFR2 compared to that of the well studied TNFα receptors. TNFα 
receptors lack intrinsic enzymatic activity and bring about their functions by the 
recruiting different adaptor molecules, which in turn transduce signals for a range of 
responses like apoptotic cell death, inflammation, cellular survival and proliferation. 
 
1.2.3 TNFα-induced signaling 
The binding of the ligand, TNFα to TNFR1 leads to conformational changes in 
the intracellular domain of the TNFR which initiates  the recruitment and subsequent 
interaction of several adapter proteins to the receptors (Wallach et al., 1999). TNFR1 
contains a death domain (DD) motif towards the carboxyl-end of the receptor and is 
critical in the death- inducing and survival or inflammatory activity of TNFR1 (Tartaglia 
et al., 1993a).  The DD of a protein can associate with the DD of other proteins. SODD 
(Silencer of Death Domain), an adaptor protein is bound to TNFR1 through its DD, 
thereby preventing the binding of other molecules with DD to the TNFR (Jiang et al., 
1999).  In this manner, SODD acts as an endogenous inhibitor of TNFα signaling.  
Receptor ligation of TNFR1 initiates internalization of the ligand-receptor complex 
which is another protective mechanism present naturally to disrupt any sustained 
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signaling subsequent to receptor activation (Higuchi and Aggarwal, 1994; Schutze et al., 
1999). Receptor ligation leads to the dissociation of SODD from TNFR1, thereby 
allowing other DD containing proteins to interact with the DD of TNFR1. This event 
results in the recruitment of a DD containing signal transduction adapter molecule, 
TRADD (TNF receptor associated death domain), which recruits a variety of signaling 
pathways by interacting with other related adaptor molecules. A schematic representation 
of the signaling pathway is illustrated in (Figure 1.1, page number 26).  
 
1.2.3.1 TRADD dependent signaling 
TRADD dependent signaling is unique to TNFR1 and not TNFR2. This is due to 
the absence of DD in TNFR2. TRADD plays an unique role in directing distinct signaling 
pathways like, pro-apoptotic or survival pathway by forming a signaling complex with 
FADD (Fas associated Death Domain) and TRAF2 (TNF receptor associated factor) 
respectively (Hsu et al., 1996; Liu et al., 1996).  
 
1.2.3.1.1 Pro-apoptotic signaling 
Intracellular signaling mediators regulating TNFα−induced pro-apoptotic 
signaling discussed here are primarly FADD and JNK. The role of RIP and cPLA2 in this 
process is also discussed. 
 
FADD 
TNFR, also known as death receptors, are well known to induce death signals through 
the extrinsic apoptotic pathway using an initiator caspase (caspase-8) (Denecker et al., 
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2001a; Denecker et al., 2001b; Mak and Yeh, 2002; Wyllie, 1997) and TRADD. 
Subsequent to TNFR1 receptor activation, the TNFR1-TRADD complex recruits another 
DD containing protein FADD  which in turn activates procaspases-8 and 10 which 
eventually leads to DNA damage and programmed cell death (Ashkenazi and Dixit, 
1998; Hsu et al., 1995). FADD recruitment of procaspase-8 is facilitated by protein–
protein interaction through their death effector domains (DED), thus leading to the 
formation of a death inducing signal complex (DISC) along with TNFR1 and TRADD. 
Procaspase-8 is then autolytically cleaved to release an active form of caspase-8 from the 
DISC, which then acts on downstream effector caspases, especially caspase-3. These 
effector caspases cleave or lead to the degradation of a number of substrates necessary for 
normal cell homeostasis, thus resulting in morphologic and biochemical characteristic of 
apoptotic cell death. Caspase-8 also cleaves Bid (BH3-interaction death domain agonist, 
a member of Bcl-2 family) to form t-Bid, which translocates to mitochondria causing the 
release of cytochrome c (Luo et al., 1998). This is followed by the formation of 
Apoptosome - a complex made up of cytochrome c, Apaf-1 (Apoptosis-activating factor 
1) and procaspase-9, which is capable of activating effector caspases like caspase-3  to 
bring about programmed cell death (Wang, 2001). It was also found that activated 
caspase-3 can in turn activate the cleavage of procaspases-8 to caspase-8 and thereby 
creating a positive feed back system (Wieder et al., 2001).  
 
JNK 
JNK (c-Jun N-terminal Kinases), an important member of the MAPK (Mitogen 
activated protein kinase) family influences a variety of cellular functions including 
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apoptosis (Davis, 2000). JNK is known to be activated by a variety of stimuli like 
cytokines, UV irradiation, growth factors, serum and DNA damaging agents. 
TNFα−induced prolonged activation of JNK has long been associated with the induction 
of apoptosis or necrosis. It is has been reported that TNFR2 activates JNK and not other 
MAPKs (Jupp et al., 2001). TRAF2 has been identified to be essential in the activation of 
JNK (Baud et al., 1999; Natoli et al., 1997). Efforts to elucidate the mechanism of 
TNFα−induced JNK activation has led to the identification of the role of ASK1 in the 
process (Ichijo et al., 1997). TRAF2 brings about JNK activation by effecting its 
influence on ASK1 (Apoptosis stimulating kinase / apoptosis signal regulating kinase), a 
MAPKKK (Nishitoh et al., 1998) and GCK (Germinal center kinase) (Yuasa et al., 1998). 
ASK1 activates or phosphorylates MKK4 and MKK7 leading to the activation of JNK 
(Weston and Davis, 2002). TNFα activation of JNK is brought about as two distinct 
phases. There is TNFα-induced TRAF2 mediated early and transient JNK activation 
(Lamb et al., 2003) which is followed by a delayed and persistent activation of JNK 
mediated by reactive oxygen species (ROS) induced by TNFα (Ventura et al., 2004). It 
was also reported that ROS mediated JNK activation is followed by ROS production 
mediated by JNK which exhibits a positive feedback of ROS production and JNK 
activation (Ventura et al., 2004) which would contribute to the induction of apoptosis. 
TNFα−induced ROS was found to facilitate the activation of ASK1 by oxidizing 
thioredoxin and its dissociation from ASK1. This is followed by oligomerization and 
phosphorylation of ASK1 and subsequent JNK activation, leading to apoptosis (Gotoh 
and Cooper, 1998; Saitoh et al., 1998). A more recent study has shown that, in addition to 
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activation of ASK1, TNFα−induced increased ROS production inhibited the function of 
MAPK phosphatase thereby leading to a prolonged or persistent JNK activation resulting 
in cell death (Kamata et al., 2005). A review by Shen et al can be referred for a detailed 
discussion on the role of ROS in TNFα−induced JNK activation and associated cell death 
(Shen and Pervaiz, 2006). All these reports indicate the role of ROS as a co-activator in 
TNFα-induced JNK mediated cell death. JNK is well known to induce c-Jun dependent 
transcription leading to AP-1 activation (Karin et al., 1997; Weston and Davis, 2002) and 
it also phosphorylates transcription factors like ATF2, NF-AT, HSF and STAT3 to bring 
about it various cellular responses (Kyriakis and Avruch, 2001).  
 
RIP 
Receptor interacting protein (RIP) was found to be associated with TNFα−induced 
apoptosis (Lin et al., 1999). It was found that caspase-8 cleaves RIP to form RIPc and 
nRIP. It has been reported that RIPc blocks TNFα-induced survival signaling and the 
association of RIPc with TRADD has been associated with TNFα−induced apoptosis 
(Lin et al., 1999). Subsequent to cleavage, RIP was found to dissociate from the TRADD, 
thus enabling the recruitment of FADD and thereby indicating its role in TNFα-induced 
apoptosis (Lin et al., 1999). 
 
cPLA2 
cPLA2 (cytosolic phospholipase A2) has been associated with TNFα-induced 
apoptosis (Lee et al., 2006a; Pilane and LaBelle, 2002; Pirianov et al., 1999; Wolf and 
 12 
Laster, 1999). By contrast, some earlier studies reported that cPLA2 and sPLA2 mediated 
TNFα-induced NFκB activation in human keratinocytes (Anthonsen et al., 2001; 
Thommesen et al., 1998). However, other studies have clearly shown and emphasized 
that cPLA2 expression and activation is vital for TNFα-induced cell death in a variety of 
cell types (De Valck et al., 1998; Jayadev et al., 1997; Wu et al., 1998a; Wu et al., 
1998b). cPLA2 activated by TNFRs (Clark et al., 1991; Hoeck et al., 1993; MacEwan, 
1996) leads to the generation of arachidonic acid (Jayadev et al., 1997) which is further 
converted to form eicosanoids (Prostaglandins and Leukotrienes). cPLA2 based 
eicosanoids induce the generation of ROS which in turn plays a role in determining cell 
fate (Chang et al., 1992). TNFR1 is thought to play a role in the activation of cPLA2, 
whereas TNFR2 is said to be involved in regulating the expression of cPLA2 (MacEwan, 
1996; MacEwan, 2002a). 
 
1.2.3.1.2 Survival or Inflammatory  
TNFR1 facilitates a survival or an anti-apoptotic signal through the recruitment of 
TRAF to the receptor signaling complex through TRADD. TRAF family of proteins are 
involved in a range of cellular responses like survival, inflammation and anti-apoptosis 
(Chung et al., 2002). Of the seven members of the mammalian TRAF family, TRAF2 is 
well studied and has been found to be associated with TNFR1 and TNFR2 signaling (Xia 
and Chen, 2005). TRADD was found to be specific for TRAF1 and TRAF2.  It has also 
been reported that TRAF2 has higher affinity for TRADD rather than the TNFRs (Park et 
al., 2000) and this indicates the predominant role of TRAF2 in TNFR1 signaling. Along 
with TRAF2, receptor interacting protein (RIP) has also been found to be recruited by 
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TRADD to the receptor signaling complex. RIP was found to be necessary in 
TNFα−mediated survival signals (Devin et al., 2000; Hsu et al., 1996) and is also 
involved in TNFα−induced activation of NFκB (Nuclear Factor kappa B), an important 
transcription factor (Kelliher et al., 1998). TRAF2 and TRAF5 together are also 
necessary in TNFα induced NFκB  activation (Tada et al., 2001).  
Intracellular signaling mediators other than NFκB playing a crucial role in pro-
survival and/or anti pro-apoptotic signaling discussed here are IAP (Inhibitor of 
Apoptotic proteins), PLC (Phospholipase C), PLD (Phospholipase D), PKC (Protein 
Kinase C), Sphingolipids, p38 kinase and PKB (Protein Kinase B). The other survival 
mediators like ERK1/2, TNFR2 and FAN (Factor associated with neutral 
sphingomyelinase) are discussed in section 1.2.3.2 in this chapter. 
 
NFκB 
TNFα brings about survival responses predominantly by the activation of NFκB, an 
important anti-apoptotic and pro-inflammatory transcription factor. NFκB is known to 
play an important role in regulating the expression of genes responsible for mediating 
immune responses (Baeuerle and Henkel, 1994; Ghosh et al., 1998). If NFκB signaling is 
blocked, TNFα can bring about rapid programmed cell death in a variety of cells 
(Hayden and Ghosh, 2004) which indicates the importance of NFκB in the cellular 
response specificity, when induced by TNFα. The canonical or the classical NFκB 
pathway (Pomerantz and Baltimore, 2002) is considered to be the predominantly 
triggered pathway in most cells and stimuli. Binding of TNFα to TNFR1 is known as the 
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potent activator of the classical NFκB pathway. In this pathway, NFκB is present in the 
form of a dimer made up of p50 and p65 subunits. In unstimulated cells or in cells prior 
to activation, NFκB is sequestered in the cytoplasm in an inactive form and its DNA 
binding ability is prevented by IκB family of inhibitor proteins (Hoffmann and 
Baltimore, 2006). On TNFα stimulation, there is a  rapid activation of the IKK complex 
(Hayden and Ghosh, 2004). The IKK complex consists of two catalytic subunits, IKKα 
and IKKβ, and a regulatory subunit, NFκB essential modulator (NEMO) (Ghosh and 
Karin, 2002). Subsequent to TNFα stimulation TRAF2 is suggested to interact with 
IKKα and IKKβ recruits the IKK complex to the receptor complex (Devin et al., 2001). 
RIP is said to help in the shuttling of IKK complex to the receptor complex by binding to 
NEMO (Zhang et al., 2000) and this role of RIP, independent of TRAF2 is necessary for 
the activation of the IKK complex (Devin et al., 2001). Activation of IKK complex is 
followed by the ubiquitination and proteosomal degradation of IκBα within ~10 min 
(Hayden and Ghosh, 2004). TRAF2 was also found to be capable of interacting with NIK 
(NFκB inducing kinase) which is reported to phosphorylate IκB and which leads to the 
latter’s degradation (Ling et al., 1998; Malinin et al., 1997). TNFα induced degradation 
of IκBα triggers activation of NFκB by the release of the dimer to translocate from the 
cytoplasm to the nucleus and to initiate the activation of its target genes by binding to the 
DNA (Hoffmann and Baltimore, 2006; Karin and Ben-Neriah, 2000). 
It was originally thought that NFκB was a potent inhibitor of  JNK activation induced 
cell death and this was mediated by the activation of NFκB target genes like XIAP (X-
chromosome linked inhibitor of apoptosis),  GADD45β and cFLIP (De Smaele et al., 
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2001; Shu et al., 1997; Tang et al., 2001). This effect was challenged when reports 
showed that JNK activation was not affected despite the disruption of XIAP and 
GADD45β (Amanullah et al., 2003; Harlin et al., 2001). This fueled the search for 
mediator or mediators which enables the crosstalk between NFκB and JNK following 
TNFα stimulation. This lead to the identification of ROS in the interplay between TNFα 
induced cell survival and cell death (Papa et al., 2005; Zhang and Chen, 2004). It is now 
known that NFκB brings about the regulation of ROS through MnSOD (Manganese 
superoxide dismutase) and FHC (Ferritin heavy chain) (Delhalle et al., 2002; Pham et al., 
2004). The antioxidant property of MnSOD and FHC aid in the elimination and 
prevention of ROS build up in TNFα treated cells (Delhalle et al., 2002; Liochev and 
Fridovich, 1997). This event prevents the ROS mediated JNK activation. For further 
information on the role of ROS in TNFα−induced NFκB activation and pro-survival 
signaling, one can refer a well discussed review by Shen and Pervaiz (Shen and Pervaiz, 
2006). PKB activated via PI3K signaling and GSK3β was also found to be necessary in 
the transcriptional activity of NFκB, thereby preventing TNFα-induced apoptosis 
(Delhase et al., 2000; Hoeflich et al., 2000; Madrid et al., 2001). Therefore, NFκB brings 
about its anti-apoptotic, pro-survival signaling by activating key apoptosis inhibitory 
proteins and also by inhibiting ROS mediated JNK activation and subsequent cell death. 
 
cIAP  
TNFR1 also mediates survival by regulating or controlling its pro-apoptotic signaling 
by the recruitment of Inhibitor of Apopotic Proteins (IAPs), cIAP1 and cIAP2 by TRAF2 
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to the TNFR1 signaling complex (Rothe et al., 1995; Shu et al., 1996). cIAP1 and cIAP2 
are proteins which inhibit apoptosis by inhibiting caspase-3 and caspase-7 (Roy et al., 
1997) and proteosomal degradation of caspase-3 and caspase-7 (Huang et al., 2000). 
Therefore, in TNFR1 signaling,  TRAF2 recruited cIAPs can effectively inhibit caspase 8 
which has been recruited to the TNFR1 signaling complex by the TRADD-FADD 
complex (Roy et al., 1997). This would impede the signaling for programmed cell death 
and facilitate cell survival.  
 
PLC 
Lipases are involved in the transduction and regulation of TNFα-mediated signals 
and responses. Phospholipase C (PLC) is a well known phospholipase that acts on 
phosphatidylinositol 4, 5-bisphosphate (PIP2) to generate DAG (Diacyl glycerol) and IP3 
(Inositol 1, 4, 5-trisphosphate). Activation of Phosphatidyl-Choline specific PLC (PC-
PLC) leads to the production of choline and DAG, a potent secondary messenger 
involved in signal transduction. PLC is known to be activated on TNFα receptor 
stimulation (Plo et al., 2000; Schutze et al., 1991; Wiegmann et al., 1992) and the 
resulting second messenger like DAG are extremely relevant in the downstream signal 
transduction events, like the activation of PKC (Protein Kinase C) (Nishizuka, 1992).  
 
PLD 
TNFα signaling was also found to be associated with the activity of another 
lipase, PLD (Phospholipase D). PLD is a phosphodiesterase which hydrolyzes PC to form 
PA (Phosphatidic Acid), a potent second messenger and a relatively inert choline. PA can 
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be further converted to DAG by Phosphatidic Acid Phosphohydrolase (PAP). PLD has 
been shown to be involved in a range of immune cell signaling and responses. However, 
there are conflicting reports regarding the apoptotic and survival role PLD in TNFα 
signaling (Bechoua and Daniel, 2001; De Valck et al., 1993; Kang et al., 1998; Oprins et 
al., 2001; Oprins et al., 2002; Plo et al., 2000).  TNFα−induced PLD was found to 
influence ERK1/2 phosphorylation and p38 kinase in neutrophil like HL 60 cells 
(Bechoua and Daniel, 2001). All these findings indicates an antiapoptotic and 
inflammatory role of PLD in TNFα-induced signaling and responses. Recent studies 
were more conclusive and detailed about the role of PLD in TNFα signaling. The 
apoptotic and survival role of PLD in general including those induced by TNFα is well 
discussed by Nozawa Y (Nozawa, 2002) and recent report has indicated a protective role 
of PLD against TNFα−induced apoptosis (Birbes et al., 2006). ROS which was found to 
be a key regulator in TNFα-induced apoptosis and cell survival was also found to play a 
role in the activation of PLD in endothelial cells (Parinandi et al., 1999). All these facts, 
strongly urge the fact that future studies should address the need in understanding the role 
and interaction of PLD with other TNFα signaling mediators. 
  
PKC 
The role of PKC (Protein Kinase C) in TNFα−induced signaling and responses in 
a variety of cells was well summarized by Schutz et al (Schutze et al., 1994). 
TNFα−induced PKC (Protein Kinase C) activation is considered to be via DAG produced 
by PLC rather than by PLA2 or DAG produced by PLD. This is because kinetic studies 
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have shown that TNFα−induced PC-PLC activation precedes PKC activation and 
TNFα−induced PLA2 and PC-PLD activation is a delayed response, occurring much 
later than the PKC activation (Schutze et al., 1994). However, a variety of PKC isoforms 
exist with distinct activation patterns and distributions. Some of the classical isoforms 
like PKCα, β, δ and atypical isoforms like PKC ζ, λ, τ have been implicated in TNFα-
induced responses and signaling events like the activation of MAPKs and NFκB (Bonizzi 
et al., 1999; Cohen, 1997; Laouar et al., 1999; Lee et al., 2000; Muller et al., 1995; Sanz 
et al., 1999). An atypical PKC associated protein, p62, interacts exclusively with RIP to 
facilitate involvement of aPKC  to the TNFα−induced NFκB pathway (Sanz et al., 1999). 
 
Sphingolipids 
The sphingolipid based sphingomyelin pathway is known to be utilized in TNFα 
mediated signal transduction. TNFα stimulates both neutral SMase (Sphingomyelinase) 
and acidic SMase (Chatterjee, 1994; Dressler et al., 1992; Schutze et al., 1992; 
Wiegmann et al., 1994). TNFα induced NFκB activation is said to be via the endosomal 
acidic SMase (Schutze et al., 1992). Studies have proven that PC-PLC derived DAG is 
involved in the activation of acidic SMase (Kolesnick, 1987; Quintern et al., 1987; 
Schutze et al., 1992). Evidence has shown that sphingomyelin pathway is involved in 
TNFα−induced NFκB activation in neutrophil like cells (Yang et al., 1993).  TNFR1 was 
found to stimulate membrane associated neutral SMase (sphingmyelinase) (Wiegmann et 
al., 1992; Wiegmann et al., 1994) either directly or through the activation of another 
adaptor protein called FAN. This pathway involves the hydrolysis of sphingomyelin, a 
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major membrane associated sphingolipid to ceramide by action of a neutral 
sphingomyelinase (NSmase) and subsequently by the stimulation of ceramide-activated 
protein kinase (Dressler et al., 1992). A study on alveolar epithelial cells has reported that 
ceramide production by sphingomyelin hydrolysis induced by TNFα activation can 
activate survival pathway rather than initiating programmed cell death (Mallampalli et 
al., 1999). Ceramide functions as a selective mediator of the cytotoxic or cytostatic 
effects of TNFα by playing a positive feedback role in the activation of NFκB (Dbaibo et 
al., 1993). Ceramide can also be converted to form sphingosine. The latter is 
phosphorylated by sphingosine kinase (SphK) to form sphingosine 1 phosphate (S1P), a 
potent second messenger which can act both intracellularly and extracellularly through 
specific receptors. S1P through its receptor can influence a range of responses like 
proliferation, differentiation, migration, inflammation and apoptosis. It is also known to 
play role in the mobilization of intracellular Ca
2+
 (Pyne and Pyne, 2000). The role of 
SphK in immune cell signaling and responses has been extensively reviewed by Kee et al 
and Melendez AJ, can be referred for further reading (Kee et al., 2005; Melendez, 2007). 
TNFα-induced signaling and effector responses are mediated by SphK1 in human 
monocytes (Zhi et al., 2006). SphK is necessary for TNFα−induced NFκB activation, 
which is essential for the survival and proinflammatory signaling has also been reported 
(Zhi et al., 2006). The main effect of SphK is brought about by S1P, which induces 
mitogenesis, stimulates ERK, survival transcription factors and hindering ceramide 
mediated JNK activation. Thus, the fate of the cell depends on the tight balance between 
SIP and ceramide. 
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p38 kinase       
A stress activated protein kinase, p38 MAPK is also well known to be activated 
by environmental stress and pro-inflammatory cytokines including TNFα. Activation of 
p38 by TNFα is mediated by its upstream MAPKKKs (ASK1) (Ichijo et al., 1997) and 
MEKs (MEK-3 and MEK-6) (Enslen et al., 1998) and transduced through TRAF2 (Baud 
et al., 1999). p38 kinase is activated only by TNFR1 and not by TNFR2 (Jupp et al., 
2001). TNFα-induced cellular responses found to be mediated by p38 kinase are 
considered predominantly to mediate proinflammatory responses (Barone et al., 2001; 
Nakada et al., 2001). p38 activates the downstream targets like cPLA2, microtubule 
associated protein Tau, transcription factors like ATF1, ATF2, MEFs, Elk-1 (Kyriakis 
and Avruch, 2001), AP-1 (Karin et al., 1997) and several MKs (MAPK activated protein 
kinases) (Roux and Blenis, 2004).  
 
PKB 
The importance of PKB (Protein kinase B / AKT) in the regulation of cell survival 
responses is by the modulation of signaling molecules like IKK, Raf, ERK, Bad and 
caspase-9 (Scheid and Duronio, 1998). Phosphoinositide 3-kinases (PI3Ks) generate 
specific inositol lipids like PIP3 (Phosphatidylinositol-3, 4, 5-triphosphate) found to be 
relevant in the regulation of cell proliferation, survival and differentiation. PIP3 recruits 
PKB to the cellular membrane on stimulation and the latter is subsequently 
phosphorylated by PDK1 (3'-phosphoinositide-dependent kinase-1) (Vanhaesebroeck and 
Alessi, 2000). PKB is known to play an important role in TNFα-induced stimulation of 
NFκB activity, since NIK activation is PKB dependent (Burow et al., 2000; Ozes et al., 
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1999). Recently, TNFα-induced PKB and NFκB activation in endothelial cell survival 
was reported along with the role of integrin-mediated adhesion contributing to the 
mentioned response (Bieler et al., 2007). Destruction of PKB by caspases and inhibition 
of PKB by ceramide results in the inhibition of survival signals and favors cell death 
(Schubert et al., 2000; Widmann et al., 1998; Zinda et al., 2001). The antiapopotic 
activity of PKB partly contributes to cyclic nucleotides (cAMP and cGMP) mediated 
suppression of  apoptosis (Li et al., 2000). PKB activated via PI3K signaling and GSK3β 
was also found to be necessary in the transcriptional activity of NFκB, thereby preventing 
TNFα induced apoptosis (Delhase et al., 2000; Hoeflich et al., 2000; Madrid et al., 2001). 
 
1.2.3.2 TRADD independent signaling 
 TNFR1 also exhibits TRADD independent signaling, as there are proteins which 
associate directly to TNFR1. The nature of signaling and resulting responses depends on 
the type of the associating protein and its influence in the signaling pathways. 
 
ERK1/2 
ERK1/2 is a classical member of the MAPK (Mitogen activated protein kinases) 
family. ERK1/2 activation pathway, like p38 is considered as a potential target for cancer 
therapeutics, due to its regulatory effect in cellular proliferation (Kohno and Pouyssegur, 
2003). ERK1/2 activation associated cellular responses are brought about by the 
phosphorylation of membrane proteins (including Syk, CD120a), nuclear substrates 
(including NFAT, Elk-1, c-Fos, c-Myc, STAT3), cytoskeletal proteins and MAPK 
activated protein kinases (MKs) (Chen et al., 2001; Roux and Blenis, 2004). It is known 
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that MAPKs are activated by TNFα (Kyriakis and Avruch, 2001; Roux and Blenis, 2004) 
and ERK1/2 (p44/p42) were identified to be activated through their respective MEK 
(MEK1 and MEK2) phosphorylations (Van Lint et al., 1992). Like p38 kinase, ERK 
activation was found to be triggered by TNFR1 only and not TNFR2 (Jupp et al., 2001). 
Studies have shown the relevance of ERK in modulating TNFα induced survival and 
apoptotic signals (Cuvillier et al., 1996; Rao, 2001). TNFR1 is thought to bring about its 
ERK activation through an adaptor protein, MADD. This protein with low homology to 
DD was found to interact directly with the DD of TNFR1 and activate the ERK signaling 
pathways (Schievella et al., 1997). TNFR1 induces the activation of ERK also via Grb2, 
an adaptor protein which interacts with PLAP motif of TNFR1 (Hildt and Oess, 1999). 
Grb2 is known to interact with SOS which in turn leads to the activation of Ras, followed 
by c-Raf  which leads to the activation of ERK1/2 (Hildt and Oess, 1999). Interestingly, 
contrary to other reports, a study also reported that TNFα induced ERK activation was 




FAN (Factor associated with neutral sphingomyelinase) is an adaptor protein 
found to have binding ability to the membrane-proximal region of TNFR1 (Adam-Klages 
et al., 1996) and it has been found to aid in the stimulation of neutral sphingomyelinase 
(SMase) (Adam-Klages et al., 1996; Adam-Klages et al., 1998; Kreder et al., 1999). 
SMase catalyzes the sphingolipids to form ceramide which in turn can influence caspase-
3 activation and bring about cell death. It is also capable of activating ceramide activated 
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protein kinase (CAPK) as well (Dressler et al., 1992). Ceramide can also be converted to 
sphingosine as well. The sphingolipid pathway is discussed in detail in section 1.4 in this 
chapter. The signaling events following the activation of SMase and the resulting 
possibility of transducing apoptotic and survival responses have been discussed earlier 
(Sphingolipids in section 1.2.3.1.2).   
 
TNFR2 
TNFR2 mediated signaling can be categorized as TRADD independent signaling, 
since TNFR2 is devoid of DD. TRAF2 is directly associated with TNFR2 to initiate its 
pro-survival signaling and responses. TNFR2 is also known to induce cell death 
(Medvedev et al., 1994) and this is thought to be brought about by the induction of 
endogenous mTNF which activates TNFR1 (Grell et al., 1999; Weiss et al., 1998) along 
with the depletion of TRAF2 by cIAPs. It is also thought that TNFR2 induces apoptotic 
signals directly by ligand-passing mechanism, where it increases the local TNF 
concentration in TNFR1 region enabling the latter to initiate the apoptosis (Tartaglia et 
al., 1993b). 
 
TNF receptor associate proteins (TRAPs) have been found to be associated 
directly to the regions proximal to the DD in TNFRs to contribute their influence in TNF 
signaling and responses (Boldin et al., 1995).  TRAP1 (Hsp75) localized in the 
mitochondria (Felts et al., 2000) and TRAP2 (p97) which influences the regulation of 
proteosomal functions has been found to exhibit DD independent association with 
TNFRs (Boldin et al., 1995; Dunbar et al., 1997; Felts et al., 2000). 
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BRE, a stress response protein was found to be interact directly with TNFR1 and 
it is thought to regulate TNF receptor mediated response by inhibiting and dampening 
TNFR1 induced signaling (Gu et al., 1998).  
An alternative pathway in TNFα−induced phosphatidylinositol signaling via 
PIP5K-IIβ (Phosphoinositol 4 Phosphate 5 Kinase IIβ) has been reported. TNFR1 but not 
TNFR2 was found to interact in its juxta-membrane region and activates PIP5K-IIβ  
(Castellino et al., 1997).  PIP5K-IIβ is necessary for the generation of PIP2, a substrate 
for PI-PLC mediated IP3 and DAG (Castellino et al., 1997).   
In general, the binding of TNFα to the TNF receptors (TNFR1 and TNFR2) can 
bring about its varied effects like cellular apoptosis, proliferation or inflammatory 
responses due to the interplay of signaling mediators, in a TRADD dependent and 
independent pathway. The differences in the site of action, cell or tissue type, expression 
patterns and interactions of these signaling molecules play a pivotal role in determining 










































































Figure 1.1: TNFα-induced intracellular signaling events  
Schematic representation shows TNFR1 mediated intracellular signaling events. The 
events in the diagram include interaction between pro-apoptotic and pro-survival 
signaling events triggered by TNFα. The representation also includes TRADD dependent 
and independent signaling events. 
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1.2.4 TNFα signaling mediators as therapeutic targets 
Inflammation is involved in the maintenance of tissue homeostasis, defense 
against infection and mediating immune responses. However, dysregulated or prolonged 
inflammatory process contributes to tissue injury and morbidity, especially in certain 
chronic diseases and autoimmune conditions. This leads to the necessity to dampen the 
inflammatory response. TNFα is well known for its role in host defense to bacterial, viral 
and parasitic infections by mediating and amplifying inflammatory response.  Therefore, 
aberrant TNFα response has been associated with a spectrum of inflammatory disorders 
as discussed earlier.  Biopharmaceutical agents like antibodies and soluble receptors that 
target TNFα production are being increasingly used in the management of TNFα related 
disorders.  A range of them are currently licensed as TNFα blocking agents and are being 
used in the management of inflammatory diseases like, rheumatoid arthritis, ankylosing 
spondylitis and Crohn’s disease. The TNFα antagonist exhibits varying degree of 
efficacy and specificity. The mechanism of action and therapeutic effects in a variety of 
conditions for most of the currently available TNFα antagonist has been extensively 
discussed in some recent reviews (Bradley, 2008; Tracey et al., 2008; Valesini et al., 
2007; Wong et al., 2008).  TNFα blockade has been associated with increase in 
susceptibility to bacterial, viral and parasitic infections including Listeria, Mycobacteria 
and granulomatous infections (Pfeffer et al., 1993; Roach et al., 2002; Van Hensbroek et 
al., 1996; Wallis et al., 2005). It has also been found to be associated with the incidence 
of opportunistic infection, demyelinating syndromes and autoimmune conditions like 
lupus. A recent report by Jan Lin et al (Lin et al., 2008) has discussed in detail about the 
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adverse effects induced by TNFα blockade which clearly indicates the limitations of the 
use of such biopharmaceuticals. The lack of responsiveness to certain disorders, 
susceptibility to infections and resistance on long-term use has increased the look out for 
alternative therapeutic agents.  
The search led to the consideration of signaling molecules and mediators 
regulating inflammatory signals and responses as potential targets. Mediators and 
molecules involved in various pathways triggered by TNFRs including that of the MAPK 
and NFκB has gained attention in the recent past. TNFα blockade by inhibiting its 
production and molecules involved in the TNFα-triggered signaling pathways  such as 
PDE4, p38 MAP-kinase and NFκB inhibitors are currently being explored (Palladino et 
al., 2003).  Especially compounds targeting specific molecules of these pathways such as 
p38 kinase inhibitors and IKK inhibitors are in various stages of drug development 
including clinical trials. The present status and future in the treatment of inflammatory 
diseases by targeting signal transduction has been well discussed by O’Neill LA (O'Neill, 
2006). The advancements in the elucidation of signaling pathways have increased the 
choice of such targets. Identification of suitable and predictable targets for intervention in 
TNFα-associated inflammatory disorders requires a more detailed understanding of the 





1.3 Phospholipase D (PLD) 
Phospholipase D (PLD) is a membrane associated enzyme. It is a phospholipid 
specific phosphodiesterase that hydrolyzes phosphaditylcholine (PC) to form 
phosphatidic acid (PA) and choline. PLD hydrolyzes the terminal diester bond of PC to 
liberate a bioactive phosphatidic acid and water soluble relatively inert free polar head 
group, Choline (Exton, 2002a; Exton, 2002b; Pelech and Vance, 1984).  PLD 
superfamily was found to be expressed in bacteria, viruses, plants, yeast, animals and 
humans (Liscovitch et al., 2000). PLD type activity was first observed in carrot extracts 
(Hanahan, 1947). It was observed in mammalian system much later in rat brains (Saito et 
al., 1975). Now, there is accumulating evidence that PLD and its product PA are 
associated with a range of homeostatic and pathologic processes like inflammatory 
conditions, diabetes and oncogenesis (Huang and Frohman, 2007).  
 
1.3.1 Phospholipase D metabolic pathway 
Phosphatidic Acid (PA) produced by the hydrolysis of PC by PLD can be 
converted into diacyl glycerol (DAG) by the family of enzymes known as phosphatidic 
acid phosphohydrolases (PAP) (Brindley and Waggoner, 1996; Brindley and Waggoner, 
1998; Sciorra and Morris, 1999). Therefore, activation of PLD led to an increase in the 
levels of both PA and DAG. The DAG thus produced can be converted back to PA via 
phosphorylation by diacylglycerol kinases (DGKs). The activities of PAP and DGK 
tightly control the regulation of PA and DAG levels and their resulting responses. In 
addition, PA can be converted to form lysoPA (LPA) by the action of phospholipase A 
(PLA)(Tang et al., 1997). LPA can also be reconverted to PA by lysophosphatidic acid 
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acyltransferases (LPAAT). Figure 1.2 illustrates the mentioned PLD mediated lipid 
metabolite conversion pathways. Along with PA, DAG and LPA as potent lipid based 
second messengers contribute to the effects attributed to PLD. It is well known that 
intracellular DAG is involved in the activation of both conventional and novel PKC 
isoforms (Hug and Sarre, 1993). The DAG produced by the PLD pathway is mono or 
unsaturated. DAG, which is also formed by the hydrolysis of PIP2 by Phospholipase C 
(Takai et al., 1979), is polyunsaturated, which is the form that activates PKCs in cells 
(Pettitt et al., 1997). The LPA formed can function as mitogen, thus inducing cell 
proliferation and survival (Moolenaar et al., 2004). PA is a potent second messenger and 
it is involved in the activation of PLC (Jackowski and Rock, 1989), P14K (Moritz et al., 
1992), Sphinogine kinase (Olivera et al., 1996) and GTPase activating proteins (Tsai et 
















1.3.1.1 Transphosphatidylation reaction 
A unique property of PLD is its ability to catalyze a transphosphatidylation 
reaction (Yang et al., 1967). The PLD catalyzed reaction is based on a phosphatidyl 
group transfer reaction. Normally, the phospholipid substrate acts as a phosphatidyl 
group donor and water acts as the phosphatidyl acceptor. However, in the presence of a 
short-chain primary aliphatic alcohol, PLD has the unique ability to utilize the alcohol as 
the phosphatidyl group acceptor instead of water (Heller, 1978). Thus, generating a 
phosphatidylalcohol and this reaction is called the transphosphatidylation reaction 
(Figure 1.3).  
In this reaction, the primary alcohol can either be ethanol or butan-1-ol. The 
preferential utilization of primary alcohol over water is due to the stronger nucleophile 
nature of the primary alcohol by at least 1000 fold. Due to their steric hindrance both 
secondary and tertiary alcohols do not have access to the binding pocket of PLD to 
catalyze this unique reaction. Therefore, they can be used as non-specific effector 
controls. Phosphatidylalcohols like phosphatidylethanol (PtdEtOH) or 
phosphatidylbutanol (PtdBut) are produced only by PLDs and the phosphatidylalcohols 
thus obtained are biologically stable and inactive. As a result this reaction could be used 
to determine or quantify the enzymatic activity of PLD specifically (Morris et al., 1997). 
This unique reaction can also be used to study the downstream events triggered by PLD 
via PA. Since, addition of alcohol shunts the phosphatidyl moieties to the production of 




























1.3.2 Isoforms and localization of PLD 
 The classical mammalian PLD enzyme family consists of two PLD isoforms, 
PLD1 and PLD2 (Hammond et al., 1995; Kodaki and Yamashita, 1997; Lopez et al., 
1998). Mammalian PLD1 and PLD2 are widely expressed in most of the tissues and the 
levels of expression vary based on tissue and cell types. There was a slight difference in 
the level of expression of the two isoforms in different tissues. PLD1 was found to be 
highly expressed in the heart, pancreas, spleen, small intestine, ovary, brain, placenta, 
uterus and liver, and relatively lower levels in lungs, skeletal muscle, kidney, thymus, 
prostate, testis and colon (Saqib and Wakelam, 1997). Placenta, thymus, prostate, ovary, 
Figure 1.3: Schematic representation of transphosphatidylation reaction unique 
to PLD 
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uterus, thyroid, spinal cord and trachea showed high PLD2 expression, whereas, liver, 
skeletal muscle, testis and brain had the lowest (Saqib and Wakelam, 1997). 
Structurally both the isoforms contain two HKD catalytic motifs which contribute 
to the enzymatic activity (Sung et al., 1997). The other conserved domains in PLD genes 
are the pleckstrin homology (PH) domain, phox consensus sequence (PX) and PI4,5P2 
binding site. The PH domain is necessary for the location of the protein (Sugars et al., 
2002) whereas, PX domain mediates protein-protein interaction (Xu et al., 2001). A 
conserved loop region which functions as a negative regulatory element  was found in 
PLD1 and not in PLD2 (Sung et al., 1999a; Sung et al., 1999b). 
Reports on the subcellular distribution of PLD1 and PLD2 are varied. PLD was 
reported to be in cellular membranes including the ER, Golgi, vesicles, plasma membrane 
and the nuclear envelope based on biochemical activity (Liscovitch et al., 1999).  PLD1 
was reported to localized in the perinuclear region, ER, golgi, endosomes, secretory 
granules and plasma membrane (Brown et al., 1998; Colley et al., 1997; Freyberg et al., 
2001; Lucocq et al., 2001; Sung et al., 1999b; Toda et al., 1999). Recent reports have 
described PLD1 translocating to the plasma membrane subsequent to stimulation (Brown 
et al., 1998; Du et al., 2003). PLD2 has been reported to be associated with the plasma 
membrane, cytosol and submembranous vesicles (Colley et al., 1997; Divecha et al., 
2000; Du et al., 2004; Honda et al., 1999). It was also found to translocate to the 





1.3.3 Activation and regulation of PLD 
Ligand mediated activation of cell surface receptors are known to generate lipid 
based intracellular signaling molecules from cellular phospholipids (Divecha and Irvine, 
1995; Steed and Chow, 2001). This includes the action of PLD on PC to generated PA 
and DAG. It is reported that PLD activity is regulated by a group of factors which 
includes phosphoinositides, Protein kinase C (PKC), ADP-ribosylation factor (ARF), Rho 
GTPases, protein phosphorylation and lipidation (McDermott et al., 2004). However, the 
exact mechanism of these factors in the regulation of PLD activity is far from clear. 
Phosphoinositides like PI4,5P2 are  required for the activation and regulation of 
both of the PLD isoforms (Colley et al., 1997; Hammond et al., 1995; Hammond et al., 
1997; Lopez et al., 1998). PI4,5P2  acts directly on PLD, as it is quite evident that there is 
a PI4,5P2 binding domain in both the isoforms. It is also said to play a role in the 
anchoring of PLD to the membranes during activation. Though other phosphoinositides 
like PIP3 can influence PLD activity, they are not as effective as PI4,5P2 (Hammond et 
al., 1997). 
PKC is another well reported essential regulator for PLD1 isoform. However, the 
actual mechanism and isoform selectivity is still unclear. It has been suggested that PKC 
regulated PLD through direct phosphorylation, interaction and also by other indirect 
mechanisms (Exton, 1997; Exton, 1999). The classical PKC have been found to activate 
PLD independent of their kinase activity. PLD is directly stimulated by PKCα and 
PKCβ (Hammond et al., 1997; Singer et al., 1996). However, inhibition of PLD activity 
via PKCδ has also been reported (Hornia et al., 1999).  
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PLD activity is regulated by a subfamily of GTPases, the ARF subfamily 
(Dascher and Balch, 1994; Shome et al., 1998). It has been reported the ARF directly 
activates both the PLD isoforms (Hammond et al., 1995; Lopez et al., 1998). However, 
accessory factors like guanine nucleotide exchange factors have been found to play a role 
suggesting its indirect regulatory role (Caumont et al., 1998; Lambeth et al., 1995). ARF 
has been strongly implicated in PLD mediated vesicular trafficking (Rothman and Orci, 
1992). 
PLD is also regulated by the Rho subfamily.  RhoGTPases like RhoA, Cdc42Hs 
and Rac1 have been found to activate PLD (Bowman et al., 1993; Singer et al., 1996). 
Rho proteins are said to regulate PLD by direct and indirect interactions. Rho is involved 
PLD mediated cytoskeletal changes (Ridley and Hall, 1992).  
The combined regulation of PKC, ARF and Rho has all been shown to have 
synergistic effect on the regulation of PLD1 activity. Receptor and non receptor tyrosine 
kinase, serine/threonine kinase, cAMP kinases are suggested to be involved in the 
regulation of PLD as well (Jenkins and Frohman, 2005). 
 
1.3.4 Cellular responses mediated by PLD 
PLD is known to mediate membrane trafficking including exocytosis and 
endocytosis. It reported to influence the structure of golgi, transport from ER to golgi and 
the release of secretory vesicles (Bi et al., 1997; Chen et al., 1997; Jenkins and Frohman, 
2005). PLD has been reported to be a key player in the exocytosis pathway in adipocytes, 
pancreatic beta cells, neuroendocrine cells and mast cells (Choi et al., 2002; Huang et al., 
2005; Humeau et al., 2001; Waselle et al., 2005). PLD has been associated with 
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membrane fusion during exocytosis. This action can either be facilitated by PA either by 
functioning as a lipid anchor or as a fusogenic lipid (Honda et al., 1999; Kooijman et al., 
2003).  
PLD has been associated with the regulation of endocytosis and phagocytosis as 
well. This is shown clearly during endocytosis of EGFR. PLD recruitment and binding to 
dynamin stimulates GTP hydrolysis, accelerates the GTPase activity of dynamin. This in 
turn triggers membrane fission and clathrin-coated vesicle formation. This potentiates the 
endocytosis of receptor (Lee et al., 2006b; Shen et al., 2001). 
PLD is also associated with cell survival pathways and downregulation of its 
activity has been observed during apoptosis. The pro-survival is due to the role of PA and 
its direct downstream targets which includes sphingosine kinase (Olivera et al., 1996), 
mammalian Target Of Rapamycin (mTOR) – an effector of cell cycle progression and 
proliferation (Fang et al., 2001) and Raf-1 of mitogen activated protein kinase signaling 
pathway (Rizzo et al., 2000). mTOR has become a clear target of PA and is proposed to 
be parallel to the PI3K kinase survival pathway (Jenkins and Frohman, 2005). 
 
1.3.5 Role of PLD in immune and inflammatory responses 
 PLD has been shown to play an important role in the various effector responses 
like, NADPH oxidative burst, calcium release, phagocytosis, degranulation, cytokine 
release and chemotaxis in a variety of immune cells (Melendez and Allen, 2002). PLD 
activity is also required in signaling events triggered by a wide range of cytokines and 
chemokines, as well as by chemotactic peptides and chemotactic lipids in immune cells. 
PLD influences both Fcγ receptor mediated and peptide activated responses like 
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phagocytosis, oxidative burst and degranulation in neutrophils (Dana et al., 2000; Morgan 
et al., 1997; Yasui and Komiyama, 2001).  A similar effect with PLD regulating these 
responses were observed in monocytes and macrophage following cell surface receptor 
activation (Gillooly et al., 1999; Kusner et al., 1999; Melendez et al., 1998b; Melendez et 
al., 2001). PLD is involved in IgE-mediated functions in mast cells as well (Way et al., 
2000). T lymphocytes activation and responses are regulated by PLD activity (Bacon et 
al., 1995; Mollinedo et al., 1994). It is was also reported that the cross-linking of B cell 
receptor led to an increase in PLD activity (Hitomi et al., 1999). The activation of Natural 
Killer cells via CD16 and their triggered responses like degranulation was found to be 
dependent on PLD as well (Balboa et al., 1992; Milella et al., 1999). This clearly 
illustrates the functional importance of PLD in immune responses. 
 The relevance of PLD in health and disease led to the search of PLD inhibitors to 
harness its activity. Two fungal metabolites, Sch 53823 and Sch 53825 (Chu et al., 1996) 
and Fodrin, a non-erythroid form of spectrin (Lukowski et al., 1996) was reported to 
inhibit PLD activity. Rat brain synaptojanin was stated to act as a potent PLD1 inhibitor 
(Chung et al., 1997).  α, β, γ - synuclein was  found to inhibit PLD2 (Jenco et al., 1998; 
Payton et al., 2004). Recently, a new pharmacological inhibitor, FIPI has been identified 
which inhibits PLD activity and its associated responses (Su et al., 2008). Despite the 
presence of these inhibitors, a more reliable way currently being followed to characterize 
the isoform specific role of PLD is by the use of antisense and RNA interference 
technology both in vitro and in vivo. However, pharmacological inhibitors against 
specific isoforms of PLD will certainly be benefical for both research purpose and 
therapeutics. 
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1.4 Sphingosine Kinase 
Sphingosine Kinase (SphK) is a unique lipid kinase and is a member of the family 
of sphingolipids, which in the recent past has gained increasing attention as key source of 
potent signaling molecules. The sphingolipid derived signaling mediators which includes 
Ceramide and Sphingosine – 1 – phosphate (S1P) are potent bioactive molecules which 
are being associated with both physiological and pathological responses (Hla, 2004; Hla 
and Maciag, 1990; Kappos et al., 2006; Kee et al., 2005; Kitano et al., 2006; Melendez, 
2008; Sekiguchi et al., 2008). These molecules are major contributors in cellular 
processes like proliferation, apoptosis and differentiation (Melendez, 2008; Spiegel and 
Milstien, 1995; Spiegel and Milstien, 2002; Spiegel and Milstien, 2003). 
 
1.4.1 Sphingolipid metabolic pathway 
The sphingolipid metabolism is associated with the generation of the above 
mentioned bioactive molecules.  Ohanian and Ohanian in their review has discussed the 
sphingolipid metabolic pathway very lucidly (Ohanian and Ohanian, 2001). The initial 
bioactive metabolite generated in this metabolic pathway is ceramide. It is produced via 
the hydrolysis of sphingomyelin (a major membrane sphingolipid) by sphingomyelinase. 
Ceramide is also generated by the condensation of serine and palmitoyl-CoA in an 
alternative pathway. The produced ceramide in turn becomes a precursor to the other 
bioactive molecule, S1P. Ceramide is hydrolyzed by ceramidases to form sphingosine or 
phosphorylated to form ceramide – 1 – phosphate or can be converted back to 
sphingomyelin by sphingomyelin synthase. Sphingosine generated via ceramide is then 
phosphorylated by sphingosine kinase to form S1P (Spiegel, 1999; Spiegel and Milstien, 
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2002) and sphingosine on the other hand can also be converted back to ceramide by 
ceramide synthase. Ceramide – 1 – phosphate can be dephosphorylated back to ceramide 
by lipid phosphate phosphatase (LPP). Sphingosine-1-phosphate can also be 
dephosphorylated by S1P phosphatases or LPP to yield sphingosine. S1P can be cleaved 
by S1P lyase to from hexadecanal and phosphoethanolamine. The sphingolipid 












It is evident that SphK is an important player in the sphingolipid metabolism, 
because it modulates the relative levels of S1P, sphingosine and ceramide which 
determines the cell fate. Ceramide has been associated with cellular death, arrest and 
differentiation (Hannun, 1994; Kolesnick and Kronke, 1998). On the contrary, the other 
sphingolipid metabolite, S1P is known to be involved in cellular survival, proliferation 
Figure 1.4: Schematic representation of the Sphingolipid metabolic pathway  
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and angiogenesis (Spiegel and Milstien, 1995; Spiegel and Milstien, 2002; Spiegel and 
Milstien, 2003). 
 
1.4.2 Isoforms and localization of SphK 
SphK do not share homology with other lipid kinases and are evolutionarily 
conserved (Labesse et al., 2002; Liu et al., 2002). They are expressed in humans, mice, 
yeast, bacteria and plants. There are two mammalian isoforms (SPHK1 and SPHK2) that 
have been cloned, sequenced and characterized (Kohama et al., 1998; Liu et al., 2000; 
Melendez et al., 2000). They are found to possess a unique kinase catalytic domain, an 
ATP-binding site and as well as five conserved domains (Kohama et al., 1998; Liu et al., 
2000; Melendez et al., 2000). The two isoforms have distinct cellular functions due to the 
difference in kinetic properties, tissue distribution and temporal expression pattern during 
development (Spiegel and Milstien, 2003). Erythro-sphingosine, sphinganine and 
phytosphingosine are the only set of lipids which get phosphorylated by these two 
isoforms (Kohama et al., 1998; Liu et al., 2000; Melendez et al., 2000; Ozaki et al., 
2003). SphK1 has a lower molecular weight and possesses a higher enzymatic activity 
than SphK2 (Billich et al., 2003). 
The localization of SphK was originally thought to be cytosolic but it is shown 
that the subcellular localization and distribution of SphK would differ based on the 
organs and tissue type (Olivera et al., 1998). Reports have also shown that on activation 
SphK can re-localize from the cytosol to the cell membrane (Ibrahim et al., 2004; 
Johnson et al., 2002; Melendez and Ibrahim, 2004; Melendez and Khaw, 2002). This 
could be due to the presence of its substrate in the plasma membranes. In addition, 
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Ca+/Calmodulin has been reported to assist SphK in this translocation process (Young et 
al., 2003). SphK1 was reported to be highly expressed in the brain, heart, thymus, spleen, 
kidney and lung (Melendez et al., 2000). The highest expression of SphK2 was reported 
to be in the kidney and liver (Liu et al., 2000). Reports have also been made that there are 
different isoforms present in mouse compared to other mammalian isoforms and they 
possess diverse properties and distribution patterns (Fukuda et al., 2003). 
 
1.4.3 Activation and regulation of SphK 
SphK can be activated by a variety of biological effectors like growth factors, 
hormones, cytokine, G protein couple receptors and other cell surface receptor activation. 
Ligand binding to the receptors like FcγR1 (Melendez et al., 1998b), FcεR1 (Melendez 
and Khaw, 2002),  fMLP receptor (Alemany et al., 1999), C5aR (Ibrahim et al., 2004; 
Melendez and Ibrahim, 2004), TNFR (Xia et al., 1998; Zhi et al., 2006) and PDGF 
receptors (Olivera et al., 1999)  resulted in the activation of SphK in immune cells. The 
activation involves phosphorylation of SphK at Ser225 which results in the translocation 
of SphK from the cytosol to the cell periphery (Johnson et al., 2002; Pitson et al., 2002). 
This translocation is necessary because sphingosine, the substrate of SphK is primarily in 
the cell membrane. S1P is released following the action of SphK on sphingosine. S1P 
generated is one of the important functional metabolite of the sphingolipid pathway. 
Other regulatory mechanism in the activation of SphK include PLC induced Ca+ release 
(Van Koppen et al., 2001), PLD, PKC, protein-protein interaction and proteolysis (Taha 
et al., 2006). Phosphatidic acid, a bioactive molecule of phospholipid metabolism thought 
to have direct interaction with SphK to activate the latter (Olivera et al., 1996) 
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1.4.4 Cellular responses mediated by SphK 
The cellular responses regulated by SphK are primarily by its bioactive 
lysophospholipid metabolite, sphingosine – 1 – phosphate (S1P). The levels of S1P are 
tightly regulated by SphK, S1P phosphohyrdolase and S1P lyase (Olivera and Spiegel, 
2001). S1P acts both as an intracellular second messenger and as an extracellular ligand 
by binding to its specific receptors, S1P receptors (Pyne and Pyne, 2000; Spiegel and 
Milstien, 2002). As extracellular ligand, S1P acts by binding to G protein coupled 
receptor belonging to the endothelial differentiating gene (EDG) family and there are five 
receptors, S1P1 – S1P5 (Ozaki et al., 2003; Rosen and Goetzl, 2005).  S1P and its dihydro 
analogue can bind to these receptors with great affinity. In mammals S1P1 – S1P3 are 
found in all tissues, S1P4 is present only in the lungs and lymphoid organs and S1P5  is 
seen only in skin and brain (Melendez, 2008).  
S1P is known to activate diverse signaling transduction pathways to different 
stimuli in varied cell types. It regulates cell growth and proliferation by expediting the 
G1-S phase transition in the cell cycle and also by increasing DNA synthesis (Olivera et 
al., 1999). Its pro-survival profile is also due to its role in Ras and ERK1/2 signaling (Shu 
et al., 2002; Xia et al., 2000).  S1P required for cell growth is either produced by de novo 
synthesis or it is present as a pre-stored form. The latter is reported in the case of platelets 
with increased store of S1P with high SphK activity. This is due to high basal activity and 
the absence of degradative enzymes. In the event of tissue injury, the release of S1P gets 
activated by thrombin and collagen which function in an autocrine and a paracrine 
manner aiding repair (Yang et al., 1999; Yatomi et al., 1997). S1P aids in cellular 
survival, proliferation and angiogenesis (Spiegel and Milstien, 1995; Spiegel and 
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Milstien, 2002; Spiegel and Milstien, 2003). S1P has an anti-apoptotic role by opposing 
the apoptotic effects of ceramide and sphingosine. Thus, the balance between S1P and 
ceramide would play a greater role in  determining the fate of the cell as shown in the 











It is quite evident the calcium plays important roles in cellular processes and S1P 
has the potential to trigger intracellular calcium signals to render its varied functional 
responses (Alemany et al., 1999; Melendez et al., 1998b; Melendez and Ibrahim, 2004; 
Melendez and Khaw, 2002). SphK facilitated receptor mediated mobilization of cytosolic 
calcium which was dependent on PLC activation and was also found to be independent of 
IP3 (Choi et al., 1996; Melendez et al., 1998b; Zhi et al., 2006). S1P regulates cell 
motility and migration both by binding to the cell surface S1P receptors and as well as 
acting as a chemoattractant (Alemany et al., 1999; Kaneider et al., 2002; Spiegel and 
Milstien, 2003; Yanai et al., 2000). Therefore, it has been suggested that S1P is involved 
Figure 1.5: The Sphingolipid rheostat 
The representation showcases the crucial role SphK in determining 
cell fate by regulating the balance between S1P and ceramide. 
Image source (Spiegel and Milstien, 2003). 
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in inside and out signaling (Figure 1.6). Since, agonist / ligand binding to receptor induce 
the increase in intracellular S1P production. This in turn is released out of the cell after 
rendering its intracellular effects. Once outside the cell, S1P acts on its respective 
















Figure 1.6: S1P signaling 
The schematic representation of inside and out signaling by 
S1P. Image source (Spiegel and Milstien, 2003). 
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1.4.5 Role of SphK in immune and inflammatory responses 
Increase in SphK activity with S1P production are associated with responses like 
intracellular calcium release, cytokine – chemokine production, chemotaxis, super-oxide 
production, degranulation and increase in the expression of cell adhesion molecule in a 
variety of immune cells (Melendez, 2008). Extensive studies have implicated the role of 
SphK in intracellular signaling and responses in leukocytes such as, neutrophils (Ibrahim 
et al., 2004; Niwa et al., 2000; Vlasenko and Melendez, 2005), mononuclear cells like 
monocytes, macrophages (Melendez et al., 1998b; Melendez and Ibrahim, 2004; Zhi et 
al., 2006), mast cells (Choi et al., 1996; Melendez and Khaw, 2002) and T lymphocytes 
(Lai et al., 2008a; Matloubian et al., 2004; Pappu et al., 2007).   
SphK plays a role in neutrophil priming, activation and chemotaxis (Ibrahim et 
al., 2004; MacKinnon et al., 2002). SphK has also been reported to regulate the 
expression of various cell adhesion molecules both in leukocytes and endothelial cells 
which is necessary in immune cell infiltration (Xia et al., 1998). Consistent with this, Fc 
receptor and anaphylatoxin, C5a mediated responses in monocytes and macrophages 
were reported to depend on SphK1 activity (Melendez et al., 1998a; Melendez and 
Ibrahim, 2004). Similarly, IgE receptor mediated activation of mast cells, including its 
calcium release and its responses are mediated by S1P (Melendez and Khaw, 2002; 
Prieschl et al., 1999).  A more detailed study on the role of SphK isoform on mast cell 
activation has reported that SphK2 regulates mast cell activation and SphK1 increases the 
susceptibility to antigen challenge (Olivera et al., 2007).  SphK2 positively modulates the 
effect of IL-12 in T cell responses resulting in the production of IFNγ (Yoshimoto et al., 
2003). Moreover, S1P receptors play a role in the egress of lymphocytes from the 
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lymphoid organs and inhibition of S1P leads to the sequestration of lymphocytes in 
secondary lymphatic tissues (Brinkmann et al., 2001; Mori et al., 2007).  
Studies have also shown that blockade of SphK reduced the severity of 
inflammatory responses by inhibiting the production of proinflammatory cytokines 
(Ibrahim et al., 2004; Lai et al., 2008a; Lai et al., 2008b; Melendez et al., 1998b; 
Melendez and Ibrahim, 2004; Zhi et al., 2006) and chemotaxis (Ibrahim et al., 2004; 
Melendez and Ibrahim, 2004). The role of SphK and its isoform specificity in 
inflammation and immune responses in in-vivo has been well documented with use of 
both SphK inhibitors and RNA interference technology (Lai et al., 2008a; Lai et al., 
2008b; Lee et al., 2004a; Vlasenko and Melendez, 2005). 
SphKs can be inhibited by  inhibitors which are analogues of sphingosine, such as 
N,N-dimethylsphingosine (DMS) and DL-threo-dihydrosphingosine (DHS) (Buehrer and 
Bell, 1993; Edsall et al., 1998). However, these inhibitors are not very specific for SphKs 
and they also inhibit other enzymes at different concentrations. A latest inclusion in the 
list is FTY720, sphingosine analogue which is effective in improving graft survival and 
dampening the severity of autoimmune conditions in animals (Mansoor and Melendez, 
2008; Yanagawa et al., 1998). SphK2 specifically plays a role in the phosphorylation of 
FTY720 (Allende et al., 2004; Zemann et al., 2006) which is currently in the clinical 
trials for the management of renal transplantation and multiple sclerosis (Kieseier et al., 
2007; Tedesco-Silva et al., 2005). More analogues of sphingosine are being developed to 
obtain isoform specific inhibition of SphK for its potential therapeutic application. 
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1.5 Rationale & Aims 
 Inflammation is an important and highly relevant homeostatic host response. 
Dysregulation in this physiologic process contributes to the pathogenesis of inflammatory 
disorders with significant morbidity. TNFα has been identified as one of the major 
factors associated in such immune mediated inflammatory conditions. Alternate or 
additional therapies like harnessing the role of signaling mediators have been proposed to 
overcome certain set backs reported in the current anti-TNF therapies. Phospholipase D 
(PLD) and Sphingosine Kinase (SphK) have been proposed to be useful candidates in this 
approach. This is due to the fact that PLD and SphK are important lipid based signaling 
mediators whose role in the immune cell signaling and responses are being extensively 
explored. 
In this research study, we sought to elucidate the relevance of PLD in certain key 
TNFα-induced intracellular signaling events and responses. Antisense based in vitro 
studies will be performed to understand the isoform specific role PLD in the TNFα-
induced signaling events and responses in vitro. The study will also include studying the 
signaling hierarchy between PLD and SphK. The in vivo roles of these inflammatory 
mediators (PLD & SphK) will be studied using RNA interference in a TNFα−induced 
peritonitis model in mice. 
The working hypothesis and strategy is that inhibition or knock down of the 
mentioned lipid based signaling mediators would reduce the degree of TNFα-induced 
inflammatory responses. Targeting these mediators can be potentially used in the 
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dampening of aberrant inflammatory response and hence can be used in the management 
of TNFα-associated inflammatory conditions (Figure 1.7). 
 
 





2. Materials and Methods 
2.1 Chemicals and Reagents 
The chemicals and reagents listed were purchased from the following companies. 
• Sigma-Aldrich, Singapore 
o RPMI 1640, IFNγ, L-glutamine, Iodine crystals, Leupeptin, Pepstatin, 
Aprotinin, PMSF, Penicillin/Streptomycin antibiotic cocktail, 
Sphingosine, Sphingosine-1-phosphate, BSA, Tris-Base, HEPES, 
Glucose, Sodium Citrate, Sodium deoxycholate, Glycine, Glycerol, NaCl, 
MgCl2, NaHCO3, KCl, H2SO4, EDTA, EGTA, MgSO4, NaF, ZnCl2, H2O2, 
Bromophenol blue, Trypan blue dye, Bisindolylmaleimide I, rabbit 
polyclonal anti-PLD2 antibody, HRP or FITC conjugated antibodies, 4-
deoxypyridoxine, SB203580. 
• NUMI (National University Medical Institutes) Media Preparation Facility 
o 10 x PBS, SDS, Absolute ethanol, Acetic acid, Ethyl acetate, 1-Butanol, 
Chloroform, Methanol, β-Mercaptoethanol. 
• GE Healthcare Bio-Sciences, Singapore 
o ECL Western Blotting detection system, [H
3









• Santa Cruz Biotech, Santa Cruz, CA, USA. 
o Primary antibodies – mouse monoclonal anti-GAPDH (6C5), mouse 
monoclonal anti-Raf-1 (E10), mouse monoclonal anti-PLD1 (F12), rabbit 
polyclonal anti-PLD1 (H160), rabbit polyclonal anti-PLD2 (H133), rabbit 
polyclonal anti-ARF (H50), rabbit polyclonal anti-p38 (C20),  mouse 
monoclonal  anti-α tubulin (B7), rabbit polyclonal anti-VCAM (H276) 
and goat polyclonal anti-ICAM1 (E15). 
o Secondary antibodies – goat anti-mouse IgG-HRP, , goat anti-rabbit IgG-
HRP, goat anti-mouse IgG-FITC, donkey anti-goat IgG-FITC and goat 
anti-rabbit IgG-FITC. 
• Cell Signaling Technology, Danvers, MA, USA. 
o Primary antibodies – mouse monoclonall anti-phospho ERK1/2 (Thr 
202/Tyr204; E10), mouse monoclonal anti-phospho p38 (Thr180/Tyr182; 
28B10), mouse monoclonal anti-IκBα (L35A5). 
• Exalpha Biologicals, Inc, MA, USA. 
o Primary antibodies – Rabbit polyclonal anti-SphK1. 
• Calbiochem, Merck, Singapore 
o N,N-dimethylsphingosine, Na3VO4, PD98059, t-butanol, Protein A-
agarose. 
• Bio-Rad Laboratories, Singapore  
o Triton-X 100, Tween-20, Ammonium persulphate, 30% Bis-acrylamide, 
TEMED, Kaleidoscope protein standard. 
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• Molecular Probes, Invitrogen, Singapore 
o FURA2-AM and FBS 
• Roche  Molecular Biochemicals, Singapore 
o Complete, Mini – Protease Inhibitor Cocktail Tablets 
• MP Biomedicals Inc, Singapore 
o Phosphatidylethanol and Phosphatidyl-1-butanol standard 
• Chemicon International, Temecula, CA, USA 
o QCM
TM
 Chemotaxis 3µM 96-well cell migration assay kit 
• The following were purchased from PeproTech Inc.Rocky Hill, NJ, USA 
o Recombinant human TNF and recombinant mouse TNF 
• The following were purchased from Pierce Biotech, Rockford, IL, USA 
o EZ-Detect
TM
 NFκB p65 transcription factor kit 
• The following were purchased from BD Biosciences, San Jose, CA 
o OptEIA
TM
 Cytokine kits and BD Mercury
TM
 TransFactor Profiling Kit 
(NFκB p50 Kit and NFκB p65 Kit) 
• The following were purchased from Qiagen, Valencia, CA 
o siRNAs (mouse  SphK1 and mouse PLD1) 
• The following were purchased from Avanti Polar Lipids, Inc., Alabaster, AL 
o Sphingosine-1-phosphate standard 
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2.2 Solutions and Buffers 
• RIPA buffer for total cell lysate preparation 
o 50 mM Tris-HCl (pH 7.4), 150 nM NaCl, 1 mM EDTA, 0.25% sodium 
deoxycholate, 1%NP-40, 1 mM PMSF, 1mM Na3VO4, 10 µg/ml 
leupeptin, 10 µg/ml pepstatin A, 10 µg/ml aprotinin 
• Sphingosine kinase assay buffer 
o 20 mM Tris-HCl (pH7.4), 1 mM β-mercaptoethanol, 1mM EDTA, 20% 
glycerol, phosphatase inhibitors (20mM ZnCl2, 1 mM sodium 
orthovanadate and 15 mM sodium fluoride), protease inhibitors (10 µg/ml 
leupeptin, 10 µg/ml pepstatin A, 10 µg/ml aprotinin and 1 mM PMSF) and 
0.5 mM 4-deoxypyridoxine 
• Sphingosine kinase assay running buffer 
o 1-butanol, ethanol, acetic acid and distilled water in the ratio of 
80:20:10:20) (v:v:v:v) 
• PLD assay running buffer 
o Ethyl acetate, iso-octane, acetic acid and distilled water in the ration of 
65:10:15:50 (v:v:v:v) 
• Lysis buffer for nuclear extract preparation 
o 10 mM HEPES (pH7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 




• Extraction buffer for nuclear extract preparation 
o 10 mM HEPES (pH7.9), 0.4M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM 
DTT and 1 mM PMSF. 
• Buffers used in ELISA 
o Coating buffer – 1M NaHCO3 in 1 x PBS  
o Assay buffer – 1% FBS in 1 x PBS 
o Washing buffer – 0.05% Tween-20 in 1 x PBS 
o Substrate solution – 1 tablet of TMB in 10ml of 0.05M citrate phosphate 
buffer (in 1xPBS) and 2 µl of 30% H2O2. 
o Stop solutions – 1M H2SO4 
• Buffers used in SDS-PAGE Gel electrophoresis and Western Blot 
o Resolving gel – Distilled water, 30% bis-acrylamide, 1.5M Tris (pH 8.8), 
10% SDS, 10% APS, TEMED. 
o Stacking gel – Distilled water, 30% bis-acrylamide, 1M Tris (pH 6.8), 
10% SDS, 10% APS, TEMED. 
o Running buffer – 25mM Tris base, 250mM glycine(pH 8.3), 0.1% SDS 
o Loading buffer – 50mM Tris-HCl (pH 6.8), 100mM β-mercaptoethanol, 
2% SDS, 0.1% bromophenol blue, 10% glycerol. 
o Transfer buffer – 48mM Tris base, 39mM glycine (pH 8.3), 0.037% SDS, 
20% Methanol. 
o Washing buffer – 0.1% Tween-20 and 1 x PBS 
• HEPES Ca2+ supplemented buffer for calcium assay 
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o 145 mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM CaCl2, 10mM HEPES, 
0.18% Glucose, 0.2% BSA. 
• MACS buffer 
o 2 mM EDTA in 1 x PBS. 
 
2.3 Cells  
The U937 cell line was chosen as the monocytic cell model for the study. U937 
cells (pro-monocytic cells) were cultured in RPMI 1640 (Gibco, Rockville, MD) 
supplemented with 10% Fetal Calf Serum (FCS), 1% glutamine, 150 units/ml penicillin, 
and 150 µg/ml streptomycin at 37°C in 5% carbon dioxide in a water-saturated 
atmosphere. Differentiation of these pro-monocytic cells to attain a monocytic phenotype 
was established by treating the cells with Interferon-γ (200 ng/ml) for 16 hours prior to 
experiments. Cell viability was determined using Trypan blue and morphology was 
observed using a light microscope to ensure the state of the cells prior to all experiments. 
 
2.4 Isolation of human peripheral blood monocytes 
Human peripheral blood monocytes were isolated from heparinized venous blood 
obtained from fasting healthy donors. Initially peripheral blood mononuclear cells 
(PBMCs) were isolated from whole blood using Ficoll-Hypaque density gradient 
centrifugation. During this process, owing to the density differences between 
mononuclear cells and other cells in whole blood, the mononuclear cells would collect on 
top of the Ficoll-Hypaque layer due to their lower density. In contrast, red blood cells and 
granulocytes which have higher density would collect at the bottom of the Ficoll-
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Hypaque layer.  This was done by carefully layering heparinized whole blood on Ficoll-
Paque
TM
 (GE Healthcare Bio-Sciences, Singapore) gradient (density – 1.077 g/liter) and 
centrifuging at 500 x g, without brakes for 30 minutes at room temperature. The PBMC 
layer above the Ficoll was gently aspirated and washed three times with sterile 1 x PBS 
and the number of cells were counted using a hemocytometer. 
To meet the demands of our objective to conduct functional studies, including 
cytokine secretion in primary monocytes, required obtaining untouched or monocytes 
that are not already activated. Therefore, we also used the Monocyte Isolation Kit II 
human (Miltenyi Biotec Inc, Auburn CA, USA.) which uses the magnetic cell sorting 
(MACS) principle to isolate human monocytes from the PBMCs. This kit involved the 
isolation of monocytes by depleting non-monocytes (negative selection) from PBMCs. 
Non-monocyte PBMCs are indirectly magnetically labeled with a mixture of biotin 
conjugated monoclonal antibodies specific for lineage marker and anti-biotin monoclonal 
antibodies conjugated to the microbeads. When such magnetically labeled PBMCs are 
passed through the column in a magnetic field, the magnetically labeled non monocytes 
are retained in the column and only the unlabeled monocytes will pass through the 
column to be collected in the eluate. The step by step protocol and sample preparation 
was performed by strictly following the procedures and instruction provided by the 
manufacturer along with the kit. This technique is considered to be more appropriate to 
our experimental design as it provides highly pure monocyte population. It also prevents 
the activation of monocytes compared to those isolated by MACS assisted positive 
selection of monocytes or by adherence. 
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The isolated monocytes were then washed three times with plain RPMI 1640 
medium and resuspended in the RPMI culture medium (mentioned in section 2.3) and 
incubated at 37°C in 5% carbon dioxide in a water-saturated atmosphere. Cell viability 
was determined by Trypan Blue prior to all the experiments. 
 
2.5 TNFα stimulation 
The required numbers of cells based on the experiments planned were suspended 
in culture RPMI 1640 medium prior to stimulation. The cells were either kept untreated 
or pretreated with various inhibitors as per the experimental design. The cells were then 
stimulated by the addition of recombinant human TNFα 10 ng/ml (PeproTech Inc.Rocky 
Hill, NJ, USA.) and incubated at 37°C in 5% carbon dioxide in a water-saturated 
atmosphere for the various time points indicated. 
 
2.6 Measurement of Phospholipase D activity 
The characteristic feature of PLD is a transestrification reaction – 
transphosphatidylation, in the presence of a primary alcohol. This reaction yields a 
biologically stable and inert phosphatidyl-alcohol instead of the second messenger, PA 
(Jenkins and Frohman, 2005; McDermott et al., 2004; Steed and Chow, 2001). A detailed 
description of this reaction can be seeen chapter 1, section 1.3.1.1.  PLD activity 
measurement in intact cells can be done by overnight radiolabeling of endogenous 
substrates, followed by the addition of an extracellular stimulus in the presence of a 
primary alcohol. Subsequent to this process, detection and quantification  of the 
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metabolically stable phosphatidyl alcohols produced by PLD catalyzed reaction can be 
performed (Morris et al., 1997).  
Briefly, the cells were labeled (10
6
 cells/ml) with [
3
H] Palmitic acid (5 µCi/ml) 
(GE Healthcare Bio-Sciences, Singapore) in the cell culture medium for 16 hours. 
Following washing with ice cold medium, the cells were incubated at 37°C for 15 
minutes in culture medium containing 0.3% of either one of the primary alcohols (1-
Butanol or Ethanol) and incubated with inhibitors if any, based on the experiments 
planned.  The cells were then stimulated by TNFα over the desired time indicated at 
37°C. The cellular lipids were extracted by Bligh-Dyer phase separation (Bligh, 1959). 
An aliquot of the lower organic phase was obtained from all the samples to determine the 
content of radioactivity in the total lipid fraction and equal amount of aliquot was also 
taken from the phase to quantify the product generated. Phosphatidylalcohol (PtdOH) like 
Phosphatidylethanol (PtdEtOH) or Phosphatidyl-1-butanol (PtdBut-1-ol) standard was 
added to all the latter samples and dried under vacuum (Savant ISS110). The lipid 
containing samples were then re-dissolved in 50 µl of 19:1 (v:v) chloroform/methanol 
and spot dropped on pre-run, heat-activated thin-layer chromatography plates – TLC 
silica gel G60 plates (Whatman, Maidstone, UK). The separation was initiated by placing 
the plates in the organic phase of the solvent (ethyl acetate/ iso-octane/acetic acid/water) 
for around 90 minutes and the separated phosphatidylalcohol product was detected by 





H]PtdOH) containing silica was scraped into vials containing scintillation fluid and the 
amount of radioactivity was quantified by liquid scintillation spectrometry using a 
scintillation counter (Wallace 1414 WinSpectral Liquid Scintillation Counter, 
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2.7 Fluorescent microscopy 
Cellular re-localization or translocations of PLD isoforms and Raf-1 in response 
to TNFα were analyzed using fluorescent microscopy. After TNFα stimulation, the 
suspended cells were fixed in 4% paraformaldehyde and deposited on microscope slides 
using a cytospin centrifuge. They were then permeabilised for 5 min in 0.1% Triton X-
100 in PBS. The permeabilised cells were blocked for non-specific binding with 5% Fetal 
Calf Serum for 10 min at room temperature. Fluorescent labeling was performed by 
incubating the cells with relevant primary antibodies specific for the targets of interest for 
1 hour at room temperature. The cells were washed with PBS and then incubated with 
appropriate FITC conjugated IgG based secondary antibodies. To a set of cells, only the 
secondary antibodies were added as control. Stainings were visualized with an inverted 
fluorescence Leica DM IRB microscope and the images were captured using a Leica DC 
300F digital camera. The images were analyzed with the Leica IM500 Image Manager 
software 
 
2.8 Measurement of cytokine production. 
A total of 2 x10
6 
cells/ml per category of differentiated U937 (monocytic cells) 
and human peripheral blood monocytes pretreated with appropriate inhibitors were 
stimulated with TNFα 10 ng/ml for 24 hours. At the end of the time point the cell 
suspension were centrifuged and the supernatants were collected and stored in -20°C until 
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further use. Human IL-6 and human IL-1β were measured using OptEIA
TM
 Kit (BD 
Biosciences, San Jose, CA, USA) and by strictly adhering to manufacturer’s instructions 
and protocol. The levels of mouse IL-6, mouse MIP-1α and mouse MIP-1β in the 
peritoneal lavage and serum were measured using mouse IL-6, mouse MIP-1α and mouse 
MIP-1β OptEIA
TM
 Kit (BD Biosciences, San Jose, CA, USA) and by strictly adhering to 
manufacturer’s instructions and protocol. 
 To briefly explain the procedure, a 96-well ELISA plate was initially coated with 
the relevant or specific capture antibody in coating buffer and incubated at 4°C overnight.  
The following day, the plate was washed three time with ELISA wash buffer (0.5% 
TWEEN in 1 x PBS) and tapped dried to remove the remaining wash buffer from the 
wells. This was followed by two hour incubation with ELISA blocking buffer at room 
temperature. The plate was washed as described earlier. Relevant standards were added 
by serial dilution to the designated wells and finally 50 µl of the supernatant is added to 
the marked well and incubated for 2 hours at room temperature. The plate was again 
washed as described earlier and incubated with detection antibody for 1 hour. This is 
followed by another round of washing and then enzyme concentrate; avidin-HRP added 
to all of the wells and incubated in the dark for half an hour. The plate was then washed 
six times and incubated in the dark for another half hour with 100 µl of TMB substrate. 
This reaction was quenched by the addition of 100 µl of 1M H2SO4. The OD (Optical 
Density) was then measured using a spectrophotometer (TECAN SpectrophorPlus) at 450 
nm. Based on the raw OD data obtained, a standard curve was plotted and the 
concentrations of each cytokine were then calculated.   
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2.9 Cell migration assay 
Chemotaxis of monocytes were assayed using the Chemicon QCM
TM
 Chemotaxis 
3 µm 96-well Cell Migration Assay Kit (Cat no. ECM 515; Chemicon International, 
Temecula, CA, USA) following manufacturers instructions. A total of 2 x 10
5
 cells were 
used per sample and TNFα at a concentration of 10ng/ml was used for the migration 
assays. To explain the principle of the experiment briefly, the assay utilizes 3 µm pore 
size Boyden chambers. The cells were loaded in the upper chamber and the TNFα was 
placed in the lower chamber and then the cells were incubated for 24 hours at 37°C. 
Following manufacturer’s instruction the cells in the lower chamber, considered to have 
migrated from the upper chamber were collected, lysed and detected using the CyQuant 
GR dye provided. This dye when bound to cellular nucleic acid is said to exhibit a strong 
green fluorescence which can be measured by a fluorescence plate reader using 480/520 
nm filter set.  To convert the OD values to number of migrated cells, known number of 
cells were lysed and OD values detected using the dye. These OD values were used to 
plot the standard curve and by plotting the OD values of the sample along the standard 
curve, the number of migrated cells can be determined.  
 
2.10 Cell viability assay 
The viability of cells following incubation with the various inhibitors and TNFα 
were determined using MTT; 3-(4, 5-Dimethylthiazol-2-yl)-2, 5 Diphenyltetrazolium 
assay (Sigma Aldrich, Singapore). Briefly, 1 × 10
4
 viable cells were added to each well of 
a 96 well culture plate (Nunc, Denmark) containing 100 µl medium with relevant 
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inhibitors or TNFα and incubated for 24 hours at 37°C in a 5% CO2. After the incubation 
period, 50 µl of the MTT solution (4 mg/ml in plain RPMI) was added to each well and 
the cells were incubated at 37°C for 2 hours in the dark. The cells are attached to the floor 
of the wells by centrifugation and the supernatant is aspirated and discarded. The 
resulting formazan crystals were dissolved by the addition of 190µl of dimethylsulfoxide 
– DMSO (Sigma Aldrich, Singapore) and 10µl of Sorenson’s glycine buffer and the 
absorbance of each well was measured at 570 nm in a plate reader (TECAN 
SpectrophorPlus) Cell death or survival was estimated based on the difference in the OD 
values between the controls and the treated categories. 
 
2.11 Gel electrophoresis and Western blot analysis 
This technique was used to assess the level of PLD isoforms, SphK1, TNFα 
induced phosphorylation of ERK1/2, p38 and TNFα induced IκBα degradation and to 
investigate the role of PLD in these events. Briefly, the treated and their control cells 
were lysed with 1 x RIPA buffer and then the amount of protein quantified using 
Bradford assay. Subsequently 40µg of the lysate for each category was then resolved in 
polyacrylamide gels (SDS-PAGE). Lower molecular weight proteins were resolved on 
12% Polyacrylamide gels (SDS-PAGE) and higher molecular weight proteins were 
resolved in lower percentage gels, under denaturing conditions and then transferred to 
PVDF membranes. The PVDF membranes (Millipore, Billerica, MA, USA) were handled 
as per the manufacturer’s instructions. The membranes were incubated with the relevant 
primary antibodies for 2 - 4 hours at room temperature and appropriate horseradish 
peroxidase–conjugated secondary antibody at room temperature for another 2 - 4 hours. 
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The membranes were washed with washing buffer (1% Tween 1x PBS) three time for 5 
minutes after primary and secondary antibody incubation. The bands were visualized by 
autoradiography using ECL Western Blotting Detection System (Amersham, 
Buckinghamshire, United Kingdom). 
 
2.12 Immunoprecipitation 
Phospholipase D isoforms were immunoprecipated to evaluate its knock down efficiency. 
PLD isoform specific antibodies were made to form complexes with Protein A-agarose. 
In order to achieve these complexes, the specific antibodies were incubated with 50% 
slurry agarose and rocked at 4°C for 2 hours. Cell lysates were prepared from the cells as 
descirbed earlier. The cell lysates were precleared by incubating with the protein A-
agarose for 30 minutes under the rocking condition and the agarose was subsequently 
removed. The collected lysates were then incubated with the PLD isoform specific 
antibody-Protein A-agarose complex (prepared earlier), for 4 hours at 4°C. The unbound 
complexes were removed and washed three times with ice-cold 1 x PBS before resolving 
the precipitated complexes using SDS-PAGE gel electrophoresis and western blotting. 
 
2.13 Measurement of Sphingosine kinase activity 
SphK activity was measured in monocytes after TNFα stimulation at the indicated 
time points. The cells were either untreated or pretreated with inhibitors or antisense 
oligonucleotides prior to TNFα stimulation and SphK activity was measured in cell 
extracts by an assay which is based on the SphK catalyzed transfer of the γ-phosphate 
group of ATP to a specific substrate. This was done by using a mixture of cold ATP (non 
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radio-labeled ATP) and radio-labeled [γ
32
P] ATP (GE Healthcare Biosciences, 
Singapore) (Melendez et al., 1998b; Olivera et al., 1994).  
Subsequent to TNFα stimulation, the reaction was stopped by the addition of ice-
cold PBS. The cells were centrifuged and resuspended in ice cold SphK buffer. This was 
followed by the lysing of the cells using repeated freeze thaw cycles. The supernatant 
collected after high speed centrifugation was used to measure the sphingosine kinase 
activity. The assay was performed by incubating with Sphingosine (Sigma-Aldrich, 
Singapore) and [γ
32
P] ATP (1 µCi/sample) as indicated (Olivera et al., 1994). 80 µg of 
cell or the sample lysate was placed in glass tubes and kept on ice, 10 µl of Sphingosine–
BSA complexes were added. The reaction mixture was then supplemented with SphK 





P] γ-ATP with unlabeled ATP-MgCl2) was added. Reactions were initiated 
by placing the samples in 37°C for 30 minutes. The lipids were extracted by adding of 
chloroform: methanol : HCl (100 : 200 : 1, v/v) to the sample mixture and incubated at 
room temperature for 5-10 minutes. The organic and aqueous phases were separated by 
the addition of chloroform and KCl. This mixture was mixed well and incubated at room 
temperature for 5-10 minutes followed by a 5-10 minutes centrifugation at 400g. 50 µl of 
samples from the organic phase, which contain radio-labeled S1P, were spotted onto a 
thin-layer chromatography plates – TLC silica gel G60 plates (Whatman, Maidstone, 
UK). The products were separated on TLC plates in the presence of Sphingosine kinase 
running buffer. The radioactive spots were analyzed using autoradiography by exposing 
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the plate to a Tyhoon scanner and Typhoon phosphor imager was used to measure the 
intensity of the radioactive signals which would reflect Sphingosine kinase activity. 
 
2.14 Measurement of NFκB activity 
NFκB activation was determined directly by measuring the levels of p65 and p50 
subunits of the NFκB complex in the nucleus, as it is well known that, these subunits 
translocate from the cytosol to the nucleus on activation. NFκB activity was analyzed in 
the cells subsequent to TNFα (10 ng/ml) stimulation for 30 minutes at 37°C, in resting 
cells and in those pretreated with various inhibitors prior to TNFα stimulation. NFκB 
activity was analyzed using the EZ-Detect
TM
 NFκB p65 Transcription Factor Kit (Pierce 
Biotechnology, Rockford, IL, USA) and BD Mercury™ TransFactor Kits (BD 
Biosciences, San Jose, CA, USA)  for both p50 and p65 subunits following the 
manufacturer’s instructions. The determination of the presence or increase in the amounts 
of NFκB subunits in the nucleus were analyzed using an ELISA based technique.  The kit 
is provided with a 96-well format with the bound biotinylated-consensus sequence for the 
respective subunits. The biotinylated-consensus duplexes will bind only to the active 
forms of the transcription factor subunits of interest. This system improves the 
specificity.  
Subsequent to stimulations the cells were washed with 1 x PBS and then lysed 
using the cell lysis buffer and centrifuged at 10,500 rpm for 20 mins at 4°C. The 
supernatant is the cytosolic fraction, is collected in a separate tube. The remaining crude 
nuclear pellet is then treated with nuclear extraction buffer and centrifuged at 13,000 rpm 
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for 5 minutes at 4°C. The supernatant obtained is the nuclear extract is collected in a 
fresh tube and stored at -20°C prior to its use. Bradford assay was done to estimate the 
protein concentration in the nuclear extract. 20 µg of the nuclear extract was used for the 
assay by adding it to the pre-coated wells and incubated at room temperature for an hour. 
The plate was then washed using the wash buffer and the appropriate primary antibody 
(anti-p65 or anti-p50) was added to the wells and incubated for an hour on a shaker at 
room temperature. This is followed by another round of washing and incubated with HRP 
conjugated secondary antibody for another hour at room temperature. After washing, a 
luminol based chemiluminescent substrate or TMB provided with the relevant kits was 
added to the wells and the signals were detected using a luminometer or a 
spectrophotometer at the recommended OD.  
Another indirect method to assess NFκB activation was by determining the IκBα 
degradation after stimulation. Since, the phosphorylation and subsequent degradation of 
IκBα in the cytsol is essential for the translocation of the NFκB subunits from the cytosol 
into the nucleus. NFκB activity was also determined in the cells subsequent to TNFα (10 
ng/ml) stimulation by analyzing IκBα degradation after stimulation. The cells were 
stimulated up to various time points indicated and lysates obtained. Subsequent to protein 
estimation, western blot procedure was done using specific antibodies to observe the 
TNFα−induced IκBα degradation patterns, which is an upstream event to NFκB subunit 




2.15 Use of antisense oligonucleotides 
 The cells were incubated with 10 µM antisense oligonucleotides in presence of a 
transfection reagent (Superfect –  Qiagen, Valencia, CA, USA) for a total of 36 hours (20 
hours prior to the addition of IFN-γ and then for the another 16 hours in culture after the 
addition of IFN-γ for differentiation). Antisense oligonucleotides were purchased from 1
st
 
Base, Singapore.  24-mers were synthesized, capped at either end by the phosphothiorate 
linkages (first two and last two linkages) and corresponded to the reverse complement of 
the first 8 amino acids for either PLD1 or PLD2.  The sequences of the oligonucleotides 
were, 5`CCGTGGCTCGTTTTTCAGTGACAT 3` for human PLD1 and 
5`GAGGCTCTCAGGGGTCGCCGTCAT 3` for human PLD2. The knock down 
efficacy and specificity was determined using western blotting procedure as described in 
the earlier sections. 
 
2.16 Measurement of cytosolic calcium 
 Untreated monocytic cells or cells pretreated either with antisense to human 
PLD1 or human PLD2 prior to TNFα stimulation were incubated with 1 µg/ml of Fura2-
AM (Molecular Probes, Invitrogen, Singapore) in PBS, 1%BSA and 1.5 mM Ca
2+
 for 30 
minutes in the dark. Calcium was added to the medium to prevent the depletion of 
calcium from the intracellular stores prior to stimulation or onset of the experiments. 2 x 
10
6
 cells/ml was used per category. After incubation, excess reagents were removed and 
cells were suspended in the cuvette with calcium assay buffer and warmed to 37°C in the 
spectrofluorophotometer (Shimadzu RF-5301 PC). The measurements of calcium level at 
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basal was measured for a minute and then the stimulus (TNFα 10 ng/ml) was added to 
the cell suspension in the cuvette with a magnetic stirrer. The calcium levels were 
measured using ratiometric measurements. Since, the probe used exhibits significant 
fluorescence with differene in spectrum (on either side of isoemissive point) both before 
and after binding with Ca
2+
. The ratiometeric fluorescent measurements were obtained 
from signals recorded at 340 and 380 nm over few minutes before the reaction is stopped. 
The maximum (Rmax) and minimum (Rmin) fluorescence measurements necessary for the 
calculating the ratiometric difference indicate of Ca2+ release were obtained by the 
addition of ionomycin (to cause Ca2+ saturation) and EGTA (to remove Ca2+ from the 
probe) respectively.  
 
2.17 Mice 
All the in vivo experiments were carried out on male BALB/c mice (8–10 weeks 
old) weighing 20-25gms. The animals were obtained from the National University of 
Singapore, Sembawang Laboratory Animals Centre and housed in the animal holding 
unit at NUS prior to and during the experiments. The animals were housed in appropriate 
cages with free access to food and water. All the animal experiments performed in this 
study were conducted by strictly adhering to the guidelines stated by NUS Institutional 
Animal Care and Use Committee (IACUC). 
 
2.18 TNFα−induced peritonitis model in mice 
Acute inflammation in the peritoneal cavity of BALB/c mice was induced by the 
intraperitoneal (i.p) administration of recombinant mouse TNFα (PeproTech Inc.Rocky 
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Hill, NJ, USA). Based on dose response studies, the dose of rmTNFα of 5 µg/mouse in a 
final volume of 100 µl was chosen for the experiments. Three mice were used for each 
category (n=3) per experiment. All the basal category or control mice were injected (i.p) 
with 100 µl of sterile 1 x PBS. Experiments investigating TNFα response over time, lead 
to the choice of 2 hours after TNFα injection to assess the acute inflammatory responses. 
When the effect of SphK1 and PLD1 were investigated, TNFα intra peritoneal injections 
were administered after 72 hours subsequent to the onset of siRNA treatment, as 
described in the following section. The various factors analyzed were rectal temperature; 
Interleukin-6, MIP-1α and MIP-1β levels in the serum and peritoneal lavage; neutrophils 
infiltration into the peritoneal lavage; cellular infiltration pattern and the expressions of 
VCAM and ICAM1 in the peritoneal tissues adjacent to and at the site of inflammation or 
TNFα injection. All the mice were completely anaesthetized by 100µl intra peritoneal 
administration of ketamine and medetomidine mixture (Animal Holding Unit, NUS) prior 
to any painful or terminal procedure. 
 
2.19 siRNA administration and gene knock down of mouse SphK1 and mouse PLD1 
in vivo 
The mice were anesthetized and siRNAs were administered via intravenous tail 
vein injections. Prior to intravenous injections, the tail of the mouse was immersed in 
sterile warm water for few seconds to dilate the veins for efficient administration of the 
siRNA. Based on earlier invivo siRNA optimization experiments (Pushparaj et al., 2008), 
the dose of synthetic siRNAs injected was chosen as 4 µg/mouse in 100 µl of siRNA 
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diluting buffer and repetitive administration of a specific siRNA (three doses at 24 hours 
interval) was performed. The intravenous administration was done over 60 seconds using 
a sterile 30 gauge, 1 inch long needles. siRNA for mouse PLD1(mPLD1) were 
administered separately to knock down PLD1 in mice. siRNAs and the relevant negative 
controls were obtained from Qiagen, Valencia, CA, USA. The siRNA sequence used to 
knock down mouse PLD1 were (AGAGGUGGUUGAUAGUAAA)dTdT and 
(UUUACUAUCAACCACCUCU)dTdT  and a negative siRNA control (Allstar negative 
control) was used. siRNA for mouse SphK1(mSphK1) were administered separately to 
knock down SphK1 in mice. siRNAs and the relevant negative controls were obtained 
from Qiagen, Valencia, CA, USA. The siRNA sequence used to knock down mouse 
SphK1 were (GGGCAAGGCUCUGCAGCUC)d(TT)  and 
GAGCUGCAGAGCCUUGCCC)d(TT) and  scrambled siRNA sequences 
(GACUCCAAUGGACUGGCAU)d(TT) and (AUGCCAGUCCAUGGAGUC)d(TT) 
were used as  negative controls. The siRNAs were prepared and stored as per the 
technical instructions provided by the manufacturer. 
 
2.20 Rectal temperature measurement in mice 
Temperature changes in mice as a result of the induced inflammatory response 
were measured rectally using a digital rectal thermometer (Natsume Seisakusyo Co., 
Tokyo, Japan). The thermometer probe was dipped in oil prior to measurements. The 
mice were held in a custom built restrainer during the measurements. The probe was 
inserted into the rectum up to 2 cm deep and held in the same position for 15 seconds 
until a stable temperature read out was obtained. Rectal temperature changes were 
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recorded in untreated mice and in mice pretreated with or without siRNA prior to TNFα 
intra peritoneal injection at the time points indicated. 
 
2.21 Collection of peritoneal lavage in mice 
The peritoneal lavage was obtained to analyze the cytokine levels and cellular 
infiltrations, if any. The mice were fully anaesthetized at specific time points after the 
intended treatments and their peritoneal cavity was washed with 1.5 ml of ice cold PBS 
with 0.1% BSA. The peritoneal lavage collected were either stored in -20°C for cytokine 
or chemokine concentration measurements by ELISA or analyzed immediately for 
cellular infiltration. Neutrophil infiltration in the peritoneal lavage was analyzed by using 
Turks solution (which stains the nucleus), which enables the visualization of the 
polymorphic nucleus of neutrophils under a light microscope. Hemocytometer was used 
to quantify the number of neutrophils infiltrated into the peritoneal lavage for the various 
test categories. 
 
2.22 Blood collection procedure in mice  
 Considerable amount of good quality blood samples from mice were required for 
the collection of serum for cytokine level analysis and for the isolation of PBMCs. In 
order to meet this requirement, the cardiac puncture technique was chosen to collect 
whole blood from mice. Since, it is a terminal procedure; the mice were fully 
anaesthetized prior to the procedure and were held in a dorsal recumbent position. A 
sterile 1 ml syringe with a 25 gauge needle was used for the procedure. The needle was 
inserted 0.5cm to 1cm deep under the xyphoid cartilage slightly to the left of midline. 
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The needle was inserted at a 25° to 30° angel from the horizontal axis to the sternum to 
enter the heart. The blood flow from the heart was checked by slightly aspirating and 
when successful, the blood was drawn slowly taking care to prevent the sudden collapse 
of the heart. The drawn blood samples were collected in heparinized tubes and placed on 
ice for further processing. 
 
2.23 Collection of serum from mice blood 
In order to collect serum samples from mice, whole blood was collected in non 
heparinized microfuge collection tubes and allowed to clot spontaneously on ice. Once 
the clot is formed at the bottom of the tube, the serum was gently pipetted out to a fresh 
tube. This collected serum was further clarified by centrifugation at 3000rpm for 10 
minutes and the supernatant (serum) was collected gently without disturbing the pellet 
and stored at -20°C until use. 
 
2.24 Isolation of peripheral blood leukocytes from mice 
 Peripheral blood leukocytes from mice were isolated by Ficoll-Hypaque density 
gradient centrifugation. The whole blood from mice was collected by cardiac puncture 
technique, as described earlier. The blood was collected in a heparinized collection tube 
to prevent clotting. Equal volumes of sterile 1 x PBS and whole blood were mixed at 
room temperature and layered carefully on Ficoll-Paque
TM
 (GE Healthcare Bio-Sciences, 
Singapore) gradients (density – 1.077 g/liter) and centrifuged at 500 x g, without brakes 
for 30 minutes at room temperature. The PBMC layer above the ficoll or at the interface 
was gently aspirated and washed three times with sterile 1 x PBS. The pellet obtained at 
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the bottom contained a mixture of RBCs and neutrophils. RBCs were lysed using 
hypotonic lysis procedure, based on the susceptibility of RBC to hypotonicity. The whole 
blood was subjected to hypotonic lysis by resuspending whole blood cells (obtained after 
centrifugation of whole blood) in ice-cold 0.2% NaCl for exactly 30 sec. At the end of 
this period, isotonicity was restored by the addition of equal volume of ice-cold 1.6% 
NaCl. This suspension was centrifuged and the neutrophils pellet was obtained. The 
PBMCs along with neutrophils were then lysed to obtain protein lysates for western blot 
analysis as described earlier. 
 
2.25 Cellular infiltration pattern in peritoneal tissue  
Hematoxylin and Eosin (H and E) staining was done on peritoneal tissues to 
analyze cellular infiltration pattern in response to induced the inflammation. After 
specific treatments, the mice were fully anaesthetized and euthanized. The peritoneal 
tissues at the site of induced inflammation was dissected and stored in formaldehyde. The 
peritoneal tissues were embedded in paraffin and the sections were mounted on slides. 
The sectioning and staining was performed at the core facility in NUMI (National 
University Medical Institutes), NUS. On the day of staining, the sections mounted on 
slides were dewaxed and cleared using Xylene and decreasing percentage of Ethanol. 
After washing the slides with deionized water the sections were stained using Harris’s 
Hematoxylin for 2 minutes. The sections were then washed with water prior to alkaline 
solution dips for few seconds and rinsed with water. This is followed by counter staining 
the sections with Eosin for 2-3 seconds. The sections were then rinsed with water and 
dehydrated with ascending percentage of ethanol. The sections were passed through 
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Xylene and mounted using DEPEX mounting medium. Once dried the sections were 
observed using a light microscope (Leica DM IRB microscope) and the images were 
captured using a Leica DC 300F digital camera. The images were analyzed with the 
Leica IM500 Image Manager software. 
 
2.26 Immunohistochemistry  
Immunohistochemistry (IHC) was performed on peritoneal tissues to assess the 
changes of expression of cell adhesion molecules (CAMs) during induced peritonitis. 
Subsequent to siRNA treatment and TNFα induced peritoneal inflammation; the mice 
were fully anaesthetized and euthanized. The peritoneal tissues at the site of induced 
inflammation was dissected and stored in formaldehyde. The peritoneal tissues were then 
embedded in paraffin and the sections were mounted on slides. The sectioning and 
staining was performed at the core facility in NUMI (National University Medical 
Institutes), NUS. At the time of staining the sections mounted on slides were dewaxed 
using Xylene the slides were washed with deionized water. The excess water was 
removed from the slide, taking care that the sections should not left to dry or devoid of 
moisture until ready for mounting with mounting medium. The tissue section was 
permeablized using 0.2% Triton X-100 for 10 min and washed with 1 x TBS, three times 
for 5 minutes. The sections were blocked with the relevant serum (based on the primary 
antibody) for 30 minutes are room temperature. The excess serum were then drained and 
incubated with the primary antibody against VCAM or ICAM1 over-night in a humidity 
chamber at 4°C. After washing as described earlier, the sections were incubated with the 
relevant FITC conjugated secondary antibody for 1 hour at room temperature. The 
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sections were washed and the mounted with cover slips using FluorSave
TM
 Reagent 
(Calbiochem, San Diego, CA, USA) and allowed to dry. The sections were visualized 
with an inverted fluorescence Leica DM IRB microscope and the images were captured 
using a Leica DC 300F digital camera. The images were analyzed with the Leica IM500 
Image Manager software 
 
2.27 Statistical analysis 
Statistical differences between control and treated cells or samples were calculated using 









Phospholipase D1 mediates TNFα-induced intracellular signaling events 
and responses in vitro 
 
3.1 Introduction 
Tumor Necrosis Factor alpha (TNFα), is one of the most potent and pleiotropic 
pro-inflammatory cytokines, and has been associated with a wide range of diseases, 
including acute and chronic infections, as well as in inflammatory, allergic and 
autoimmune diseases (DeVries et al., 1999; Matsumoto and Kanmatsuse, 1999; Palladino 
et al., 2003; Plo et al., 2000; Tracey and Cerami, 1993; Tracey and Cerami, 1994). TNFα 
is produced by many cells, but in higher amounts by phagocytes and mast cells; it is also 
produced by lymphocytes, NK cells, Kupffer cells, glial cells and adipocytes (Tracey and 
Cerami, 1993). TNFα binding to its transmembrane receptors (TNFR I and TNFR II), 
expressed on a wide variety of cell-types, leads to the stimulation of multiple signaling 
cascades (Vilcek and Lee, 1991), including the MAPK and NFκB cascades, leading to 
the generation of proinflammatory cytokines and other proinflammatory molecules. 
However, the mechanisms that regulate TNFα-induced MAPK and NFκB activation in 
human monocytes are still poorly understood.  
Receptor-coupled signaling transduction mechanisms are tightly regulated by a 
series of protein phosphorylation and dephosphorylation events, and MAPK is a key one 
among them. MAPKs play a crucial role in amplifying signals and regulating signal 
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transduction cascades leading to cell proliferation, chemotaxis and the translation of 
diverse extracellular stimuli to the nucleus, resulting in cellular functions like gene 
expression, mitosis, differentiation, survival and apoptosis (Roux and Blenis, 2004). Five 
distinct MAP kinase subfamilies have been identified to date: these are the Extracellular-
Regulated Kinases (p44/42 - ERK1/2), the 38 KDa MAPKs (p38 α, β, γ and δ), the c-Jun 
amino-terminal kinases (JNK1, 2 and 3), and the ERK 3 and 4 and ERK5 kinases (Roux 
and Blenis, 2004). ERK1/2 are activated by growth factors, phorbol esters, serum, 
cytokines, certain stresses and ligands of GPCRs (Lewis et al., 1998; Pearson et al., 
2001): MAPKs  are found to be key regulators of cell proliferation (Roux and Blenis, 
2004). p38 kinase activity is triggered by osmotic, physical and chemical stress, UV 
irradiation, pro-inflammatory cytokines and hormones (Chen et al., 2001; Pearson et al., 
2001; Whitmarsh et al., 1995) and is found to be vital in regulating immune and 
inflammatory responses (Roux and Blenis, 2004).  
Cell surface receptor engagement by a ligand leads to phospholipase-mediated 
hydrolysis of cellular phospholipids, leading to the generation of lipid-derived products, 
which in turn play critical roles in a wide range of intracellular signaling pathways 
(Divecha and Irvine, 1995; Steed and Chow, 2001). Intracellular signaling mediated by 
Phospholipase D (PLD) has been a target of interest in inflammation and tumor 
metastases for more than two decades (Steed and Chow, 2001). It is well-known that 
PLD is a major source of second messengers, including Phosphatidic Acid (PA) 
(Hanahan, 1947), which can be converted to another important messenger DAG 
(Diacylglycerol) (Sciorra and Morris, 1999). PLD is considered to regulate cellular 
responses that contribute to inflammation, and tumor cell migration (Steed and Chow, 
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2001). In mammalian cells, activation of phosphocholine-specific PLD has been 
proposed to control signal transduction pathways regulating a wide range of 
physiological processes, including membrane trafficking (Siddhanta and Shields, 1998) 
and cytoskeletal reorganization (Colley et al., 1997), phagocytosis (Kusner et al., 1999), 
phagocytic cell NADPH-oxidase-respiratory burst (Dana et al., 2000; Melendez et al., 
2001), and mast cell degranulation (Hammond et al., 1995). 
Some studies have suggested a role for PLD in TNFα-induced cellular 
cytotoxicity (De Valck et al., 1993; Kang et al., 1998). However, these early studies have 
not been followed or validated and the functional significance of these observations 
remains controversial (MacEwan, 2002b). The role of PLD in TNFα-induced 
intracellular signaling events remains largely unknown. Hence, in this study, we sought 
to elucidate the relevance of PLD in key TNFα-induced intracellular signaling events and 
responses in vitro. Antisense based in vitro studies were performed to understand the 
isoform specific role PLD in the TNFα-triggered response and signaling, including the 
hierarchy between PLD and SphK in human monocytes. Here, it is shown that 
phospholipase D1 is activated by TNFα, plays a key role in the signaling events like 
TNFα−triggered sphingosine kinase, NFκB and ERK1/2 activation, but not for p38 
phosphorylation. Furthermore, the physiological importance of PLD1 in the TNFα-
induced signaling pathways is emphasized by its role in mediating proinflammatory 
cytokine production.  
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3.2 Results  
3.2.1 TNFα-induced effector responses in monocytes are dependent on 
its PLD activity 
3.2.1.1 TNFα  induces PLD activity in human monocytes 
The ability of TNFα to induce the activity of PLD in the human monocytic cell 
line used was investigated by performing PLD activity assay. In this assay, the 
production of [
3
H]PtdOH was measured and it served as a means for quantitative 
measurement of PLD activity following stimulation. The monocytic cells were triggered 
with TNFα (10 ng/ml) and PLD activity was measured at the 2, 5, 10, 30 and 60 minutes. 
Subsequent to TNFα stimulation there was an increase in [
3
H]PtdOH generation 
indicating an increase in PLD activity (Figure 3.1A).  
TNFα stimulated a rapid increase in PLD activity, which was detectable as early 
as 2 minutes after TNFα stimulation and maximum PLD activity was observed at the end 
of 30 minutes after stimulation (Figure 3.1A). There was a dose dependent response in 
PLD activation following stimulation with a maximum activity at 10ng of TNFα (Figure 
3.1B). However, activity with 2 ng and 5 ng of TNFα was quite robust as well.  
Therefore, TNFα concentration of 10 ng/ml and PLD activity at 30 minutes after TNFα 
stimulation was used to assess PLD activity in the subsequent experiments. Similar 
experiments carried out on primary monocytes isolated from human peripheral blood 
exhibited a significant increase in PLD activity in 30 minutes, subsequent to TNFα (10 
ng/ml) stimulation (Figure 3.2). These observations indicate that the enzymatic activity of 















































Figure 3.1: Induction of PLD activity by TNFα in human monocytic (U937) cells  
(A). PLD activity was measured in unstimulated cells (Basal) and in cells stimulated 
with TNFα 10 ng/ml (TNFα) for 0, 2, 5, 10, 20, 30, and 60 minutes. (B). PLD activity 
was measured following stimulation with different concentrations of TNFα for 30 
minutes. Results shown are the mean ± the standard deviation of triplicate 

































Figure 3.2: Induction of PLD activity by TNFα in primary human 
monocytes 
Basal PLD activity in un-stimulated primary monocytes in culture medium 
(Basal) and PLD activity in cells stimulated with TNFα 10 ng/ml for 30 
minutes (TNF). Results shown are the mean ± the standard deviation of 
triplicate measurements and are the representative of three separate 
experiments. (*) indicates Student’s t test p value <0.05. 
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3.2.1.2 PLD mediates TNFα-induced effector responses in human monocytes 
The functional relevance of PLD in inflammatory responses was studied by 
investigating the role of PLD in TNFα-induced pro-inflammatory cytokine (IL-6 and IL-
1β) production and cellular migration. These responses were chosen as representatives of 
TNFα-triggered pro-inflammatory effector responses in this study. Cytokines and 
chemokines are soluble regulatory proteins which play vital roles in the onset, 
propagation and regulation of immune and inflammatory responses. Disproportionate 
levels of pro-inflammatory cytokines are associated with inflammatory disorders. 
The role of PLD in cellular functional responses was investigated by taking 
advantage of the characteristic transestrification reaction – transphosphatidylation of 
PLD, in the presence of a primary alcohol. This reaction yields an inert and stable 
phosphatidyl alcohol instead of a biologically active second messenger, PA (Phosphatidic 
acid), thereby inhibiting its downstream signaling events and responses. Since this 
reaction is specific for primary alcohol, tertiary alcohol was used as an added control. 
This ensures that, the effect observed was indeed due to the inhibition of downstream 
signaling of PLD and not a non specific effect of alcohol used. 
One of the potent and important physiological and pathophysiological roles for 
TNFα is to induce the release of other pro-inflammatory cytokines. In our experiments, 
we have shown that TNFα  stimulates the release of IL-6 and IL-1β from human 
monocytic cells and pre-treatment of cells with 1-Butanol (primary alcohol) but not t-
Butanol (tertiary alcohol), prior to TNFα stimulation, inhibited TNFα -induced 










































Figure 3.3: IL-6 and IL-1β release triggered by TNFα is dependent on PLD in 
human monocytic cells 
The graphs indicate the IL-6 (A) and IL-1β (B) production in 24 hours. The 
categories include the cytokine levels in unstimulated cells (Basal); in cells 
stimulated with TNFα (10 ng/ml) only (TNF), in cells pre-treated with 0.3% 1-
Butanol prior to TNFα (10 ng/ml) stimulation (1-But + TNF ); in cells pre-treated 
with 0.3% t-Butanol prior to TNFα (10 ng/ml) stimulation (t-But + TNF ) and in 
cells incubated with 0.3% 1-Butanol and 0.3% t-Butanol only (1-Butanol and t-
Butanol respectively). Results shown are the mean ± the standard deviation of 
triplicate measurements and are the representative of three separate experiments. (* *) 





In order to validate the functional importance of PLD in inflammatory responses 
in a more relevant cell model, primary monocytes from human peripheral blood were 
isolated and similar experiments were done. The results obtained also exhibited the 
inhibition of TNFα-induced IL-6 and IL-β production in primary monocytes pre-

































Figure 3.4: IL-6 and IL-1β release triggered by TNFα is dependent on PLD in 
human peripheral blood monocytes 
The graphs indicate the IL-6 (A) and IL-1β (B) production in 24 hours. The 
categories include the cytokine levels in unstimulated cells (Basal); in cells 
stimulated with TNFα (10 ng/ml) only (TNF), in cells pre-treated with 0.3% 1-
Butanol prior to TNFα (10 ng/ml) stimulation (1-But + TNF ); in cells pre-treated 
with 0.3% t-Butanol prior to TNFα (10 ng/ml) stimulation (t-But + TNF ) and in 
cells incubated with 0.3% 1-Butanol and 0.3% t-Butanol only (1-Butanol and t-
Butanol respectively). Results shown are the mean ± the standard deviation of 
triplicate measurements and are the representative of three separate experiments. (*) 




Immune cell migration to the site of inflammation is another important response 
event during inflammation. PLD has been involved in chemoattractant mediated 
chemotaxis in leukocytes and this is reported to be brought about the regulation of 
polarization of the cells by PLD (Lehman et al., 2006). Therefore, we investigated the 
role of TNFα as a chemo-attractant in monocytic cells and the role of PLD in this 
response. TNFα (10 ng/ml) triggered a chemotactic response in human monocytes. 
However, pre-treatment of cells with the 1-Butanol but not t-Butanol, substantially 
inhibited the chemotactic or the migratory response of monocytic cells (Figure 3.5). The 
measurements obtained were in RFU (Relative Fluorescence Units) as shown in Figure 
3.5A. In order to have a more relevant data representation, a standard curve was plotted 
with known number of cells and the RFU was noted. Substitution of RFU values obtained 
in the experiments on standard curve indicated the total number cells migrated for the 
categories indicated (Figure 3.5B).  
These set of experiments as shown in Figures 3.3 – 3.5 vividly portrays the 




























Figure 3.5: TNFα-induced chemotaxis is PLD dependent in human peripheral 
blood monocytes 
The graph (A) indicates indirect measurement of number of migrated cells in Relative 
fluorescence units (RFU) and graph (B) indicates the absolute cell number of migrated 
cells based on standard curve obtained with absolute cell numbers and their respective 
RFU. In graph (B) the Y axis indicates the number of migrated cells towards TNFα. 
The graphs shows basal migration of untreated cells (Basal); migration of untreated 
cells toward the TNFα 10 ng/ml containing chamber (TNF); migration of cells 
pretreated with 0.3 % 1-Butanol (1-But + TNF) and migration of cells pretreated with 
0.3% t-Butanol (t-But + TNF) towards the TNFα 10 ng/ml containing chambers. 
Results shown are the mean ± the standard deviation of triplicate measurements and are 




In order to ascertain that the inhibitory effects were indeed due to inhibition of the 
enzymatic reaction’s downstream products and not because of cell death induced by the 
reagents used, a cell viability assay was performed. MTT assay was done to investigate 
the cell viability after incubating the cells with TNFα, primary and tertiary alcohol for 24 
hours. Measurements at the end of the time point failed to show any significant decrease 
in cell viability induced by the mentioned reagents (Figure 3.6). This indicates that the 
inhibition in responses was due to the transphosphatidylation reaction causing the 








Figure 3.6: Percentage of cell viability in human monocytic cells after 24 hours 
incubation with TNFα, a primary (1-Butanol) and a tertiary alcohol (t-Butanol) 
The graphs shows the percentage of viable untreated cells (Basal); cells incubated 
with TNFα 10 ng/ml (TNF); cells incubated with 0.3 % 1-Butanol and TNFα 10 
ng/ml (1-But + TNF); cells incubated with 0.3 % t-Butanol and TNFα 10 ng/ml (t-
But + TNF) and cells incubated with 0.3% 1-Butanol and 0.3% t-Butanol only (1-
Butanol and t-Butanol respectively).  Results are the mean and ± SD of triplicate 




Based on the results in this section, we can suggest that, Phospholipase D 
mediates TNFα− triggered pro-inflammatory responses in human monocytes. 
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3.2.2 Role of PLD in TNFα−induced intracellular signaling events  
3.2.2.1 Role of PLD in TNFα-induced MAPKs activation 
3.2.2.1.1 TNFα-triggered effector responses are regulated by ERK1/2 and p38 
kinase. 
MAPKs are key intracellular signaling mediators which regulate a variety of 
cellular processes and responses. Since it is already evident from our experiments, that 
PLD influences TNFα−induced release of IL-6 and IL-1β in monocytic cells (Figure 3.7), 
we evaluated the functional relevance of MAPKs like ERK1/2 and p38 kinase in TNFα-
induced effector response prior to the evaluation of the signaling hierarchy between PLD 
and the MAPKs in TNFα-triggered signaling. In order to investigate this objective, we 
pre-treated the cells with a MEK inhibitor (PD98059) and a p38 inhibitor (SB203580), 
before stimulating them with TNFα for 24 hours and quantified the release of IL-6 and 
IL-1β.  It was observed that, MEK and p38 inhibitors decreased the level of TNFα  
induced IL-6 and IL-1β production in human monocytic cells (Figure 3.7).  Based on the 
results obtained, it can be inferred that including PLD, TNFα-triggered IL-6 and IL-1β 
production in monocytes are also regulated by ERK1/2 and p38 kinase. Therefore, our 
experiments focused on the signaling events or signaling hierarchy if any, between PLD 





























Figure 3.7: Cytokine production triggered by TNFα is dependent on ERK1/2 
and p38 kinase in human monocytic cells 
Graph (A) indicates the IL-6 production and graph (B) indicates IL-1β production 
in 24 hours. Cytokine production in unstimulated cells (Basal); in cells stimulated 
with TNFα (10 ng/ml) only (TNF); in cells pre-treated with 10 µM of SB203580 
(p38 inhibitor) prior to TNFα (10 ng/ml) stimulation (SB203580 + TNF); in cells 
pre-treated with 50 µM of PD98059 (MEK1/2 inhibitor) prior to TNFα (10 ng/ml) 
stimulation (PD98059 + TNF) and in cells incubated with 10 µM of SB203580 
and 50 µM of PD98059 only (SB203580 and PD98059 respectively). Results 
shown are the mean ± the standard deviation of triplicate measurements and are 
the representative of three separate experiments. (* * and *) indicates Student’s t test 
p value <0.01 and <0.05 respectively. 
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3.2.2.1.2 TNFα−induced ERK1/2 activation pathway is mediated by PLD  
To evaluate the significance of PLD and ERK1/2 (p44/42) in TNFα-triggered 
signaling, ERK1/2 phosphorylation by TNFα in cells pre-treated with and without 1-
Butanol and t-Butanol were investigated. TNFα was found to activate ERK1/2 (dually 
phosphorylate ERK1/2) in human monocytic cells and this phosphorylation, was 
inhibited when the cells were pre-treated with 1-Butanol (Figure 3.8). This inhibitory 
effect was absent in cells pre-treated with t-Butanol, which indicates the specific role of 
PLD in this process (Figure 3.8). This suggests that TNFα-mediated ERK1/2 
phosphorylation is indeed dependent on PLD in human monocytic cells.  
Subsequently, investigation was done to evaluate the role of ERK1/2 in 
TNFα−induced PLD activity. To meet this objective PLD activity was measured in cells 
following TNFα stimulation and was compared to that of resting cells and cells pre-
incubated with PD98059 (50 µM), a potent, selective and cell permeable inhibitor, which 
inhibits the phosphorylation of ERK1/2 (p44/42) by MAP Kinase Kinase (MEK). The 
TNFα-induced PLD activation was not affected by PD98059 pretreatment (Figure 3.9).  
These results (Figure 3.8 and 3.9) suggest that PLD is upstream of ERK1/2 and 

















Figure 3.8: TNFα−triggered ERK1/2 phosphorylation is PLD dependent in 
human monocytic cells 
Western blot analysis shows phosphorylation of ERK1/2 (p-ERK1/2) over time (0, 5, 
10 and 30 mins) following TNFα (10 ng/ml) stimulation. The figure exhibits 
untreated-control cells following TNFα stimulation (TNF); cells pretreated with the 
0.3% 1-Butanol prior to TNFα stimulation (1-Butanol + TNF) and cell pretreated with 
0.3% t-Butanol prior to TNFα stimulation (t-Butanol + TNF). GAPDH was probed for 
































Figure 3.9: TNFα-triggered PLD activity is independent of ERK1/2 in human 
monocytic cells 
Basal PLD activity in un-stimulated cells (Basal); PLD activity in cells stimulated with 
TNFα 10 ng/ml (TNF) and PLD activity in cells pre-incubated with MEK inhibitor, 
PD98059 at 50 µM prior to stimulation with TNFα 10 ng/ml (PD98059 + TNF). 
Results shown are the mean ± S.D. of triplicate measurements and are a representative 
of three separate experiments. 
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We also investigated Raf-1 translocation from the cytosol to the cell periphery on 
stimulation, an upstream event of agonist induced ERK1/2 phosphorylation. Fluorescence 
microscopic results show that in resting cells Raf-1 is primarily cytosolic, and after 
TNFα (10 ng/ml) stimulation Raf-1 has been found to translocate to the cell periphery 
(Figure 3.10). TNFα-induced translocation of Raf-1 was inhibited when the cells were 
pre-treated with 1-Butanol and not when the cells were pre-treated with t-Butanol (Figure 
3.10). This indicates that TNFα−induced Raf-1 translocation is mediated by PLD as well. 
Therefore, we can suggest that PLD mediates TNFα-induced ERK1/2 activation cascade 
by influencing the translocation of Raf-1 in human monocytic cells.
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Figure 3.10: TNFα triggered Raf-1 translocation is PLD dependent in human 
monocytic cells 
Fluorescence microscopic images of cells stimulated with TNFα 10 ng/ml and 
subsequently immune-stained for Raf-1 are exhibited. Untreated-control cells 
stimulated by TNFα are shown in row (A); cells pre-treated with 0.3% 1-Butanol 
prior to TNFα stimulation are shown in row (B)  and cells pre-treated with 0.3% t-
Butanol prior to TNFα stimulation are shown in row (C). The panels includes cells at 




3.2.2.1.3 PLD and p38 kinase are independent of each other in TNFα−induced 
signaling 
To evaluate the relevance of PLD to p38 kinase in TNFα-triggered signaling 
pathway, we looked at the phosphorylation of p38 induced by TNFα. It was found that 
TNFα activated p38 kinase in human monocytic cells and this phosphorylation of p38 
kinase was not inhibited when the cells were incubated with 1-Butanol, prior to TNFα 
stimulation (Figure 3.11). This result indicates that TNFα-mediated phosphorylation of 
p38 is independent of PLD.  
Since, TNFα-induced p38 kinase phosphorylation was independent of PLD; 
investigation was done to find out whether p38 kinase was necessary for TNFα−induced 
PLD activity. As a result, TNFα-induced PLD activity was measured in normal resting 
cells and in those cells pre-incubated for 20 minutes with SB203580 (10 µM), a potent 
and highly selective p38 kinase inhibitor. PLD activity showed a significant increase 
subsequent to 30 minute of TNFα stimulation over the basal and this activity was not 
affected or inhibited by SB203580 (Figure 3.12). Thus suggesting that, TNFα-induced 











Figure 3.11: TNFα-triggered p38 phosphorylation is PLD independent 
Western blot analysis shows phosphorylation of p38 kinase (p-p38) over time 
(0, 5, 10 and 30 mins) following TNFα (10 ng/ml) stimulation. The figure 
indicates untreated-control cells following TNFα stimulation (TNF) and cells 
pretreated with the 0.3% 1-Butanol prior to TNFα stimulation (1-Butanol + 
TNF). GAPDH was probed for loading control. Results shown are a 
representative of three separate experiments.  
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Figure 3.12: TNFα-triggered PLD activity is independent of p38 
Basal PLD activity in un-stimulated cells (Basal); PLD activity in cells 
stimulated with TNFα 10 ng/ml (TNF) and PLD activity in cells pre-incubated 
with p38 inhibitor, SB203580 at 10µM prior to stimulation with TNFα 10 
ng/ml (SB203580 + TNF). Results shown are the mean ± S.D. of triplicate 
measurements and are a representative of three separate experiments. 
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3.2.2.2 Role of PLD in TNFα-induced SphK activity 
3.2.2.2.1 TNFα -triggered effector response is regulated by SphK. 
We evaluated the functional relevance SphK in TNFα-induced effector response 
prior to the evaluation of the signaling hierarchy between PLD and SphK in TNFα-
triggered signaling. In order to investigate this objective, we pre-treated the cells with 
SphK inhibitor – N,N-dimethylsphingosine (DMS), an analogue of sphingosine, before 
stimulating them with TNFα for 24 hours and quantified the release of IL-6 and IL-1β.  It 
was observed that SphK inhibitor decreased the level of TNFα -induced IL-6 and IL-
1β production (Figure 3.13). This indicates a role of SphK in TNFα-induced pro-






Figure 3.13: Cytokine production triggered by TNFα is dependent on SphK in 
human monocytic cells 
The graph (A) indicates the IL-6 production and graph (B) indicates IL-1β production 
within 24 hours. Cytokine production in unstimulated cells (Basal), in cells stimulated 
with TNFα (10 ng/ml) only (TNF), in cells pretreated with 10 µM of DMS (SPHK 
inhibitor) prior to TNFα (10 ng/ml) stimulation (DMS + TNF), in cells pretreated with 
10 µM of DMS only (DMS only) and in cells incubated with DMSO prior to TNFα 
stimulation (DMSO + TNF) as an added control. Results shown are the mean ± the 
standard deviation of triplicate measurements and are the representative of three 




3.2.2.2.2 TNFα−induced SphK activity is downstream of PLD  
To evaluate the significance of PLD and SphK in TNFα-triggered signaling, 
investigation was done to determine the role of SphK in TNFα-induced PLD activity. To 
evaluate this, PLD activity measured in cells following TNFα stimulation was compared 
to that of resting cells and cells pre-incubated with DMS, a potent SphK inhibitor for 20 
minutes. The TNFα (30 minutes) induced PLD activation was not affected by DMS pre-
treatment (Figure 3.14). This indicates that TNFα−induced PLD activity is not influenced 
by SphK 
Experiments were then performed to determine whether PLD influence 
TNFα−stimulated SphK activity. TNFα was found to activate SphK in human monocytic 
cells and this activation was inhibited when the cells were pre-treated with 1-Butanol 
(Figure 3.15). This inhibitory effect on SphK activity was not observed in cells pre-
treated with t-Butanol (Figure 3.15). These two findings clearly suggest that 




















Figure 3.14: TNFα−triggered PLD activity is independent of SphK 
Basal PLD activity in un-stimulated cells (Basal); PLD activity in cells stimulated 
with TNFα 10 ng/ml (TNF) and PLD activity in cells pre-incubated with SphK 
inhibitor, DMS at 10 µM prior to stimulation with TNFα 10 ng/ml (DMS + TNF). 
Results shown are the mean ± S.D. of triplicate measurements and are a 
representative of three separate experiments. 
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Figure 3.15: TNFα−triggered SphK activity is dependent on PLD 
Basal SphK activity in un-stimulated cells (Basal); SphK activity in cells stimulated 
with TNFα 10 ng/ml (TNF); SphK activity in cells pre-incubated with 0.3% 1-Butanol 
prior to stimulation with TNFα 10 ng/ml (1-But + TNF); SphK activity in cells pre-
incubated with 0.3% t-Butanol prior to stimulation with TNFα 10 ng/ml (t-But + TNF); 
SphK activity in cells treated with 0.3% 1-Butanol and 0.3% t-Butanol only (1-Butanol 
and t-Butanol respectively). Results shown are the mean ± S.D. of triplicate 
measurements and are a representative of three separate experiments. (* *) indicates 
Student’s t test p value ≤0.01. 
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3.2.2.3 Role of PLD in TNFα-induced NFκB activation  
NFκB (Nuclear Factor kappa B) is one of the important transcription factors that 
contributes in the amplification of inflammatory responses by being responsible for the 
production of pro-inflammatory mediators and also signals for cell survival. NFκB is 
responsible for the transcription of inflammatory genes which includes that of cytokines, 
chemokines, cell adhesion molecules and other immune response mediators. Therefore, 
NFκB has been associated with the pathogenesis of inflammatory disorders (Yamamoto 
and Gaynor, 2001). In the following set of experiments, we have investigated the 
association of PLD and NFκB in TNFα-triggered inflammatory signaling and responses. 
 
3.2.2.3.1 TNFα -induced inflammatory response is mediated by NFκB  
The direct role of NFκB in TNFα-triggered inflammatory response like pro-
inflammatory cytokine (IL-6 and IL-1β) production in human monocytic cells was 
investigated by the use of an NFκB inhibitor (Ro106-9920). This inhibitor is known to 
interfere with NFκB activity by inhibiting IκBα ubiquitination by E3 ligase, thereby 
preventing IκBα degradation and thus preventing NFκB activation (Swinney et al., 
2002). Results indicate that TNFα-induced IL-6 and IL-1β production was found to be 
inhibited in cells pre-treated with Ro106-9920 (Figure 3.16). This suggests the direct 
involvement of NFκB in TNFα-mediated inflammatory response. 
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Figure 3.16: Cytokine production triggered by TNFα is dependent on NFκB in 
human monocytic cells 
The graph (A) indicates the IL-6 production and graph (B) indicates IL-1β 
production within 24 hours. Cytokine production in unstimulated cells (Basal), in 
cells stimulated with TNFα (10 ng/ml) only (TNF), in cells pretreated with 10 µM 
of Ro106-9920 (NFκB inhibitor) prior to TNFα (10 ng/ml) stimulation (Ro + TNF) 
and in cells pretreated with 10 µM of Ro106-9920 only (Ro only) Results shown are 
the mean ± the standard deviation of triplicate measurements and are the 






3.2.2.3.2 TNFα−triggered NFκB activity in human monocytic cells requires PLD  
Since, our earlier experiments have shown that TNFα−induced responses were 
also influenced by PLD, we investigated whether PLD influenced TNFα−induced NFκB 
activity. We evaluated or quantified TNFα-triggered NFκB activity by measuring the 
amount of p65 subunits of NFκB in the nuclear fraction after stimulation. p65 subunit is 
primarily cytsolic in unstimulated cells and on activation, it translocates into the nucleus  
to bring about its transcription function by binding to DNA. An ELISA based assay was 
done to quantify the amount of p65 subunits in the nuclear fraction. Based on the current 
results, there was an increase in the amount of p65 subunits in untreated cells stimulated 
by TNFα (Figure 3.17). This increase in p65 levels in the nucleus was inhibited when the 
cells were pre-treated with 1-Butanol and not t-Butanol prior to TNFα stimulation 












































Figure 3.17: TNFα-triggered NFκB activity is dependent on PLD in human 
monocytic cells 
NFκB activity was measured based on the presence of p65 subunit of the NFκB 
heterodimer in the nuclear fraction, 30 minutes after TNFα 10 ng/ml stimulation. 
Activity in control resting cells (Basal); activity in control cells after TNFα 
stimulation (TNF); activity in cells pretreated with 0.3% 1-Butanol prior to 
TNFα stimulation (1-But + TNF) and activity in cells pretreated with 0.3% t-
Butanol prior to TNFα stimulation (t-But + TNF). Results shown are the mean ± 
S.D of triplicate measurements. (*) indicates Student’s t test p value <0.05. 
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Experiments were conducted further to investigate as to how PLD prevented the 
translocation of p65 subunit into the nucleus. It is well known that IκBα degradation is a 
crucial event in the process of NFκB activation, as the latter’s degradation is essential for 
the release of p50 and p65 subunits of NFκB from the inhibitory complex in the cytosol 
and facilitate its translocation into the nucleus to bring about its transcriptional activity 
(Ghosh and Karin, 2002; Moynagh, 2005). Therefore, we looked into the IκBα 
degradation pattern induced by TNFα and the role of PLD in this process. We have 
shown by western blotting procedure that in untreated cells, TNFα induces IκBα 
degradation (Figure 3.18). TNFα-triggered IκBα degradation was either inhibited or 
delayed in cells pre-treated with 1-Butanol prior to TNFα stimulation (Figure 3.18), thus 
explaining the reduction in the p65 subunit levels in the nucleus. However, this inhibition 
of IκBα degradation was absent in cells pre-treated with t-Butanol, indicating the role of 
PLD in TNFα−induced IκBα degradation or NFκB activation in human monocytic cells. 
These results suggest that NFκB is downstream of PLD and the latter is required for 
TNFα-induced NFκB activation and associated responses. Ro106-9920 selectively 
inhibits essential ubiquitination activity associated TNFα-induced IκBα degradation. 
This prevents the translocation of both the p65 & p50 subunits into the nucleus which 
essential for the activation of the subunits. However, only the levels of p65 subunits in 















































Figure 3.18: TNFα−triggered IκBα degradation is influenced by PLD 
Western blot analysis shows degradation of IκBα in 20 minutes following TNFα (10 
ng/ml) stimulation. The figure indicates untreated-control cells following TNFα 
stimulation; cells pretreated with the 0.3% 1-Butanol prior to TNFα stimulation; cells 
pretreated with the 0.3% t-Butanol and cell pretreated with Ro106-9920 prior to TNFα 
stimulation.  α Tubulin was probed for loading control. Results shown are a 




Similarly, studies were done to evaluate whether PLD dependent ERK1/2 or PLD 
independent p38 kinase influences TNFα−induced NFκB activation. Since it has been 
reported that members of the MAPK family can regulate the activation of NFκB by 
phosphorylating the IκB alpha kinase complex (Lee, 1997; Tergaonkar, 2006). An 
ELISA based experiment described earlier was used to quantify the levels of p65 in the 
nuclear fraction after following TNFα stimulation. Cells incubated with MEK inhibitor 
and p38 inhibitor failed to exhibit a decrease in p65 levels in the nuclear fraction after 
TNFα stimulation (Figure 3.19). Western blot analysis has shown that these above 
mentioned inhibitors also failed to alter or affect the IκBα degradation patterns after 
TNFα stimulation (Figure 3.20). These set of results indicates that TNFα−induced NFκB 

































































Figure 3.19: TNFα−triggered NFκB activity is not dependent on ERK1/2 and 
p38 kinase in human monocytic cells 
NFκB activity was measured based on the presence of p65 subunit of the NFκB 
heterodimer in the nuclear fraction, 30 minutes after TNFα 10 ng/ml stimulation. 
Activity in control resting cells (Basal); activity in control cells after TNFα 
stimulation (TNF); activity in cells pretreated with the 50 µM of PD98059 (MEK 
inhibitor) prior to TNFα stimulation (PD98059 + TNF) and activity in cells 
pretreated with the 10 µM of SB203580 (p38 kinase inhibitor) prior to TNFα 
stimulation (SB203580 + TNF). Wild type duplex (WT + TNF) and mutant duplex 
(MT + TNF) in cells stimulated with TNFα was used added controls to prove 
specificity. Wild Type and Mutant NFκB Competitor Duplex is provided along 
with the detection system is to ensure signal specificity. Adding the Wild Type 
NFκB Competitor Duplex in the reaction prior to the addition of the sample 
extracts will prevent NFκB subunit in the extracts from binding to the sequence 
attached to the plate and thus eliminating specific signals. However, if a Mutant 
NFκB Competitor Duplex was added to the reaction mixture instead, it will not 
affect specific NFκB binding, thus exhibiting the specific signal. Results shown 











































Figure 3.20: TNFα-triggered IκBα degradation is not dependent on ERK1/2 and 
p38 kinase in human monocytic cells 
Western blot analysis shows degradation of IκBα in 20 minutes following TNFα (10 
ng/ml) stimulation. The figure indicates untreated-control cells following TNFα 
stimulation; cells pretreated with the 10 µM of SB203580 (p38 kinase inhibitor) prior to 
TNFα stimulation and cells pretreated with the 50 µM of PD98059 (MEK inhibitor) 
prior to TNFα stimulation.  α Tubulin was probed for loading control. Results shown 




MTT assay was done to investigate the cell viability after incubating the cells 
with the various inhibitors used in the study mentioned in this section. This is to ensure 
that the inhibitory effects are not due to cell death / decrease proliferation and are indeed 
due to the inhibition of activity of the specific proteins of interest.  Measurements at the 
end of the time point failed to show any significant cell death or changes in the number of 
















Figure 3.21: Percentage of cell viability in human monocytic cells after 24 
hours incubation with various inhibitors used 
The graphs shows the percentage of viable untreated cells (Basal); cells 
incubated with 10 µM of Sphingosine kinase inhibitor, DMS (DMS); cells 
incubated with 10 µM of SB203580, p38 kinase inhibitor (SB203580); cells 
incubated with 50 µM of PD98059, MEK inhibitor (PD98059) and cells 
incubated with 10 µM of Ro106-9920, NFκB inhibitor (Ro106-9920).  Results 









Figure 3.22: Schematic representation of the role of PLD in      
TNFα-induced intracellular signaling events and responses 
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3.2.3 Isoform specific function of PLD1 in TNFα−induced signaling and 
responses 
3.2.3.1 TNFα  induces sub cellular re-localization of PLD1 in human monocytic cells 
PLD isoforms (PLD1 and PLD2) were found to be expressed in the human 
monocytic cells used in this study (Melendez et al., 2001). Therefore, we investigated the 
localization of these two isoforms and whether TNFα stimulated their re-localization, as 
a means to start dissecting the specific isoform(s) activated by this cytokine. 
Fluorescence microscopy derived results, in this study, reveals that in resting cells both 
PLD isoforms have a general cytosolic localization and that TNFα induces the re-
localization of PLD1, but not PLD2, to the cells’ periphery (Figure 3.23). This would 


















Panel A Panel B 
Figure 3.23: PLD1 re-localization subsequent to TNFα stimulation in human 
monocytic cells 
Fluorescence microscopic images of cells stimulated with TNFα 10 ng/ml and 
subsequently immune-stained for PLD1 and PLD2 are shown in Panel A and Panel B 
respectively. The panels includes cells at various time points (0 minute or Basal; 2 
minutes; 5 minutes and 10 minutes) after TNFα stimulation. 
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3.2.3.2 Specific knockdown of PLD isoforms using antisense oligonucleotides 
Since it is known that U937 cells express both the PLD isoforms (PLD1 and 
PLD2), experiments were performed to identify the PLD isoform which specifically plays 
a role in TNFα induced signaling and responses in human monocytic cells.  To address 
this, the expression of the PLD isoforms were specifically knocked down using specific 
antisense oligonucleotides designed against each of the PLD isoforms (i.e. antisense to 
PLD1 and antisense to PLD2). It has been previously shown that U937 cells are sensitive 
to antisense manipulation and the latter can be used to study the isoform specific role of 
PLD (Melendez et al., 2001).  
IFN-γ primed cells were treated with antisense oligonucleotides specific against 
the two PLD isoforms. The knock down specificity of the antisense oligonucleotides on 
the respective PLD isozymes expression was analyzed by western blot analysis of 
immunoprecipates of PLD1 and PLD2 cell lysates (Figure 3.24). Cells treated with 
antisense against PLD1 isoform showed a reduction in PLD1 immunoreactivity or protein 
expression, without affecting PLD2 expression. Likewise, in cells treated with antisense 
to PLD2, there was a reduction in PLD2 expression without affecting the expression of 














3.2.3.3 TNFα-stimulated PLD activity is coupled to PLD1 isoform 
 Unstimulated cells treated with antisense oligonucleotides were assayed for 
PLD activity to measure basal levels of activity and it was found that treatment of cells 
with the antisense oligonucleotide to PLD1 resulted in no change in basal PLD activity.  
However, following TNFα stimulation, the increase in PLD activity was significantly 
reduced compared to the control cells (Figure 3.25). In contrast, treatment of cells with 
the antisense oligonucleotide to PLD2 slightly reduced basal PLD activity, but TNFα 
induced PLD activity was only marginally reduced in cells treated with the antisense to 
PLD2 (Figure 3.25). This reduction was accounted for by the reduction in basal levels. 
Therefore, this experiment demonstrates that, at least in the present system, TNFα-
stimulated PLD activity is specifically contributed by PLD1 isoform.   
 
Figure 3.24: Specific knockdown of PLD isoforms (PLD1 and PLD2) using 
antisense oligonucleotides in human monocytic cells 
Western blot analysis of immunoprecipitates of either PLD1 or PLD2 to assess 
expression of either isozymes in human monocytic cells, following 36 hours 
treatment with antisense oligonucleotides (10 µM) specific for either PLD1 
(a.s.PLD1) or PLD2 (a.s.PLD2) and untreated cells severed as controls 
(Control). ARF1 (ADP-ribosylation factor 1) was used as loading control and the 
samples were obtained from whole cell lysates. The results shown are typical 






Figure 3.25: PLD1 isoform was found to be coupled with TNFα signaling 
PLD activity following TNFα (10 ng/ml) stimulation in cells pretreated with 10 
µM antisense oligonucleotides for either PLD1 (a.s.PLD1) or PLD2 (a.s.PLD2). 
PLD activity in untreated cells (Basal); in cells stimulated with TNFα (TNF); in 
cells pretreated with a.s.PLD1 only (a.s.PLD1 only); in cells pretreated with 
a.s.PLD1 prior to TNFα stimulation (a.s.PLD1 + TNF); in cells pretreated with 
a.s.PLD2 only(a.s.PLD2 only) and in cells pretreated with a.s.PLD2 prior to TNFα 
stimulation a.s.PLD2 + TNF).  Results are the mean ± S. D. of triplicate 




3.2.3.4 TNFα-triggered intracellular signaling events is coupled to PLD1 
TNFα−induced intracellular signaling events like ERK1/2 phosphorylation, 
Sphingosine kinase activity, calcium release from intracellular stores and transcription 
factor – NFκB activation in human monocytic cells were dependent on PLD1 isoform. 
 
TNFα-triggered ERK1/2 phosphorylation is coupled to PLD1, but TNFα induced 
p38 phosphorylation is independent of PLD activity 
TNFα coupled to the activation of MAPKs have important functional 
consequences for several functional cellular responses, including in the generation of 
proinflammatory cytokines.  This study demonstrates a critical role for PLD1 in 
mediating the TNFα-induced phosphorylation of ERK1/2.  Treatment of cells with the 
antisense oligonucleotide to PLD1 resulted in the inhibition of the phosphorylation levels 
of ERK1/2 triggered by TNFα (Figure 3.26). In contrast, treatment of cells with the 
antisense oligonucleotide to PLD2 did not alter TNFα-induced ERK1/2 phosphorylation, 








































Figure 3.26: TNFα−triggered ERK1/2 phosphorylation is PLD1 dependent in 
human monocytic cells 
Western blot analysis shows TNFα (10 ng/ml) triggered ERK1/2 phosphorylation 
over the time points indicated. Categories include TNFα induced phosphorylation 
status of ERK1/2 in untreated cells (TNF); in cells pretreated with the PLD1 
antisense prior to TNF stimulation (a.s.PLD1 + TNF); in cell pretreated with the 
PLD2 antisense prior to TNF stimulation (a.s.PLD2 + TNF) and in cells pretreated 
with the MEK inhibitor, PD98059 at 50 µM (PD98059 + TNF). Results shown are 
typical of three separate experiments. GAPDH was probed for loading control.  
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To evaluate the relevance of PLD1 in p38 kinase-activity in the TNFα-triggered 
signaling pathway, we looked at the phosphorylation of p38 induced by TNFα. We found 
that TNFα did indeed trigger p38 phosphorylation, in the human monocytic cells. 
However, in contrast to ERK1/2 phosphorylation, the phosphorylation of p38 was not 
inhibited when the cells were pretreated with antisense oligonucleotide to PLD1 (Figure 
3.27). Similarly, pretreatment of cells with the antisense oligonucleotide to PLD2 did not 



























Figure 3.27: TNFα-triggered p38 phosphorylation is not dependent on PLD1 
and PLD2 in human monocytic cells  
Western blot analysis shows TNFα (10 ng/ml) triggered p38 kinase 
phosphorylation over the time points indicated. Categories include TNFα−induced 
phosphorylation status of p38 in untreated cells (TNF); in cells pretreated with the 
PLD1 antisense prior to TNF stimulation (a.s.PLD1 + TNF); in cell pretreated with 
the PLD2 antisense prior to TNF stimulation (a.s.PLD2 + TNF) and in cells 
pretreated with the p38 kinase inhibitor, SB203580 at 10 µM, (SB203580 + TNF). 
Results shown are typical of three separate experiments. GAPDH was probed for 
loading control.  
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Results in the earlier section (Figure 3.9 and 3.12) have clearly shown that TNFα-
induced PLD activity is not mediated by ERK1/2 and p38 kinase.  Together, with the 
results seen in this section (Figure 3.26 and 3.27), we can suggest that PLD1 mediates 
TNFα-induced ERK1/2 activation, but TNFα-mediated p38 phosphorylation is 
independent of both PLD1 and PLD2.  
 
TNFα-induced sphingosine kinase activity; cytosolic calcium release and NFκB 
activation are dependent on PLD1. 
SphK is known to be an important signaling event which is necessary for signal 
transduction and various effector responses. Intracellular or cytosolic calcium release has 
also been a key regulator in intracellular signaling and responses. Here, we have shown 
that SphK activity, cytosolic calcium responses and NFκB activity triggered by TNFα 
depend on PLD1. 
Pretreating cells with the antisense oligonucleotide to PLD1 to knock-down this 
specific isozyme/isoform expression significantly reduced the activation of sphingosine 
kinase, following TNFα stimulation. Reduction in expression of PLD2 isozyme had no 
effect on the ability of TNFα to activate the enzymatic activity of sphingosine kinase 







































Figure 3.28:  TNFα-induced sphingosine kinase activity is dependent on PLD1 
Sphingosine kinase activity following TNFα (10 ng/ml) stimulation is shown. Cells 
were harvested at given time points indicated in the figure to measure sphingosine 
kinase activity. Sphingosine kinase activity, in untreated control cells (● – Basal); in 
untreated cells following TNFα stimulation (○ – TNF) and in cells pretreated with 
antisense oligonucleotides (10 µM) for either PLD1 (∆ – a.s.PLD1 + TNF) or PLD2 (♦ – 
a.s.PLD2 + TNF) prior to TNFα stimulation. Results are the mean ± S.D of triplicate 




Similarly, reduction in expression of PLD1 by pre-treatment of cells with 
antisense PLD1 oligonucleotide resulted in the attenuation of the cytosolic calcium 
response following TNFα stimulation (Figure 3.29).  Reducing expression of PLD2 had 




Figure 3.29: Intracellular cytosolic calcium changes following TNFα stimulation 
is PLD1 dependent 
Intracellular cytosolic calcium responses after TNFα stimulation were compared in 
control cells and cells pretreated with antisense oligonucleotides (10 µM) to either 
PLD1 or PLD2.  Traces shown are: blue, control cells treated with TNFα 10 ng/ml 
(TNF); black, cells pretreated with antisense to PLD1 (a.s.PLD1 + TNF) and red, 
cells pretreated with antisense to PLD2 (a.s.PLD2 + TNF).  The arrow marks the 
addition of TNFα. Traces are typical from three separate experiments. 
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 NFκB is one of the key transcription factors that trigger the generation of many 
proinflammatory mediators and aid in the onset and propagation of inflammatory 
response. It is shown here that the TNFα triggered activation of NFκB in human 
monocytes is mediated by PLD1. This is substantiated by the reduction in the 
translocation of both p50 and p65 subunits from the cytoplasm into the nucleus 
subsequent to TNFα stimulation in cells pretreated with the antisense oligonucleotide 
against PLD1, whereas pretreatment with a PLD2 antisense oligonucleotide had no such 
observed effect on NFκB subunits after TNFα stimulation in human monocytic cells 
(Figure 3.30).  
 
Figure 3.30:  PLD1 mediates TNFα−induced NFκB activity in human 
monocytic cells 
Activities of p50 and p65 subunits of NFκB following TNFα 10 ng/ml stimulation 
for 30 minutes were measured. Activities in normal untreated resting cells (Basal); 
in untreated cells following TNFα stimulation (TNF); in cells pretreated with 
antisense for PLD1 prior to TNFα stimulation (a.s.PLD1 + TNF) and in cells 
pretreated with antisense for PLD2 prior to TNFα stimulation (a.s.PLD2 + TNF). 
Results shown are the mean ± S.D. of triplicate measurements. (**) indicates 
Student’s t test p value <0.01. 
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3.2.3.5 PLD1 is required for TNFα-triggered inflammatory responses like 
proinflammatory cytokine generation 
TNFα is capable of amplifying the inflammatory response by promoting the 
generation and release of several proinflammatory cytokines and chemokines. Here, the 
results indicate that TNFα stimulates IL-6 and IL-1β production and release from human 
monocytic cells and this TNFα−induced response was inhibited in cells pretreated with 
the antisense PLD1 oligonucleotide (Figure 3.31). In contrast, pretreatment with a PLD2 
antisense had no inhibitory effect on these TNFα-induced proinflammatory cytokine 
productions (Figure 3.31). Thus, suggesting that PLD1 mediates the TNFα−triggered 
















Figure 3.31: TNFα-triggered cytokine release is inhibited in cells pretreated with 
the PLD1 antisense  
Measurements of IL-6 and IL-1β in unstimulated cells (Basal) and after stimulation with 
TNFα 10 ng/ml (TNFα), pretreated or not with the antisense oligos: Basal (Basal 
control); TNFα stimulation (TNF); Basal in cells pretreated with a.s.PLD1 (a.s.PLD1); 
TNFα stimulation in cells pretreated with a.s.PLD1 (a.s.PLD1 + TNF); Basal in cells 
pretreated with a.s.PLD2 (a.s.PLD2) and TNFα stimulation in cells pretreated with 
a.s.PLD2 (a.s.PLD2 + TNF).  Results shown are the mean ± S.D. of triplicate 
measurements and from three separate experiments. (**) indicates Student’s t test p value 
<0.01.  
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3.2.3.6 TNFα  activated the PLD1 pathway in primary human monocytes to mediate 
its inflammatory response 
The experiments discussed earlier were carried out in a human monocytic cell line 
(U937 cells) differentiated to a mature monocyte phenotype with IFNγ. In order to 
validate these findings in a more relevant model, it was then decided to investigate 
whether TNFα is also capable of activating the PLD1 pathway in primary human 
monocytes. 
It has been shown in the earlier section that TNFα stimulated PLD activity in 
primary monocytes as well (Figure 3.2), similar to that observed for U937 cells (Figure 
3.1).  PLD1 and PLD2 were also present in primary monocytes and have a general 
cytosolic localization in resting cells (Figure 3.32). Similar to the monocytic cell model, 
TNFα triggered the re-localization of PLD1, but not PLD2, to the cells’ periphery or cell 
membrane (Figure 3.32). 
Figure 3.32: PLD1 re-localization subsequent to TNFα stimulation in primary 
human monocytes  
Fluorescence microscopic images of cells stimulated with TNFα 10 ng/ml and 
subsequently immune-stained for PLD1 and PLD2 are shown in Panel A and Panel 
B respectively. The panels include cells at various time points (0 minute or Basal; 
2 minutes; 5 minutes and 10 minutes) after TNFα stimulation. 
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The primary monocytes obtained were pretreated with antisense oligonucleotides 
against the two PLD isoforms. The levels of PLD1 and PLD2 expression has been 
significantly downregulated following the respective antisense oligonucleotide treatment 
can be seen in Figure 3.33.  Based on the figure mentioned it is evident that there is an 
isoform specific reduction in the expression of PLD following antisense treatment. This 
is similar to the results in the earlier section dealing with human monocytic cell line. 
 


























Figure 3.33: Specific knockdown of PLD isoforms (PLD1 and PLD2) using 
antisense oligonucleotides in primary human monocytes 
Western blot analysis of immunoprecipitates of either PLD1 or PLD2 to assess 
expression of either isozyme in human monocytic cells, following 36 hours 
treatment with antisense oligonucleotides (10 µM) specific for either PLD1 
(a.s.PLD1) or PLD2 (a.s.PLD2) and untreated cells severed as controls 
(Control). ARF1 (ADP-ribosylation factor 1) was used as loading control and the 
samples were obtained from whole cell lysates. The results shown are typical 
from three separate experiments.  
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Treatment of cells with the antisense oligonucleotide to PLD1 resulted in no 
change in basal PLD activity.  However, following TNFα stimulation, the increase in 
PLD activity was significantly reduced, compared to the control cells (Figure 3.34). In 
contrast, treatment of cells with the antisense oligonucleotide to PLD2 only had an effect 
on the basal PLD activity and not on the TNFα−induced increase in PLD activity (Figure 




























Figure 3.34: PLD1 isoform was found to be coupled with TNFα signaling in 
primary human monocytes 
PLD activity following TNFα (10 ng/ml) stimulation in cells pretreated with 10 µM 
antisense oligonucleotides for either PLD1 (a.s.PLD1) or PLD2 (a.s.PLD2). PLD 
activity in untreated cells (Basal); in cells stimulated with TNFα (TNF); in cells 
pretreated with a.s.PLD1 only (a.s.PLD1 only); in cells pretreated with a.s.PLD1 prior 
to TNFα stimulation (a.s.PLD1 + TNF); in cells pretreated with a.s.PLD2 only 
(a.s.PLD2 only) and in cells pretreated with a.s.PLD2 prior to TNFα stimulation 
a.s.PLD2 + TNF).  Results are the mean ± S. D. of triplicate measurements from three 
separate experiments. (**) indicates Student’s t test p value <0.01. 
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Furthermore, it is also shown here that, as observed in the U937 cells, PLD1 is 
coupled to TNFα−triggered intracellular signaling events like the activation of cytosolic 
calcium release and SphK activity in peripheral blood derived primary human monocytes 
(Figures 3.35 and Figure 3.36 respectively).  
Figure 3.35: Intracellular cytosolic calcium changes following TNFα 
stimulation is PLD1 dependent in primary human monocytes 
Intracellular cytosolic calcium responses after TNFα stimulation were compared 
in control cells and cells pretreated with antisense oligonucleotides (10 µM) to 
either PLD1 or PLD2.  Traces shown are, control cells treated with TNFα 10 
ng/ml (TNF); cells pretreated with antisense to PLD1 (a.s.PLD1 + TNF) and 
cells pretreated with antisense to PLD2 (a.s.PLD2 + TNF).  The arrow marks the 


























Figure 3.36:  TNFα-induced sphingosine kinase activity is dependent on PLD1 in 
primary human monocytes 
Sphingosine kinase activity following TNFα (10 ng/ml) stimulation is shown. Cells were 
harvested at given time points indicated in the figure to measure sphingosine kinase activity. 
Sphingosine kinase activity, in untreated control cells (● – Basal); in untreated cells 
following TNFα stimulation (○ – TNF) and in cells pretreated with antisense 
oligonucleotides (10 µM) for either PLD1 (◊ – a.s.PLD1 + TNF) or PLD2 (▲ – a.s.PLD2 + 
TNF) prior to TNFα stimulation. Results are the mean ± S.D of triplicate measurements and 
from three separate experiments. (*) indicates Student’s t test p value <0.01. 
 131 
 In addition to the intracellular signaling events, PLD1 was also found to be 
essential for TNFα−induced effector responses like proinflammatory cytokine (IL-6 and 





























 Based on the results discussed in this chapter, it can be comprehended that PLD in 
general and PLD1 in particular mediates TNFα-induced intracellular signaling events and 
pro-inflammatory responses both in the chosen cell line and primary cell model. 
Figure 3.37: TNFα-triggered cytokine release in primary human monocytes are 
mediated by PLD1 
Measurements of IL-6 and IL-1β in unstimulated (Basal) and after stimulation with 
TNFα 10 ng/ml (TNFα), pretreated or not with the antisense oligos: Basal (Basal 
control); TNFα stimulation (TNF); Basal in cells pretreated with a.s.PLD1 
(a.s.PLD1); TNFα stimulation in cells pretreated with a.s.PLD1 (a.s.PLD1 + TNF); 
Basal in cells pretreated with a.s.PLD2 (a.s.PLD2) and TNFα stimulation in cells 
pretreated with a.s.PLD2 (a.s.PLD2 + TNF).  Results shown are the mean ± S.D. of 
triplicate measurements and from three separate experiments. (**) indicates Student’s 




In this study, it has been shown that TNFα is functionally coupled to PLD1, but 
not PLD2, in IFN-γ primed U937 cells, as well as in human primary monocytes, even 
though both the enzymes were expressed in these cells. We further show that PLD1, and 
not PLD2, is required for TNFα−induced activation of the sphingosine kinase, 
intracellular calcium responses, the activation of a key transcription factor and cytokine 
generation.  
Understanding the intracellular signal transduction mechanisms that regulate 
TNFα-mediated responses has profound implications, not the least of which is to identify 
novel molecules as potential therapeutic targets. There is overwhelming evidence for 
believing that TNFα is associated with a variety of inflammatory conditions in several 
diseases (Aderka et al., 1985; Bolling et al., 1992; Feldmann, 2002; Feldmann et al., 
1995; Lahdevirta et al., 1988; Lang et al., 1992; Maury and Teppo, 1987; Oliff et al., 
1987; Remick et al., 1987; Roux-Lombard et al., 1989; Selmaj et al., 1991; Stephens and 
Pekala, 1991; Tracey et al., 1986; Tracey et al., 1987; Tracey et al., 1988; Ulich et al., 
1991). Efforts are being made to find novel ways to balance TNFα levels or TNFα-
induced responses in several diseases, including rheumatoid arthritis and SLE. Regulation 
of molecules involved in the TNFα-triggered signaling pathways has gained attention in 
this regard, as a variety of signaling molecules such as PDE4, p38 MAP-kinase and 
NFκB inhibitors are being studied in clinical trials (Palladino et al., 2003). More efficient 
therapies may become available by elucidation of the molecular mechanisms, and the role 
of key molecules, involved in the TNFα-triggered signaling events. Thus, the role of 
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PLD isoforms in TNFα-induced intracellular and effector responses in human monocytes 
was investigated.  
Results in this study show that TNFα triggers PLD activity and that PLD1 (but 
not PLD2) is rapidly translocated from a cytosolic distribution to the plasma-membrane 
periphery. The cells used in this study expresses both PLD isoforms (PLD1 and PLD2) 
(Melendez et al., 2001). The selective re-localization of PLD1 to the cell membrane after 
TNFα stimulation suggests that TNFα signaling might be associated with the selective 
activation of PLD1. However, as there are many reports indicating the stimulation of 
isoform-specific PLDs in different cells, responding to distinct stimuli (Bechoua and 
Daniel, 2001; Jenkins and Frohman, 2005; McDermott et al., 2004; Melendez et al., 
2001; Paruch et al., 2006). Therefore, this study was designed to further the investigation 
of the specific isoform activation of PLD by TNFα. Antisense oligonucleotides were 
utilized to specifically knockdown the expression of either PLD1 or PLD2. The results 
from the antisense experiments demonstrate that TNFα specifically activates PLD1 but 
not PLD2.  
To improve our understanding, studies were conducted to elucidate the role of 
PLD1 in TNFα−induced intracellular signaling events. It has been previously shown that 
PLD plays a role in inflammatory signals (Jenkins and Frohman, 2005) and may 
stimulate MAPK phosphorylation events (Fang et al., 2001; Ghosh et al., 1996; Jones and 
Hannun, 2002; Rizzo et al., 1999) or prevent protein de-phosphorylation (Jones and 
Hannun, 2002). MAPKs are vital regulators and/or amplifiers of extracellular stimuli 
leading to cellular functions. They are regulated by sequential phosphorylation of their 
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preceding kinase-family members (Roux and Blenis, 2004). Regulation of cell survival, 
growth and differentiation are some of the important roles of ERK1/2 (Cowley et al., 
1994; Hill and Treisman, 1995).  In this study, the results indicate that PLD is upstream 
of ERK1/2. It is quite well known that Raf-1 translocation subsequent to an agonist 
activation is an upstream event prior to ERK1/2 phosphorylation (Chen et al., 2001; Roux 
and Blenis, 2004). The results show that PLD mediates TNFα induced Raf-1 
translocation via phosphatidic acid. Previous studies have also shown that Raf-1 can be 
activated by phosphatidic acid as the latter has been suggested to possess a binding site 
for PA (Ghosh et al., 1996; Rizzo et al., 1999). The current finding that ERK1/2 is 
downstream of PLD is, therefore, consistent with these other previous in vitro studies 
(Ghosh et al., 1996; Rizzo et al., 1999). This study also shows that the TNFα stimulated 
ERK1/2 phosphorylation is dependent on PLD1. However, the phosphorylation of p38 is 
not. Interestingly, several studies have reported receptor-coupled activation of ERK1/2 to 
be not only independent of PLD activity, but that PLD activity was actually dependent on 
ERK1/2 activity (Paruch et al., 2006). It is shown here that, at least in human monocytic 
cells, TNFα signals in a very different way, i.e., TNFα stimulated PLD activity is 
upstream of ERK1/2 phosphorylation, while p38 phosphorylation is independent of PLD 
activity. This is in contrast to an elegant report by Bechoua and Daniel, that showed that 
fMLP-triggered p38 activation in HL-60 cells was dependent on PLD activity, whereas 
ERK1/2 phosphorylation was not (Bechoua and Daniel, 2001). In order to clarify these 
potential contradictions, and to establish the molecular specificity in our system, we 
utilized MEK and p38 inhibitors and looked at PLD activity triggered by TNFα. Our 
results showed that neither inhibition of MEK nor p38 had any effect on TNFα−mediated 
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PLD activity and the inhibitors were shown to be effective and functioning appropriately 
as they inhibited their respective targets and their associated effector responses.  
To further our studies on the role of PLD1 in TNFα-triggered intracellular 
signaling events, we looked at its role in SphK activation triggered by TNFα. It has been 
previously shown that, in these cells, TNFα activates Sphingosine kinase to mediate its 
responses (Zhi et al., 2006). Here, the results show that in cells pretreated with the 
antisense against PLD1, the TNFα stimulated SphK activity was substantially inhibited, 
whereas in the cells pretreated with the antisense against PLD2, the TNFα−mediated 
SphK activity remained intact. This is further proof for the specificity of PLD1 in the 
TNFα−mediated signaling events. The finding the PLD is upstream of SphK in this 
model reiterates the fact suggested by Olivera et al that SphK is directly activated by 
phosphatidic acid (Olivera et al., 1996). Therefore, we can suggest that TNFα-triggered 
PLD derived PA regulates the activation of SphK and its down stream mediators and 
responses.  
 Intracellular calcium is well known as an important intracellular second 
messenger and is known to regulate cellular responses. Cytosolic calcium influences 
cellular responses by participating in a variety of biological process like the activation of 
kinases, phosphatases, degranulation and activation of transcription factors. Increase in 
the level of cytsolic calcium and release from internal stores following immune receptor 
activation has been reported (Floto et al., 1995; Mandeville and Maxfield, 1996). Here it 
is shown that TNFα induces an increase in cytosolic calcium which dependent on PLD1. 
It has already been shown in a similar model that TNFα−induced calcium release is 
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SphK1 dependent (Zhi et al., 2006). Consistent with the previous study, our results are 
clear that TNFα-induced SphK regulated intracellular calcium release is mediated by 
PLD1. Based on the current study and the earlier study (Zhi et al., 2006) we can propose 
that TNFα mobilizes intracellular calcium through the coupling of PLD1 to SphK1. This 
is the first example of this pathway to be shown in cytokine signaling.  
Results in this study clearly showcase the importance of PLD in TNFα−induced 
NFκB activation and the consequent inflammatory response. This was demonstrated by 
the decrease in the levels of p65 subunit in the nucleus when PLD activity was blocked 
prior to stimulation. This current study also indicated that PLD activity was responsible 
for regulating p65 by targeting the upstream event of IκB alpha degradation subsequent 
to agonist stimulation. This regulatory event is of primary importance, as it facilitates the 
release of the active NFκB subunits which translocate from the cytoplasm into the 
nucleus. As mentioned earlier, this study demonstrates that PLD1 is required for the 
phosphorylation/activation of ERK1/2 MAPKs. Interestingly, it has long been established 
that members of the MAPK family can phosphorylate the IκB alpha kinase complex, 
which in turn leads to the activation of NFκB (Lee, 1997; Tergaonkar, 2006). However, 
the results in this investigation clearly shows that TNFα induced IκB alpha degradation 
and NFκB activity is dependent on PLD but TNFα−induced IκB alpha degradation and 
NFκB activity are not dependent on ERK1/2 and p38 kinase. The fact that TNFα needs 
to couple to PLD1 to trigger calcium release from internal stores may, at least in part, 
explain the role of PLD1 in TNFα stimulated NFκB activation, as it has been shown that 
calcium amplitude and/or modulation is required for NFκB activation (Aoki, 1997; 
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Dolmetsch R. E, 1997; Tergaonkar, 2006). Moreover, it has also been shown that the 
product of SphK activity, S1P can activate NFκB in U937 cells (Shatrov V. A., 1997).  
As the NFκB and ERK1/2 pathways appear to be dependent on PLD activity, we 
went on to measure the TNFα-triggered proinflammatory cytokine production and 
cellular migration, and showed that the antisense to PLD1 substantially blocked the 
responses measured. Taken together, the data presented here suggest that TNFα 
stimulation in cells triggers a number of effector functions, including the generation of 
several cytokines and chemotaxis. The novel intracellular signaling pathway 
demonstrated here appears to be functionally interactive / associated with these. In the 
study reported here, silencing PLD1 reduced the ability of TNFα to mobilize calcium 
from intracellular stores and, significantly reduced the activation of signal ampifiers like 
ERK1/2 and key transcription factors, such as NFκB. It is of interest that these 
transcription factors play major roles in the inflammatory responses, by triggering 
cytokine and chemokine genes, as well as cycloxigenases and other genes involved in the 
inflammatory responses (Shaffer et al., 2001). The finding that TNFα triggers the rise in 
cytosolic calcium and cytokine production, via a novel pathway that utilizes the 
sequential activation of PLD1 and SphK, has profound implications for the development 






Figure 3.38: Schematic representation of the isoform specific role of 








Ligand mediated activation of cell surface receptors is known to generate lipid 
based intracellular signaling molecules from cellular phospholipids (Divecha and Irvine, 
1995; Steed and Chow, 2001). Phosphatidylcholine specific phospholipase D (PLD) is an 
enzyme which hydrolyzes phosphatidylcholine, a membrane bound cellular phospholipid 
to generate phosphatidic acid (PA) and choline (Heller, 1978; Yang et al., 1967). PA, a 
potent second messenger by itself, can be further converted to other mediators like 
diacylglycerol (DAG) and Lysophosphatidic acid (LPA) by Phosphatidic acid 
phosphohydrolases and Phospholipase A2 respectively (English, 1996; English et al., 
1996; Exton, 2002a; Exton, 2002b; Sciorra and Morris, 1999). Since, PLD is a major 
source of these bioactive molecules, it is considered to be an important lipid based 
intracellular signaling mediator. It thereby regulates a variety of homeostatic cellular 
functions like membrane trafficking, vesicular transport, cytoskeletal re-organization, 
cellular migration, proliferation and survival (Colley et al., 1997; Exton, 2002a; Exton, 
2002b; Siddhanta and Shields, 1998). The role of PLD in immune cell responses and 
inflammation has been well documented. It is known to mediate receptor activated 
effector responses like phagocytosis (Gewirtz and Simons, 1997; Kusner et al., 1999), 
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NADPH-oxidative burst (Dana et al., 2000; Melendez et al., 2001), immune cell 
migration (Atta ur et al., 1999; Lehman et al., 2006; Sethu et al., 2008), immune cell 
degranulation (Hammond et al., 1995; Morgan et al., 1997) and cytokine production 
(Sethu et al., 2008; Singh et al., 2006). Therefore, PLD has been a potential target for 
managing aberrant inflammation (Steed and Chow, 2001).  
PLD comprises of two major isoforms, PLD1 and PLD2 (Colley et al., 1997; 
Hammond et al., 1995). They are expressed in a wide range of almost all the mammalian 
tissues. The isoforms have been reported to mediate specific immune responses based on 
their differential expression profiles on immune cells. The PLD isoforms are reported in 
neutrophils (Di Fulvio and Gomez-Cambronero, 2005), monocytes (Melendez et al., 
2001), macrophages (Iyer et al., 2004), lymphocytes (Diaz et al., 2005), NK cells (Milella 
et al., 1999) and dendritic cells (Lee et al., 2004b). PLD1 has been associated with 
inflammatory and immune responses in monocytes, macrophages and neutrophils 
(Cadwallader et al., 2004; Iyer et al., 2006; Locati et al., 2001; Melendez et al., 2001; 
Sethu et al., 2008) and PLD2 has been reported to mediate responses in T lymphocytes 
(Hamdi et al., 2008; Mor et al., 2007). However, both PLD1 and PLD2  together have 
also been found to mediate phagocytosis in macrophages as well (Iyer et al., 2004; 
Lehman et al., 2006). Studies have also reported the stimuli or agonist specific activation 
of selective PLD isoforms in various cells types (Bechoua and Daniel, 2001; Jenkins and 
Frohman, 2005; McDermott et al., 2004; Melendez et al., 2001; Paruch et al., 2006). 
Therefore, PLD isoforms are potential targets to dampen specific immune responses.  
Tumour Necrosis Factor alpha (TNFα), a potent pleiotropic pro-inflammatory 
cytokine is associated with a variety of inflammatory disorders (DeVries et al., 1999; 
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Matsumoto and Kanmatsuse, 1999; Palladino et al., 2003; Plo et al., 2000; Tracey and 
Cerami, 1993; Tracey and Cerami, 1994). It is produced by a variety of cells including 
immune cells, glial cells, keratinocytes and fibroblasts. In an attempt to identify strategies 
to reduce TNFα-associated morbidity,  molecules involved in the TNFα-triggered 
signaling pathways  such as PDE4, p38 MAP-kinase and NFκB inhibitors are being 
explored (Palladino et al., 2003).  PLD has gained attention in this regard as it is a major 
player in receptor mediated signaling cascade. However, the studies have reported the 
role of PLD in TNFα-mediated signaling and responses with contrasting findings  (De 
Valck et al., 1993; Kang et al., 1998; MacEwan, 2002b). In our recent study we have 
reported that PLD1 is coupled to TNFα signaling and associated inflammatory responses 
in vitro (Sethu et al., 2008).  In vivo studies will be useful to demonstrate the potential 
therapeutic implication of PLD1 in inflammation. In vivo validation of the function of 
PLD1 in general and its role in inflammation in specific is yet to be explored. The 
peritonitis model in mice is a dependable method to study the inflammatory process in 
vivo. TNFα can induce an inflammatory response with the associated characteristic signs 
and symptoms when injected directly into the peritoneal cavity. The detailed description 
of the model has been described in section 2.18 in chapter 2. Therefore, in this study the 
role of PLD1 in TNFα-induced peritonitis in mice was evaluated. The results indicate 
that PLD1 mediates responses associated with peritonitis, implying that PLD1 is coupled 




The dose of TNFα and time of maximum inflammatory response following intra-
peritoneal injection of TNFα was to be determined in BALB/c mice.  
 
4.2.1 Determination of TNFα dosage 
Classical inflammatory responses like changes in body temperature and increase 
in the levels of proinflammatory cytokine like IL-6 were chosen as parameters to 
determine the appropriate dose and time of maximum response. Therefore, we evaluated 
the changes in body temperature of mice following intra-peritoneal administration of 
varying doses (2.5 µg/mouse, 5 µg/mouse and 10 µg/mouse) of TNFα using a rectal 
thermometer. Mice injected with different doses of TNFα exhibited an increase in body 
temperature (Figure 4.1). The temperature changes were initially monitored every hour 
for 6 hours. This increase in temperature peaked at two hours of TNFα administration 
followed by gradual drop in the increase in temperature in the subsequent hourly 
measurements. There was approximately a 2°C increase in temperature from that of the 
observed basal temperature with TNFα doses of 5 µg/mouse and 10 µg/mouse.  
Another parameter evaluated was the levels of IL-6, an important 
proinflammatory cytokine useful in the amplification of TNFα-induced responses. 
Therefore, we measured the levels of IL-6 in both the peritoneal lavage and in the serum 
following 2 hours and 6 hours subsequent to TNFα administration via i.p injection. There 
was a marked increase in the levels of IL-6 both in the serum and peritoneal lavage, 2 
hours after TNFα treatment (Figure 4.2). However, this increase in levels dropped at the 
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end of 6 hours (Figure 4.2). Though there was an increase in IL-6 levels in all the doses 
tested, 5 µg/mouse and 10 µg/mouse of TNFα showed a more marked response.  
Based on this data set (Figure 4.1 and 4.2), TNFα of 5 µg/mouse was chosen as 
the dose to induce the required experimental inflammatory response. The choice is due to 
the observation that this dose was the lowest dose tested which initiated a marked 
response among the doses tested. In other words, 5 µg/mouse of TNFα induced a 
response greater than 2.5 µg/mouse but similar to 10 µg/mouse.  2 hours post intra-
peritoneal administration was chosen as the time point to evaluate the various acute 
inflammatory responses associated with intra-peritoneal TNFα administration. 
Figure 4.1: Rectal temperature pattern triggered by TNFα in BALB/c mice 
The graphs indicate TNFα-induced rectal temperature changes observed over the 
time points indicated. Different doses of TNFα (2.5 µg/mouse; 5 µg/mouse and 
10 µg/mouse) as indicated were administered via intra-peritoneal (i.p) injections. 
Equal volume of sterile 1xPBS of was also administered (i.p) for the Basal 
controls. Results shown are the mean ± the standard deviation of measurements 





























Figure 4.2: IL-6 release response pattern triggered by TNFα in BALB/c mice 
The graphs indicate TNFα−induced IL-6 release in the peritoneal lavage (A) and 
in the serum (B). IL-6 production was observed over the time points indicated. 
Three different doses of TNFα (D1 – 2.5 µg/mouse; D2 – 5 µg/mouse and D3 – 10 
µg/ mouse) as indicated were administered via intra-peritoneal (i.p) injections. 
Equal volume of sterile 1xPBS of was also administered (i.p) for the Basal 
controls. Results shown are the mean ± the standard deviation of triplicate 





4.2.2 In vivo knock down of mPLD1  
Intravenous administration of a siRNA is known to result in a significant 
knockdown of the gene product in the mice. Figure 4.3A, shows a significant decrease in 
the protein level of murine phospholipase D1 (mPLD1) in peripheral blood leukocytes of 
mice, following intravenous administration of siRNA (4 µg/mouse) to knock down 
mPLD1.  siRNA administration strategy was described in chapter 2. Since both the PLD 
isoforms are expressed in BALB/c mice (Kim et al., 2007), we determined the isoform 
specific knock down of PLD1 by evaluating the expression of PLD2 as well, following 
the above mentioned siRNA intravenous administration. The level of mPLD2 expression 
remained unaffected subsequent siRNA treatment specific for PLD1 (Figure 4.3B). Thus, 




































Figure 4.3: Specific knock down of PLD1 in BALB/c mice using siRNA 
(A) Western blot analysis shows the knockdown of murine phospholipase D1 
(mPLD1) in BALB/c mice peripheral blood leukocytes, by the use of specific 
siRNA for PLD1 (4 µg/mouse) administered via intravenous tail vein 
injection regimens as described earlier. (B) Western blot analysis shows the 
expression of murine phospholipase D2 (mPLD2) in the same set of samples 
as indicated. Lysates probed for PLD1 and PLD2 from peripheral blood 
leukocytes were obtained from, untreated mice which severed as control 
(Control); from mice injected with siRNA-PLD1 (siRNA-PLD1) and from 
mice injected with scrambled siRNA (Scr-siRNA). In addition, α-tubulin 
was probed for loading control. The immunoblot shown here is a 
representative of three different replicate experiments done. This was 
performed by obtaining peripheral blood leukocytes lysates from three 







4.2.3 Role of PLD1 in TNFα-induced acute peritonitis in mice 
The functional contribution of PLD1 in TNFα−induced acute peritonitis model 
was determined by studying the responses in both control mice and in mice with 
decreased PLD1 expression in peripheral blood leukocytes following siRNA treatment. 
The responses studied include changes in body temperature, proinflammatory cytokine 
and chemokines production, cellular infiltration and/or migration and expression of cell 
adhesion molecules in the vascular endothelium following TNFα administration (intra 
peritoneal injection). 
 
4.2.3.1 Temperature response  
One of the characteristic systemic responses related to TNFα administration is 
pyrexia or increase in body temperature. Therefore, the change in body temperature of 
mice following TNFα intra-peritoneal administration and the role of PLD1 in this 
response was evaluated. Mice, injected with TNFα developed marked increase in body 
temperature in an hour (Figure 4.4). This increase in body temperature was considerably 
reduced in mice pretreated with the PLD1 siRNA. However, the temperature changes in 
mice pretreated with the negative control siRNA the temperature changes were identical 

































Figure 4.4: PLD1 knock down alters rectal temperature changes triggered 
by TNFα in BALB/c mice. 
The graphs indicate TNFα (5 µg/mouse) induced rectal temperature changes 
observed over the time points indicated. TNFα was administered via intra-
peritoneal (i.p) injections. The above indicates, temperature pattern in control 
mice (♦); temperature changes after TNFα administration (■); temperature 
changes in mice injected with siRNA-PLD1 (▲) and scrambled siRNA (●) prior 
to TNFα administration. Results shown are the mean ± the standard deviation of 
measurements from three different mice for each category. (*) indicates 





4.2.3.2 Proinflammatory cytokine production 
A key event in the inflammatory process is the production of proinflammatory 
cytokines. TNFα is capable of amplifying its inflammatory response by promoting the 
generation and release of several proinflammatory cytokines and chemokines. Therefore 
we investigated the levels of IL-6, MIP-1α (Macrophage inflammatory protein – 1 alpha) 
and MIP-1β (Macrophage inflammatory protein – 1 beta) in both the peritoneal lavage 
and in the serum following TNFα administration. We found there was a significant rise in 
the levels of these proinflammatory cytokine in the serum and peritoneal lavage of mice 
treated with TNFα (Figure 4.5 – 4.7). In contrast, an inhibition in this response was 
observed when the mice were treated with siRNA-PLD1 prior to TNFα injection (Figure 













































Figure 4.5: TNFα-induced IL-6 release is dependent on PLD1 in BALB/c mice 
The graphs indicate the TNFα (5 µg/mouse) induced (i.p) IL-6 release in 2 hours in 
peritoneal lavage (A) and in serum (B). IL-6 levels in control mice (Basal); in mice 
injected with TNFα (TNF); in mice injected with siRNA-PLD1 prior to TNFα 
administration (siRNA PLD1 + TNF) and in mice injected with scrambled siRNA 
prior to TNFα administration (scr siRNA + TNF). Results shown are the mean ± 
the standard deviation of triplicate measurements of individual samples collected 




























Figure 4.6: TNFα−induced MIP-1α release is dependent on PLD1 in BALB/c mice 
The graphs indicate the TNFα (5 µg/mouse) induced (i.p) MIP-1α release in 2 hours in 
peritoneal lavage (A) and in serum (B). MIP-1α levels in control mice (Basal); in mice 
injected with TNFα (TNF); in mice injected with siRNA-PLD1 prior to TNFα 
administration (siRNA PLD1 + TNF) and in mice injected with scrambled siRNA prior 
to TNFα administration (scr siRNA + TNF). Results shown are the mean ± the standard 
deviation of triplicate measurements of samples collected from three different mice for 











































Figure 4.7: TNFα−induced MIP-1β release is dependent on PLD1 in BALB/c 
mice 
The graphs indicate the TNFα (5 µg/mouse) induced (i.p) MIP-1β release in 2 hours 
in peritoneal lavage (A) and in serum (B). MIP-1β levels in control mice (Basal); in 
mice injected with TNFα (TNF); in mice injected with siRNA-PLD1 prior to TNFα 
administration (siRNA PLD1 + TNF) and in mice injected with scrambled siRNA 
prior to TNFα administration (scr siRNA + TNF). Results shown are the mean ± the 
standard deviation of triplicate measurements of samples collected from three 






4.2.3.3 Cellular infiltration/migration 
One of the characteristic events in an inflammatory response is the increase in 
vascular permeability, which leads to the influx of immune cells to the site of 
inflammation. This was confirmed by investigating the number of neutrophils in the 
peritoneal lavage at the end of two hours. Intra-peritoneal administration of TNFα-
induced a significant influx of neutrophils into the peritoneal cavity compared to that of 
the untreated controls (Figure 4.8). This increase in the neutrophils counts in the 
peritoneal lavage following TNFα administration was significantly inhibited in those 






















































Figure 4.8: Neutrophils infiltration into the peritoneum lavage induced by 
TNFα is dependent on PLD1 in BALB/c mice 
The graphs indicate the TNFα (5 µg/mouse) induced (i.p) neutrophil 
infiltration in 1.5ml of peritoneal lavage after 2 hours of TNFα administration. 
Number of neutrophils, in peritoneal lavage of control mice (Basal); in the 
peritoneal lavage of mice injected with TNFα (TNF); in the peritoneal lavage 
of mice injected with siRNA-PLD1 prior to TNFα administration (siRNA-
PLD1 + TNF) and in the peritoneal lavage of mice injected with scrambled 
siRNA prior to TNFα administration (scr siRNA + TNF). Results shown are 
the mean ± the standard deviation of triplicate measurements of lavage samples 
collected from three different mice for each category. (* *) indicates Student’s t 




The role of PLD1 in TNFα-triggered migration of neutrophils or immune cells to 
the site of inflammation was further evaluated using H and E staining of the inflamed 
peritoneal tissues. The peritoneal tissues from mice treated with TNFα intra-peritoneal 
injection exhibited an increase in cellular infiltration pattern following H and E staining 
(Figure 4.9). However, these changes in the cellular infiltration pattern were markedly 




































Figure 4.9: Cellular infiltration pattern in peritoneal tissue induced by TNFα 
is dependent on PLD1 in BALB/c mice 
The panels show TNFα (5 µg/mouse) induced (i.p) cellular infiltration pattern 
using H and E staining in the peritoneal tissues after 2 hours of TNFα 
administration. The panels indicate the peritoneal tissues from control mice 
(CONTROL); from mice injected with TNFα (TNF); from mice injected with 
siRNA-PLD1 prior to TNFα administration (siRNA-PLD1 + TNF) and from mice 
injected with scrambled siRNA prior to TNFα administration (scrambled siRNA 
+ TNF). Results shown are representatives of multiple sections and fields from 
three different mice for each category. 
. 
 157 
4.2.3.4 Expression of cell adhesion molecules 
It is well known that cell adhesion molecules are important mediators in the cellular 
migration and infiltration. Therefore, we evaluated the expression of ICAM1 and VCAM 
on the vascular endothelium using immunohistochemistry in the peritoneal tissues of 
mice in our study model. There was an increase in the expression of VCAM and ICAM1 
(Figure 4.10 and 4.11 respectively) on the vascular endothelial cells following intra-
peritoneal TNFα injection. On the contrary, there was a decrease in the expression of the 
cell adhesion molecules investigated in the tissues samples obtained from mice injected 
with siRNA – PLD1 prior to TNFα administration (Figure 4.10 and 4.11). 
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Figure 4.10: TNFα-induced VCAM expression in peritoneal tissues is 
dependent on PLD1 in BALB/c mice 
The panels show TNFα (5 µg/mouse) induced (i.p) VCAM expression pattern 
using immunohistochemistry in the peritoneal tissues after 2 hours of TNFα 
administration. The panels indicate the peritoneal tissues from control mice 
(CONTROL); from mice injected with TNFα (TNF); from mice injected with 
siRNA-PLD1 prior to TNFα administration (siRNA-PLD1 + TNF) and from mice 
injected with scrambled siRNA prior to TNFα administration (scrambled siRNA + 
TNF). Results shown are representatives of multiple sections and fields from three 
different mice for each category. 
. 
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Figure 4.11: TNFα−induced ICAM1 expression in peritoneal tissues is 
dependent on PLD1 in BALB/c mice 
The panels show TNFα (5 µg/mouse) induced (i.p) ICAM1 expression pattern 
using immunohistochemistry in the peritoneal tissues after 2 hours of TNFα 
administration. The panels indicate the peritoneal tissues from control mice 
(CONTROL); from mice injected with TNFα (TNF); from mice injected with 
siRNA-PLD1 prior to TNFα administration (siRNA-PLD1 + TNF) and from mice 
injected with scrambled siRNA prior to TNFα administration (scrambled siRNA + 
TNF). Results shown are representatives of multiple sections and fields from three 




The PLD isoform expression profile in BALB/c mice has been reported in detail, 
including its differential expression in the various organs and tissues (Kim et al., 2007). 
However, the expression profiles in murine leukocytes were not reported and we have 
confirmed the presence of both the isoforms of PLD in murine peripheral blood 
leukocytes of this background. In the present study using a peritonitis model in mice, we 
have validated the function of PLD1 in the mediation of TNFα−induced inflammatory 
process in vivo. This is in concordance with our earlier in vitro finding that PLD1 
mediates TNFα-triggered responses (Chapter 3). This study is the first study which 
validates the in vivo relevance of PLD isoform in the process of inflammatory responses. 
Increase in body temperature is a systemic response to infection or inflammation and it is 
known to be mediated by endogenous pyrogens like TNFα and IL-6 (Zanetti et al., 1992). 
It has also been reported that TNFα−induced pyrexia in mice was found to be mediated 
by IL-6 (Sundgren-Andersson et al., 1998). Our study shows that TNFα-induced pyrexia 
was inhibited when PLD1 was knocked down. We have also shown that PLD1 is 
necessary for TNFα-induced IL-6 production in both in vitro (Chapter 3) and in vivo. The 
inhibition of TNFα−induced increase in body temperature could be due to the decrease in 
the levels of IL-6. Therefore, we can suggest that PLD1 mediates TNFα−induced pyrexia 
by modulating the production of IL-6. The production of proinflammatory cytokines are 
one of the characteristic features of inflammation. Our study has vividly shown that 
PLD1 is essential in TNFα (i.p) induced systemic and local increase in the levels 
proinflammatory cytokine and/or chemokines which are important in the amplification of 
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the inflammatory process. This we suggest, based on the fact that the knock down of 
PLD1 in vivo prevented the TNFα-triggered increase in levels IL-6, MIP-1α and MIP-1β 
both in the peritoneal lavage and serum. IL-6, apart from modulating homeostatic 
functions like proliferation, differentiation, survival and apoptosis also plays a major role 
in the amplification of inflammatory responses (Kamimura et al., 2003; Kishimoto, 
2006). Its level  is reported to rapidly increase during inflammatory responses due to 
injury, infection and stress (Kamimura et al., 2003; Kishimoto, 2006). Increased or 
abnormal IL-6 levels are associated with a plethora of inflammatory conditions like 
inflammatory bowel disease, multiple myeloma, rheumatoid arthritis and some 
autoimmune diseases (Grisius et al., 1997; Hirano et al., 1988; Holtkamp et al., 1995; 
Kawano et al., 1988; Stuart et al., 1995; Wong et al., 2001). IL-6 level was also been 
found to be increased in C5a mediated peritonitis is mice in an earlier study (Vlasenko 
and Melendez, 2005). Decrease in the levels or effects of IL-6, a key amplifier of 
inflammatory process are being considered as an option to reduce inflammation 
associated morbidity. MIP-1α (Macrophage inflammatory protein -1 alpha) and MIP-1β 
(Macrophage inflammatory protein -1 beta) produced in response to inflammatory stimuli 
contribute to the process by modulating responses like chemotaxis, degranulation, 
phagocytosis and signaling mediator synthesis (Maurer and von Stebut, 2004). 
Dysregulation of MIP-1 has been associated with inflammatory disorders including 
arthritis (Maurer and von Stebut, 2004; Murdoch and Finn, 2000).  Inhibiting PLD1 can 
reduce the concentrations of these cytokines. Thus, reducing the latter’s adverse effect on 
the injured or inflamed tissue. The next important feature of an inflammatory response 
followed by the increase in the levels of proinflammatory cytokines is cellular adhesion 
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and cell migration into the inflamed tissue. Neutrophil migration and cellular chemotaxis 
have been reported to be mediated by PLD (Cui et al., 1997; Hayes et al., 1999; Lehman 
et al., 2006). We have shown that there has been an increase in the infiltration of 
neutrophils to the inflamed peritoneum as shown by the neutrophil counts in the 
peritoneal lavage and cellular migration by H and E staining in the inflammed region of 
the peritoneal tissue. This response was found to be mediated by PLD1. Cell adhesion is 
a stage which occurs prior to cellular migration and PLD has been implicated in the 
process of cell adhesion in phagocytes (Iyer et al., 2006). This is mediated by the cell 
adhesion molecules consisting of Integrins. Cell adhesion molecules also plays a role in 
the amplification of the inflammatory process by regulating and aiding in leukocyte 
migration (Granger and Kubes, 1994). Intercellular adhesion molecule -1 (ICAM-1) and 
vascular cell adhesion molecules (VCAM) expressed in immune cells and endothelial 
cells are known to be upregulated in inflammatory conditions (Koizumi et al., 1992; 
Staunton et al., 1989). CAMs are therefore being targeted in the treatment for 
inflammatory disorders. We have observed in this study that the increase in ICAM-1 and 
VCAM expression in the peritoneal tissue following TNFα administration is dependent 
on PLD1. In other words CAM expressions were downregulated when PLD1 was 
inhibited. A study reported that LPS induced cell adhesion is mediated by ICAM-1 and 
VCAM was regulated by ERK1/2 and NFκB but was not affected by p38 and JNK 
(Ogawa et al., 2003). This corroborates our earlier finding that PLD1 selectively mediates 
TNFα−induced responses including proinflammatory cytokines via ERK1/2 and NFκB 
(Sethu et al., 2008).  Therefore, we can suggest PLD1 dampens the inflammatory process 
by inhibiting the amplifying responses by interfering with TNFα-triggered ERK1/2 and 
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NFκB activation. It is an accepted fact that proinflammatory cytokine production and 
phagocytic cells infiltration mediate and amplify the inflammatory process. Targeting 
these events will aid in the dampening of any aberrant inflammation. In this accord, our 
earlier in vitro study and the present in vivo study strongly showcase the potential for 
PLD1 as a novel therapeutic target in the management of TNFα associated inflammatory 
conditions. 
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 CHAPTER 5 
 
Sphingosine Kinase1 mediates TNFα−induced inflammatory 
response in vivo 
 
5.1 Introduction 
Over the recent past, Sphingolipids have emerged as key contributors in the 
cellular signaling process, in addition to their structural role in eukaryotic cell 
membranes.  Sphingolipids influence signaling cascades by their potent bioactive 
metabolites like Ceramide and Sphingosine – 1 – phosphate (S1P) which regulates 
cellular homeostasis like cellular proliferation, differentiation and apoptosis (Melendez, 
2008; Spiegel and Milstien, 1995; Spiegel and Milstien, 2002; Spiegel and Milstien, 
2003). S1P mediates signaling as an intracellular second messenger and as an 
extracellular ligand to specific receptors (Spiegel and Milstien, 2002; Spiegel and 
Milstien, 2003).  S1P is generated by the specific phosphorylation of Sphingosine by an 
enzyme called Sphingosine Kinase (SphK). Two mammalian highly conserved SPHK 
isoforms (SPHK 1 and SPHK 2) has been identified, cloned and characterized (Kohama 
et al., 1998; Liu et al., 2000; Melendez et al., 2000). The SphK isoforms are associated 
with distinct cellular functions due to their differing kinetic properties, tissue distribution 
and temporal expression patterns (Spiegel and Milstien, 2003).   
Increase in SphK activity with S1P production and associated responses like  
intracellular calcium release, cytokine – chemokines production, chemotaxis, super-oxide 
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production, degranulation and increase in the expression of cell adhesion molecules 
following the activation of plasma membrane receptors like FcγR1 (Melendez et al., 
1998b), FcεR1 (Melendez and Khaw, 2002),  fMLP receptor (Alemany et al., 1999), 
C5aR (Ibrahim et al., 2004; Melendez and Ibrahim, 2004), TNFR (Xia et al., 1998; Zhi et 
al., 2006) and PDGF receptors (Olivera et al., 1999)  in immune cells have been reported. 
SphK has also been strongly implicated in T cell activation and migration (Matloubian et 
al., 2004; Pappu et al., 2007). Based on these reports it is quite evident that SphK in 
response to inflammatory stimuli triggers proinflammatory cytokine production, cellular 
migration and activation of vascular endothelial cells, thereby, associating it with 
inflammatory responses. SphK and S1P have been associated with inflammatory 
conditions and autoimmune conditions including rheumatoid arthritis (Kappos et al., 
2006; Kitano et al., 2006; Sekiguchi et al., 2008). 
Inflammatory disorders have been associated with a potent pro-inflammatory 
cytokine, Tumor Necrosis Factor alpha (TNFα) (DeVries et al., 1999; Matsumoto and 
Kanmatsuse, 1999; Palladino et al., 2003; Plo et al., 2000; Tracey and Cerami, 1993; 
Tracey and Cerami, 1994). It is produced by a variety of cells including immune cells and 
functions both in an autocrine and paracine way through its receptors. TNFα elicits a 
wide spectrum of cellular responses like proliferation, differentiation, mediation of 
inflammation and regulation of immune responses (Chen and Goeddel, 2002; MacEwan, 
2002a). Its immunomodulatory and inflammatory role is brought about by the production 
of various cytokines, activation of leukocytes and lymphocytes, enhancing the expression 
of adhesion molecules, initiating adherence of neutrophils and monocytes to the 
endothelium and promoting inflammatory cell migration (Baud and Karin, 2001; 
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Hehlgans and Mannel, 2002; MacEwan, 2002a; Tracey and Cerami, 1993; Tracey and 
Cerami, 1994). Dysregulation in TNFα production or signaling has been associated with 
inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, systemic lupus 
erythematosus and inflammatory bowel diseases (Aggarwal, 2003; Chen and Goeddel, 
2002; Tracey and Cerami, 1993; Tracey and Cerami, 1994). In an attempt to identify 
strategies to reduce TNFα associated morbidity in inflammatory conditions, TNFα 
blockade by decreasing its level and also by inhibiting its molecules involved in the 
TNFα-triggered signaling pathways  such as PDE4, p38 MAP-kinase and NFκB 
inhibitors are currently being explored (Palladino et al., 2003).  SphK has emerged as one 
of the potential targets in this regard to dampen TNFα associated inflammatory response 
as it is known to mediate TNFα-induced intracellular signaling and associated responses 
in immune cells (Xia et al., 1998). In our recent study we have reported that SphK1 is 
coupled to TNFα signaling events and associated inflammatory responses in vitro (Zhi et 
al., 2006). SphK modulation has been reported to manage inflammatory condition like 
rheumatoid arthritis (Lai et al., 2008b), asthma (Lai et al., 2008a) and C5a induced 
peritonitis (Pushparaj et al., 2008) in mice. However, the direct the role of SphK1 in 
TNFα-mediated responses is yet to be validated in vivo. In the present study, we 
investigated whether modulating SphK by specific blockade of SphK1 through RNA 
interference has an anti inflammatory role in TNFα−induced peritonitis in mice. Here, we 
have shown that an increase in the inflammatory mediators and responses following intra 
peritoneal administration of TNFα was suppressed in mice with specific knock down in 
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the expression of SphK1. This indicates the potential of SphK1 as a target in the 
management of TNFα associated inflammatory conditions. 
 
5.2 Results 
5.2.1 Knock down of mSphK1 in vivo 
Isoform specific knock down of murine Sphingosine kinase1 (mSphK1) was 
established by intravenous administration of a siRNA against mSphK1. The dose and 
administration regimen to obtain a significant knock down of the gene product was based 
on our earlier experiments (Pushparaj et al., 2008).  The details of the methodology are 
described in detail in Chapter 2 of this thesis. Figure 5.1 exhibits a significant decrease in 
the levels of mSphK1 in peripheral blood leukocytes. The isoform specific knock down 
of SphK1 with expression of mSphK2 unaffected using the same siRNA sequence was 
reported in our earlier study (Pushparaj et al., 2008). Therefore, this result indicates 
achievement of isoform specific knock down of SphK1 in vivo. 
 
 
Figure 5.1: Specific knock down of SphK1 in BALB/c mice using siRNA 
Western blot analysis shows the knockdown of murine Sphingosine kinase 1 
(mSphK1) in BALB/c mice peripheral blood leukocytes, by the use of specific 
siRNA for SphK1 (4 µg/mouse) administered via intravenous tail vein 
injection regimens as described earlier. Lysates probed for SphK1 from 
peripheral blood leukocytes were obtained from, untreated mice which severed 
as control (Control); from mice injected with scrambled siRNA (Scr-siRNA) 
and from mice injected with siRNA-SphK1 (siRNA-SphK1). In addition, α-
tubulin was probed for loading control. The immunoblot shown here is a 
representative of three different replicate experiments done. This was 
performed by obtaining peripheral blood leukocytes lysates from three 




5.2.2 TNFα−induced acute peritonitis in mice is mediated by SphK1 
 The role of SphK1 in TNFα−induced acute peritonitis model was evaluated by 
investigating the effects of SphK1 knock down on TNFα (i.p) induced responses like, 
increase in body temperature, proinflammatory cytokine and chemokines production, 
cellular infiltration, migration and expression of cell adhesion molecules in the vascular 
endothelium.  
 
5.2.2.1 Temperature response  
Pyrexia or increase in body temperature is a classical systemic response 
associated with increase in TNFα levels. Therefore, in this study the role of SphK1 in 
whole body temperature changes in mice injected (intra-peritoneal) with TNFα was 
investigated. Figure 5.2 indicates the increase in body temperature by a couple of degree 
celcius following TNFα administration and inhibition in this increase in temperature by 
one degree celcius in mice pretreated with SphK1 siRNA. The body temperature changes 
in mice injected with scrambled siRNA was similar to that of the TNFα control mice 








































Figure 5.2: SphK1 knock down alters rectal temperature changes triggered by 
TNFα in BALB/c mice 
The graphs indicate TNFα (5 µg/mouse) induced rectal temperature changes 
observed over the time points indicated. TNFα was administered via intra-peritoneal 
(i.p) injections. The above indicates, temperature pattern in control mice (♦); 
temperature changes after TNFα administration (■); temperature changes in mice 
injected with siRNA-SphK1 (▲) and scrambled siRNA (●) prior to TNFα 
administration. Graph A indicates changes in actual temperature and graph B 
indicates difference in temperature compared to that of the untreated controls. 
Results shown are the mean ± the standard deviation of measurements from three 




5.2.2.2 Production of proinflammatory cytokine and chemokines 
Increase in the levels of proinflammatory cytokines and chemokines are important 
events in any inflammatory response. It is quite well known that one of the means by 
which TNFα brings about its amplification of inflammatory process is by stimulating the 
release and production of proinflammatory cytokines and chemokines. Therefore, we 
measured the levels of IL-6, MIP-1α and MIP-1β in the peritoneal lavage and in the 
serum of mice in all the categories.  There was a significant increase in the levels of these 
inflammatory mediators both in the serum and peritoneal lavage of mice treated with 
TNFα compared to that of their untreated counterparts (Figure 5.3 – 5.5). However, there 
was an inhibition in the levels of the cytokine and chemokines produced in mice 
pretreated with siRNA- SphK1 prior to TNFα injection (Figure 5.3 – 5.5). This strongly 


















































Figure 5.3: TNFα−induced IL-6 release is dependent on SphK1 in BALB/c 
mice 
The graphs indicate the TNFα (5 µg/mouse) induced (i.p) IL-6 release in 2 hours 
in peritoneal lavage (A) and in serum (B). IL-6 levels in control mice (Basal); in 
mice injected with TNFα (TNF); in mice injected with siRNA-SphK1 prior to 
TNFα administration (siRNA-SphK1 + TNF) and in mice injected with 
scrambled siRNA prior to TNFα administration (scr siRNA + TNF). Results 
shown are the mean ± the standard deviation of triplicate measurements obtained 
from samples collected from three different mice for each category. (* *) 















Figure 5.4: TNFα−induced MIP-1α release is dependent on SphK1 in BALB/c 
mice 
The graphs indicate the TNFα (5 µg/mouse) induced (i.p) MIP-1α release in 2 hours 
in peritoneal lavage (A) and in serum (B). MIP-1α levels in control mice (Basal); in 
mice injected with TNFα (TNF); in mice injected with siRNA-SphK1 prior to TNFα 
administration (siRNA-SphK1 + TNF) and in mice injected with scrambled siRNA 
prior to TNFα administration (scr siRNA + TNF). Results shown are the mean ± the 
standard deviation of triplicate measurements obtained from samples collected from 







Figure 5.5: TNFα-induced MIP-1β release is dependent on SphK1 in BALB/c 
mice 
The graphs indicate the TNFα (5 µg/mouse) induced (i.p) MIP-1β release in 2 hours 
in peritoneal lavage (A) and in serum (B). MIP-1β levels in control mice (Basal); in 
mice injected with TNFα (TNF); in mice injected with siRNA-SphK1 prior to TNFα 
administration (siRNA-SphK1 + TNF) and in mice injected with scrambled siRNA 
prior to TNFα administration (scr siRNA + TNF). Results shown are the mean ± the 
standard deviation of triplicate measurements obtained from samples collected from 
three different mice for each category. (* *) indicates Student’s t test p value <0.01. 
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5.2.2.3 Cellular infiltration/migration 
Increase in vascular permeability and subsequent infiltration of immune cells to 
the inflammatory region or the site of injury is one of the early events in any 
inflammatory process. Neutrophils are the first of the immune cells to reach the site of 
inflammation. Therefore, we investigated the number of neutrophils in the peritoneal 
lavage at the end of two hours. Figure 5.6 shows a significant increase in the number of 
neutrophils in the peritoneal lavage of mice injected with TNFα when compared to that 
of the untreated controls. This indicates the influx of neutrophils into the site of 
inflammation, the peritoneal cavity. However, the observed increase in neutrophils in the 
lavage was significantly reduced in mice pretreated with SphK1 siRNA prior to TNFα 
administration (Figure 5.6).  
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Figure 5.6: Neutrophils infiltration into the peritoneal lavage induced by 
TNFα is dependent on SphK1 in BALB/c mice 
The graphs indicate the TNFα (5 µg/mouse) induced (i.p) neutrophil infiltration 
in 1.5ml of peritoneal lavage after 2 hours of TNFα administration. Number of 
neutrophils, in peritoneal lavage of control mice (Basal); in the peritoneal lavage 
of mice injected with TNFα (TNF); in the peritoneal lavage of mice injected with 
siRNA-SphK1 prior to TNFα administration (siRNA-SphK1 + TNF) and in the 
peritoneal lavage of mice injected with scrambled siRNA prior to TNFα 
administration (scr siRNA + TNF). Results shown are the mean ± the standard 
deviation of triplicate measurements of lavage samples collected from three 
different mice for each category. (* *) indicates Student’s t test p value <0.01. 
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          We further evaluated the role of SphK1 in cellular migration patterns at the site 
inflammation induced by TNFα using H and E staining of the inflamed peritoneal tissues. 
There was increase in the cellular infiltration in the peritoneal tissues of mice treated with 
TNFα intra-peritoneal injection (Figure 5.7). The peritoneal tissues obtained from mice 
with SphK1 knock down prior to TNFα injection exhibited a marked decrease in the 
cellular infiltration pattern observed earlier (Figure 5.7). 
Figure 5.7: Cellular infiltration pattern in peritoneal tissue induced by TNFα is 
dependent on SphK1 in BALB/c mice 
The panels show TNFα (5 µg/mouse) induced (i.p) cellular infiltration pattern using 
H and E staining in the peritoneal tissues after 2 hours of TNFα administration. The 
panels indicate the peritoneal tissues from control mice (CONTROL); from mice 
injected with TNFα only (TNF); from mice injected with siRNA-SphK1 prior to 
TNFα administration (siRNA-SPHK1 + TNF) and from mice injected with 
scrambled siRNA prior to TNFα administration (scrambled siRNA + TNF). Results 
shown are representatives of multiple sections and fields from three different mice 




5.2.2.4 Expression of cell adhesion molecules 
Cell adhesion molecules on both the vascular endothelium and the leukocytes 
play an important role in facilitating the cellular migration and infiltration of immune 
cells to the site of inflammation. Therefore, the expressions of ICAM1 and VCAM on the 
vascular endothelium following TNFα-induced inflammation were investigated using 
immunohistochemistry (IHC) in the peritoneal tissues of mice in our study model. TNFα 
administration induced an increase in the expression of VCAM and ICAM1 (Figure 5.8 
and 5.9 respectively) on the vascular endothelial cells in the peritoneal tissues obtained. 
We have also reported that in the peritoneal tissues obtained from mice injected with 
siRNA - Sphk1 prior to TNFα administration, there was decrease in the expression of 
these cell adhesion molecules (Figure 5.8 and 5.9). These set of results clearly indicate 
the influence of SphK1 in cellular infiltration and migration in an inflammatory response. 
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Figure 5.8: TNFα-induced VCAM expression in peritoneal tissues is dependent 
on SphK1 in BALB/c mice 
The panels show TNFα (5 µg/mouse) induced (i.p) VCAM expression pattern using 
immunohistochemistry in the peritoneal tissues after 2 hours of TNFα administration. 
The panels indicate the peritoneal tissues from control mice (CONTROL); from mice 
injected with TNFα only (TNF); from mice injected with siRNA-SphK1 prior to 
TNFα administration (siRNA-SPHK1 + TNF) and from mice injected with scrambled 
siRNA prior to TNFα administration (scrambled siRNA + TNF). Results shown are 




Figure 5.9: TNFα−induced ICAM1 expression in peritoneal tissues is dependent on 
SphK1 in BALB/c mice 
The panels show TNFα (5 µg/mouse) induced (i.p) ICAM1 expression pattern using 
immunohistochemistry in the peritoneal tissues after 2 hours of TNFα administration. 
The panels indicate the peritoneal tissues from control mice (CONTROL); from mice 
injected with TNFα only (TNF); from mice injected with siRNA-SphK1 prior to TNFα 
administration (siRNA-SPHK1 + TNF) and from mice injected with scrambled siRNA 
prior to TNFα administration (scrambled siRNA + TNF). Results shown are 





SphK and its metabolite S1P have been implicated in a wide range of 
physiological and pathological responses, including those associated with the immune 
system and inflammatory responses (Hla, 2004; Hla and Maciag, 1990; Kappos et al., 
2006; Kitano et al., 2006; Melendez, 2008; Sekiguchi et al., 2008). The pivotal role of 
SphK and S1P in inflammation has been widely established and was elegantly 
summarized in a recent review (Melendez, 2008). Aberrant inflammatory responses are 
mediated by leukocytes. Therefore, modulation in their signaling and responses holds the 
key in dampening inflammation. Extensive studies have implicated the role of SphK in 
intracellular signaling and responses in leukocytes such as, neutrophils (Ibrahim et al., 
2004; Niwa et al., 2000; Vlasenko and Melendez, 2005), mononuclear cells like 
monocytes, macrophages (Melendez et al., 1998b; Melendez and Ibrahim, 2004; Zhi et 
al., 2006), mast cells (Choi et al., 1996; Melendez and Khaw, 2002) and T lymphocytes 
(Lai et al., 2008a; Matloubian et al., 2004; Pappu et al., 2007). Infiltration of phagocytic 
cells and production of proinflammatory cytokines are characteristic features of any 
inflammatory disorder. Targeting or interfering with these events will aid in the 
dampening of aberrant inflammation.  
Studies have also shown that blockade of SphK reduced the severity of 
inflammatory response by inhibiting the production of proinflammatory cytokines 
(Ibrahim et al., 2004; Lai et al., 2008a; Lai et al., 2008b; Melendez et al., 1998b; 
Melendez and Ibrahim, 2004; Zhi et al., 2006) and chemotaxis (Ibrahim et al., 2004; 
Melendez and Ibrahim, 2004). The role of SphK in inflammation and immune response 
in vivo has been reported with SphK inhibitors (Lee et al., 2004a; Vlasenko and 
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Melendez, 2005). Though isoform specific role of SphK has been reported to be 
associated with immune and inflammatory response, the selection of isoforms to specific 
responses remains rather unclear. SphK1 has been selectively associated with immune 
responses in FcγR1, FcεR1, C5a, TNFα associated signaling and responses (Ibrahim et 
al., 2004; Melendez et al., 1998b; Zhi et al., 2006). However, a recent report has 
indicated a role of SphK2 in mast cell activation (Olivera et al., 2007). In addition, it is 
currently reported that SphK2 specifically plays a role in the phosphorylation of FTY720 
(Allende et al., 2004; Zemann et al., 2006), a sphingosine analogue currently in the 
clinical trials for the management of renal transplantation and multiple sclerosis (Kieseier 
et al., 2007; Tedesco-Silva et al., 2005). Both SphK1 and SphK2 have been reported to be 
involved in allergic responses in knock out models (Olivera et al., 2007). Other in vivo 
studies that used RNA interference method have proposed a role of  SphK1 modulation to 
manage inflammatory condition like rheumatoid arthritis (Lai et al., 2008b) and asthma 
(Lai et al., 2008a) are in agreement with our current in vivo study. However, a study has 
reported an interesting but contradictory findings that SphK1 and/or SphK2 were found 
to be dispensable in both chronic and acute inflammatory responses in knock out mice 
models (Michaud et al., 2006; Zemann et al., 2007). This could be due to the action of a 
potential compensatory mechanism initiated in response to the absence of either SphK 
isoform during embryonic development, which may not be the case when it comes to 
transient in vivo knock down studies using short interfering RNA. However, more studies 
are necessary to understand and confirm the isoform specific roles of SphK in 
inflammatory reactions and other immune responses in vivo.  
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In the present study, we have validated the function of SphK1 in the mediation of 
TNFα-induced inflammatory process in vivo using a TNFα induced peritonitis model in 
mice. This is in concordance with our earlier in vitro finding that SphK1 mediates TNFα 
triggered responses (Zhi et al., 2006). One of the systemic responses to infection or 
inflammation is pyrexia or an increase in body temperature. Endogenous pyrogens like 
TNFα and IL-6 are known to mediate this systemic response (Zanetti et al., 1992) and 
TNFα-induced pyrexia was found to be mediated by IL-6 in mice (Sundgren-Andersson 
et al., 1998). This study exhibited that a decrease in the expression of SphK1 inhibited 
this response. The reduction in TNFα−induced pyrexia could be due to the decrease in 
the levels of IL-6 as we have also shown that TNFα−induced IL-6 production is SphK1 
dependent both in vitro (Zhi et al., 2006) and in vivo in this study. It can be suggested that 
SphK1 regulates TNFα-induced body temperature changes by modulating IL-6 levels. 
Increases in the levels of proinflammatory cytokines are one of the classical features in an 
inflammatory response. We have clearly shown in this study that TNFα-induced systemic 
and local rise in the levels proinflammatory cytokine and chemokines which are 
important in the amplification of the inflammatory process are mediated by SphK1. This 
is based on the results that TNFα-induced increase in levels of IL-6, MIP-1α and MIP-1β 
in the serum and peritoneal lavage was reduced with the decrease in the expression of 
SphK1 in vivo. IL-6 plays a role in the regulation of homeostatic functions like 
proliferation, differentiation, survival,  apoptosis and in the amplification of 
inflammatory responses (Kamimura et al., 2003; Kishimoto, 2006). There is a rapid 
increases in its levels during inflammatory responses due to injury, infection or stress 
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(Kamimura et al., 2003; Kishimoto, 2006). Increased or abnormal IL-6 levels are 
associated with a inflammatory conditions like inflammatory bowel disease, multiple 
myeloma, rheumatoid arthritis and some autoimmune diseases (Grisius et al., 1997; 
Hirano et al., 1988; Holtkamp et al., 1995; Kawano et al., 1988; Stuart et al., 1995; Wong 
et al., 2001). An increase in the level of IL-6 in C5a induced peritonitis in mice in an 
earlier study was also found to be mediated SphK (Vlasenko and Melendez, 2005). 
Reductions in the levels or effects of IL-6 are being considered as an option to reduce 
inflammation associated morbidity. MIP-1α (Macrophage inflammatory protein -1 alpha) 
and MIP-1β (Macrophage inflammatory protein -1 beta) are produced in response to 
inflammatory stimuli. They contribute to the inflammatory process by modulating 
chemotaxis, degranulation and phagocytosis and signaling mediator synthesis (Maurer 
and von Stebut, 2004). Dysregulation of MIP-1 has been associated with inflammatory 
disorders including arthritis (Maurer and von Stebut, 2004; Murdoch and Finn, 2000).  
Inhibiting SphK1 can reduce the levels of these chemokines; thereby reducing it’s 
adverse effect on the affected tissues. Neutrophils and monocyte migration or chemotaxis 
in response to inflammatory stimuli have been reported to be mediated by SphK (Ibrahim 
et al., 2004; Vlasenko and Melendez, 2005). Here, the results show an increase in the 
infiltration of neutrophils to the inflamed peritoneum as seen by the neutrophils counts in 
the peritoneal lavage and leukocyte infiltration by H and E staining of the peritoneal 
tissue was dependent on SphK1. Cellular adhesion to the vascular wall is an important 
feature assisting cellular migration into the site of inflammation. This is mediated by the 
cell adhesion molecules (CAMs) consisting of Integrins. Cell adhesion molecules also 
play a role in the amplification of inflammatory processes by regulating and aiding in 
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leukocyte migration (Granger and Kubes, 1994). Intercellular adhesion molecule -1 
(ICAM-1) and vascular cell adhesion molecules (VCAM) expressed in immune cells and 
endothelial cells are known to be upregulated in inflammatory conditions (Koizumi et al., 
1992; Staunton et al., 1989). CAMs are therefore being targeted in the treatment for 
inflammatory disorders. It has been observed in this study that the increase in ICAM-1 
and VCAM expression in the peritoneal tissue following TNFα administration is 
dependent on SphK1. Studies have reported that LPS or TNFα−induced cell adhesion 
molecules expressions are regulated by ERK1/2 and NFκB (Ogawa et al., 2003; Xia et 
al., 1998). An earlier finding adds more specifics by reporting that SphK1 is the isoform 
that selectively mediates TNFα−induced responses including proinflammatory cytokine 
and cell adhesion molecule expression via NFκB (Zhi et al., 2006). Therefore, based on 
all the reports it can be proposed that SphK1 dampens the inflammatory process by 
inhibiting the amplifying responses by interfering with TNFα-triggered intracellular 
calcium release and NFκB activation. The present study along with an earlier in vitro 
study (Zhi et al., 2006) and other related reports clearly indicates that SphK1 is associated 
with the TNFα induced systemic response, proinflammatory mediators production and 
cellular infiltration in vivo. Any agent which can bring about specific inhibition of SphK1 
is bound to possess the potential as a therapeutic agent in the management of the 





Aberrant inflammatory responses have always been a major etiological factor for 
the onset and progression of a range of immune mediated inflammatory disorders. Since, 
TNFα was found to be strongly associated with inflammatory conditions, therapeutic 
management of such inflammatory disorders primarily targeted the production and action 
of TNFα. However, this strategy had certain adverse effects like increase in susceptibility 
to infections and resistant to therapy in certain patients. Therefore, the search for the 
alternative approaches resulted in targeting the signaling mediators which are involved in 
the amplification of inflammatory signals and resulting responses. For example, targeting 
signaling mediators like MAPKs and transcription factors has been shown to be 
advantageous. In this study, we have investigated the role of two important lipid based 
signaling mediators (PLD and SphK) in TNFα-mediated intracellular signaling and 
associated effector responses.  
Early reports have clearly proven the pivotal roles of PLD and SphK in immune 
cell signaling and responses. Observation from the current in vitro studies in both 
monocytic cell line and primary monocytes have revealed that PLD mediates key 
TNFα−induced signaling events including calcium release, MAPKs and NFκB 
activation. The resulting inflammatory responses like pro-inflammatory cytokines (IL-6 
and IL-1β) and chemotaxis were also found to be PLD dependent.  PLD was associated 
with selective activation of ERK1/2 by mediating the translocation of Raf-1 to the cell 
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membrane following TNFα stimulation. However, activation of p38 kinase was not 
found to be dependent on PLD. Although, the activation of the transcription factor NFκB, 
well known to be associated with inflammatory responses, was shown to be dependent on 
PLD. In particular, this study has shown that the translocation of NFκB subunits into the 
nucleus, indicative of its activation was inhibited when the PLD activity was blocked. 
This study also exhibited that PLD was necessary for the degradation of IκBα which is 
highly relevant for facilitating the translocation of the NFκB subunits from the cytosol 
into the nucleus. Interestingly, an in vitro study has reported the role of SphK1 in TNFα 
signaling and responses in monocytes. Here, in this study we showed that PLD was 
upstream of SphK. Collectively, therefore it can be suggested that PLD mediates its 
signaling through SphK.   
 It was observed in this study that TNFα−induced the selective translocation of 
PLD1 but not PLD2 from the cytosol to the cell membrane. Our antisense based 
experiments, following up on this observation designed to determine the isoform specific 
role of PLD in TNFα signaling and responses, showcased the coupling of PLD1 to the 
signaling events and responses. Having explored the role of PLD1 in TNFα responses in 
a relevant cell line and a primary cell model, we furthered this study by investigating the 
role of PLD1 in vivo. siRNA based in vivo experiments revealed that TNFα-induced 
peritonitis in BALB/c mice was found to be mediated by PLD1 complementing our in 
vitro studies.  
 Earlier work from our team and part of the present investigations reported here 
has revealed the SphK1 also plays a vital role in the propagation of TNFα−induced 
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signaling and inflammatory responses. Therefore, experiments were planned to 
investigate the role of SphK1 in vivo using RNA interference. SphK1 was also found to 
influence TNFα-induced peritonitis in BALB/c mice.  
Based on the results obtained in these studies we can propose that interfering with 
the expression and functions of specific isoforms of PLD or SphK can dampen aberrant 
inflammation. Therefore, it can be suggested that these lipid signaling mediators can be 
potential therapeutic targets in the management of immune mediated inflammatory 
disorders. Furthermore, improved or high therapeutic efficacy can be obtained either by 
only targeting the appropriate signaling mediators associated with the condition or by 
targeting these proinflammatory signaling mediators in combination with the current anti-
TNFα treatment regimens. The combination strategy should be used appropriately based 
on the molecular pathogenesis of specific inflammatory conditions to counter any 
undesired effects triggered by the conventional therapy. The combination of conventional 
therapy with the inhibition of signaling mediators could be advantageous by possibly 
reducing the dose of the agents used or by sensitizing the affected individuals to 
conventional or current anti-TNF therapeutic strategies in the management of 
inflammatory disorders. However, we strongly suggest that more detailed and 
multifaceted in vitro and in vivo work are warranted to facilitate the development and 
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